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Adverse drug reactions (ADRs) are a major obstacle for the development of new 
medicines. They are also a leading cause of patient morbidity and mortality. Although 
ADRs affect many different organs and bodily systems, drug induced liver injury has 
lead to the withdrawal of several drugs at the post licensing stage, and is a key cause of 
drug attrition. Many of the drugs that cause liver injury are thought to do so through 
metabolism to a reactive metabolite, exposure to which can cause modification of 
cellular proteins, leading to loss of function, and can result in a loss of cellular 
homoeostasis.  It is therefore important to understand the chemistry and the downstream 
biochemical events associated with bioactivation. Information on the chemistry of 
metabolism coupled with mechanistic biomarkers reflective of certain pathways of 
hepatic injury would enable both researchers and physicians to predict and diagnose 
DILI, leading to the improvement of safe drug design. 
This thesis focuses firstly on the use of in vitro models and mass spectrometry to provide 
integrated data on the metabolism and toxicity of xenobiotics, using thiophene 
containing molecules as a paradigm. The thiophene ring has the potential to be 
bioactivated via S-oxidation and epoxidation pathways, and several thiophene containing 
drugs have been associated with drug induced liver injury. The investigations described 
intended firstly to elucidate the chemistry of methapyrilene bioactivation using mass 
spectrometry and hydrogen-deuterium exchange. The following two chapters aimed to 
establish a link between bioactivation and toxicity of thiophenes and to evaluate two in 
vitro models as tool for predicting DILI.  The final experimental chapter aims to 
investigate the potential of ophthalmic acid (OA) to act as a serum biomarker reflective 
of depletion of hepatic levels of the protective tripeptide, glutathione (GSH).  
Disturbance of GSH levels through quenching of reactive metabolites can lead to 
disturbance of its anabolism and catabolism pathways.  Indeed, serum OA levels, a GSH 
analog, have been shown to rise following hepatic GSH depletion. 
This work utilises GSH adduct formation as a marker of bioactivation of thiophenes in 
several different in vitro models. Rat liver microsomal incubations were analysed using 
hydrogen deuterium exchange and LC-MS to define the reactive metabolite of 
methapyrilene as an S-oxide of the thiophene ring. Freshly isolated rat hepatocytes or 
single P450 expressing THLE cell cultures were exposed to either methapyrilene, 
tienilic acid, ticlopidine or 2-phenylthiophene and subsequent LC-MS analysis 
confirmed GSH adduct formation for all compounds in the isolated rat hepatocyte 
model, but only for 2-phenylthiophene in the THLE cell model. Cytotoxicity was also 
investigated in both models, and all compounds were found to cause a greater degree of 
toxicity in the isolated rat hepatocyte molecule than in the THLE model. 
By exposing rodents to depletors of hepatic GSH, such as acetaminophen and 
diethylmaleate, and monitoring the resultant serum OA levels, it has been determined 
that OA is not a reliable  
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mechanistic marker of hepatic GSH depletion. Kinetic studies of OA in rat serum have 
revealed that OA is subject to a similar metabolic and elimination pathway as GSH.  
The overall scope of this work reveals the usefulness of LC-MS/MS to determine S-
oxide and epoxide adducts in in vitro studies. The freshly isolated rat hepatocyte model 
was a useful tool for providing integrated metabolic and toxicological data of thiophene 
containing molecules and has the potential to be expanded to include data on covalent 
binding and levels of DILI biomarkers. The single CYP expressing THLE cell model 
was not as useful in this case, but has been used in other studies to explore the role of 
discrete P450 enzymes in toxicity and metabolism . Whilst it is unfortunate that serum 
OA did not reflect hepatic OA in such a way that it could be easily exploited as a 
biomarker, this does help us to understand that the plethora of potential biomarkers 
uncovered by proteomic, metabolomic and transcriptomic studies need to be investigated 
in depth in order to understand their applications across different species and systems.  
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1. 1. Adverse Drug Reactions 
 
Adverse drug reactions (ADRs) represent one of the major clinical challenges to 
patients‟ health, accounting for 2-6% of US hospital admissions (Bates et al., 1995; 
Classen et al., 1997; Einarson, 1993) and are a key reason for attrition in drug 
development. Mechanisms of drug induced toxicity have been reviewed and 
classified into five categories. (Liebler et al., 2005). These categories are: on target 
or mechanism related toxicity; hypersensitivity and immunological reactions; 
bioactivation to reactive metabolites; off target toxicity and idiosyncratic toxicities. 
On target reactions account for 80% of all ADRS and can be predicted from the 
known primary or secondary pharmacology of the drug and often represent an 
exaggeration of the pharmacological effect of the drug. They show simple dose–
response relationships and, therefore, can usually be avoided by dose reduction and 
are only rarely life-threatening. A good example of this toxicity is the risk of 
bleeding associated with anti-coagulant therapy. Indicated in venous thrombosis, the 
pharmacology of warfarin is to inhibit vitamin K epoxide reductase and prevent the 
coagulation casade. Warfarin has a narrow therapeutic range, and patients can be 
monitored to prevent haemorrhage (Ng, 2009).  Statins can also cause on target 
toxicity. The pharmacological action of this class of drug is to inhibit HMG-CoA 
and therefore to reduce levels of cholesterol and other products of the isoprenoid 
pathway. When large concentrations of statins accumulate outside of the liver, this 
inhibition of the isoprenoid pathway can lead to cases of muscle toxicity, and 
potentially proteinuria and even kidney failure due to release of proteins from 
overloaded muscles. 
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In contrast, off target reactions cannot be predicted from knowledge of the basic 
pharmacology of the drug, therefore the hypersensitivity, bioactivation and 
idiosyncratic categories could also be described as types of off target reaction.  
Whilst not as common as on target reactions, these can be serious and life-
threatening. A type of off target reaction that is now regularly screened for in pre-
clinical safety studies is inhibition of cardiac ion (hERG) channels. Cardiac 
arrhythmias caused by this mechanism were a side effect of antihistamine 
terfenadine (Honig et al., 1992).  Hypersensitivity reactions are common and range 
from mild skin rashes to organ failure. Formation of reactive metabolites and 
covalent binding are thought to play a part in the mechanism of this type of reaction 
(Pirmohamed et al., 2002). An example of this mechanism is the hypersensitivity 
reaction associated with sulphamethoxazole. Metabolism of sulphamethozazole to 
reactive nitroso compounds leads to protein adduct formation. These are then 
recognised by the immune system, resulting in an adverse reaction (Sanderson et al., 
2006).  Idiosyncratic reactions are incredibly rare, and difficult to reproduce and are 
thought to be a function of both the chemistry of the drug and biology of the 
individual patient. Isoniazid, an anti-tuberculosis agent, causes fatal hepatitis in less 
than 1% of patients. There is evidence to indicate formation of reactive metabolites 
may be part of this idiosyncratic reaction (Nelson et al., 1976), but it is not 
understood how these affect the hepatocyte. Bioactivation as a mechanism will be 
discussed at greater length, but there is evidence to suggest formation of reactive 
metabolites plays a part in the onset of many types of off target adverse drug 
reactions.  
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1.2 Off Target Toxicity - Drug Induced Liver Injury 
 
ADRs are known to affect every organ system within the body. Dapsone causes 
methaemoglobinaemia (Shelley et al., 1976), chronic exposure to benzene can lead 
to bone marrow hyperplasia (Ross et al., 1996) and cephaloridine can cause acute 
renal failure (Rosenthal et al., 1971).  However, those involving the liver represent a 
significant proportion with around 52% of all cases of acute liver failure in the US 
attributed to drug-induced liver injury (DILI) (Ostapowicz et al., 2002). DILI is the 
most frequent reason for the withdrawal of an approved drug from the market 
(Temple et al., 2002). Of the 548 new drugs approved by the US Food and Drug 
Administration between 1975 and 1999, four were withdrawn from the market due to 
cases of DILI and 10 received a „black box‟ warning due to their potential to cause 
liver injury (Lasser et al., 2002). Several factors contribute to this. The liver is the 
largest solid organ of the body, constituting 2-5% of human adult body weight, and 
receives a dual blood supply from the portal vein and hepatic artery (Desmet, 2001). 
The liver is the principal site of drug metabolism; therefore it is often the target of 
toxicity. Typically DILI is off target, with most being unpredictable and poorly 
understood. The manifestations range from mild, asymptomatic changes in serum 
transaminases, which are relatively common, to fulminant hepatic failure, which 
although rare, is potentially life threatening and may necessitate a liver transplant 
(Park et al., 1998).  
DILI can present in various, complex manifestations and is therefore difficult to 
diagnose. Recommendations from the FDA suggested that the use of clinical 
chemistry should be used to define DILI (FDA, 2000), such as level of serum 
transaminase enzymes or bilirubin. The various types of injury present different 
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symptoms that may be used to differentiate. Mitochondrial injury may involve lactic 
acidosis, the observation of steatosis on biopsy and slight elevations of 
aminotransferase levels (Navarro et al., 2006). This type of injury can be induced by 
tetracycline treatment (Freneaux et al., 1988). Cholestatic injury refers to damage to 
bile ducts or canaliculi by xenobiotics such as anabolic steroids (Velayudham et al., 
2003). It is characterised in the clinic by a prominent elevation in alkaline 
phosphates, followed by increase in alanine transaminase. Many compounds directly 
damage the hepatocyte, and cause the onset of apoptosis and necrosis. This is 
identified by an increase in serum transaminase followed by elevated bilirubin levels 
(Navarro et al., 2006). Drugs such as chlorpromazine and ketoconazole not only 
induce cholestasis, but also damage the hepatocyte, resulting in cholestatic hepatitis. 
As well as these types of injury, hypersensitivity or immune reactions can also occur, 
usually with delayed onset, or following repeated exposure, and can vary in severity 
from skin rash to autoimmune hepatitis (Liu et al., 2002).   
The complete mechanisms behind DILI present a complex challenge. There are 
many pathways which when disrupted could result in the types of injury described 
above, from disruption of the cell membrane, covalent binding to proteins, 
interruption of transport processes, mitochondrial disruption and induction of 
apoptosis (Lee, 2003). However, for many molecules involved in DILI, the initial 
factor sparking the onset of injury appears to be formation of a reactive metabolite 
(Park et al., 2005) 
 
. 
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1.3. Xenobiotic Metabolism 
 
The biotransformation of lipophilic compounds into water-soluble derivatives that 
are more readily excreted is the physiological role of xenobiotic metabolism. The 
principal site of drug metabolism is the liver. The liver is exposed to drugs and other 
xenobiotics immediately after their absorption from the gastro-intestinal tract and has 
a high capacity for both phase I and phase II biotransformations. Phase I enzymes 
catalyse oxidative, reductive and hydrolytic reactions. Cytochrome P450 enzymatic 
reactions are the predominant phase I processes and although the most common 
transformation catalysed by these enzymes is oxidation, other less frequent reactions 
include epoxidation, dehydrogenation and N or S-oxygenations (Guengerich, 2001a; 
Guengerich, 2001b). The P450 superfamily describes a large number of related, 
endoplasmic reticulum bound, haem protein enzymes, with ancestral genes predating 
the prokaryote/eukaryote divergence (Nelson et al., 1993). The P450 cycle is 
complex, involving the reduction of the ferric ion, incorporation of molecular 
oxygen and a proton and loss of water, resulting in the addition of oxygen to drug 
molecules to form a hydroxyl group. Seventy-four CYP families have so far been 
identified. The main families involved with drug metabolism are CYP1, CYP2 and 
CYP3 (Zimmerman, 1999). Substrate specificity is overlapping between different 
isoforms, but is dependent upon the topography of the active site, degree of steric 
hinderance impeding the haem-oxygen complex to sites of metabolism and ease with 
which electrons or protons can be abstracted from atoms within the substrate. Phase I 
reactions, however, are not confined to P450 catalysed reactions. Other enzymes 
involved include alcohol dehydrogenase, a soluble cytoplasmic enzyme which 
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metabolises ethanol, and monoamine oxidase which is responsible for inactivation of 
amines such as noradrenaline. 
Phase II reactions utilise hydroxyl, thiol and amine groups, either innate in the 
molecule or added through Phase I reactions. Large, lipophobic groups are added to 
the molecule through conjugation reactions, usually resulting in a pharmacologically 
inactive, polar molecule which are more easily excreted (Kalgutkar et al., 2005).  
Frequently observed conjugating groups are glucuronyl, sulphate, glycyl and 
glutathione. Conjugation is facilitated by dedicated enzymes for each conjugating 
agent. For example, glucuronidation is catalysed by uridine phosphate glucuronyl 
transferase (UGT) and glutathione conjugation sometimes involves glutathione 
transferase (GST). Like P450, UGT and GST proteins both compromise a family of 
enzymes. There are two families of UGT enzymes, UGT1 and UGT2, whereas there 
are eight families of GST isoforms, alpha, mu, theta, pi, zeta, sigma, kappa and 
omega.  
1.4 The Role of Metabolism in DILI 
 
Usually the conversion from a lipid to water soluble form results in loss of 
pharmacological/biological activity, but certain xenobiotics undergo 
biotransformation to toxic/reactive metabolites that can interfere with cellular 
functions and may have intrinsic chemical reactivity towards certain types of cellular 
macromolecules. These reactive metabolites have the ability to interact with cellular 
proteins, lipids and nucleic acids, leading to protein dysfunction, lipid peroxidation, 
DNA damage, and oxidative stress, potentially leading to an off target ADR. This 
impairment of cellular function can result in cell death and possible liver failure. 
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The propensity of a molecule to form either toxic and/or chemically reactive 
metabolites is simply a function of its chemistry. Such metabolites are typically 
short-lived, with half-lives of generally less than one second, and are not usually 
detectable in plasma. Formation of chemically reactive metabolites is mainly 
catalyzed by cytochromes P450, although products of phase-II metabolism can also 
lead to toxicity. Additionally, non-cytochrome P450 oxidative enzymes, such as 
myeloperoxidase and prostaglandin H synthetase, have been implicated in the 
bioactivation of drugs and other chemicals, the metabolites of which are thought to 
be responsible for observed toxicity, e.g. clozapine and agranulocytosis, benzene and 
aplastic anaemia (Fischer et al., 1991; Mason et al., 1992; Ross et al., 1996; Smith et 
al., 1989) . Cytochrome P450 isoforms are present in different proportions in many 
organs, though most abundantly in the liver, and thus bioactivate the chemicals to 
cause organ-specific toxicity (Kao et al., 1990; Pelkonen et al., 1997; Uetrecht, 
1992). The relationship between bioactivation and the occurrence of hepatic injury is 
not simple. For example, many chemicals undergo bioactivation in the liver but are 
not hepatotoxic. The best example is the absence of hepatotoxicity with therapeutic 
doses of acetaminophen. Tight coupling of bioactivation with bioinactivation may be 
one reason for this. Many enzymic and nonenzymic pathways of bioinactivation are 
present in the liver, which is perhaps the best equipped of all the organs in the body 
to deal with chemically reactive toxins. Typical examples of bioinactivation 
pathways include glutathione conjugation of quinones by glutathione S-transferases 
and hydration of arene oxides to dihydrodiols by epoxide hydrolases. The efficiency 
of a bioinactivation process is dependent on several factors including the inherent 
chemical reactivity of the substrate, substrate-selectivity of the enzymes, which is 
usually very broad, tissue expression of the enzymes, and the rapid-upregulation of 
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enzyme(s) and co-factors mediated by cellular sensors of chemical stress. It is only 
when a reactive metabolite can by-pass or saturate these defence systems of 
bioinactivation and thereby damage proteins and nucleic acids through covalent 
binding that it exerts significant toxic effects. 
 
 
Figure 1.1. Bioactivation of (A) acetaminophen (APAP); (B) isoniazid; and (C) 
furosemide. 
1.5 Toxicophores and the Thiophene ring 
Certain chemical moieties have a predisposition to be transformed into reactive 
metabolites as described above. These toxicophores are vulnerable to oxidation by 
P450, or other enzyme, and the resulting metabolite is able to react with cellular 
proteins. Functional groups which are susceptible to formation of reactive 
metabolites include aromatic amines, such as the analgesic acetaminophen, which 
can form quinone imines (Fig 1.1A); hydrazines such as the anti-TB agent izoniazid, 
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which forms a free radical metabolite via N-acetyldiazine (Fig 1.1B) and furans such 
as the diurectic furosemide, which form epoxide intermediates (Fig 1.1C) (Kalgutkar 
et al., 2005). Often, toxicophores consist of unsaturated aromatic ring moieties, 
where epoxidation can take place. The thiophene ring, a sulphur containing, 5-
membered, unsaturated aromatic heterocycle, is an example of such a moiety. 
Thiophene derivatives are commonly found in nature and exposure as a consequence 
of human activity occurs when thiophenes are released into the environment through 
fossil fuel combustion (Huffman et al., 2000) and generated in cooking processes 
(Bredie et al., 2002; Methven et al., 2007). In medicinal chemistry, thiophene rings 
can be used to improve stereoselectivity by acting as bioisosteres for benzo, phenyl, 
phenol and heterocyclic moieties (Broom et al., 1995; Kilbourn, 1989; Press et al., 
1993; Rodenhuis et al., 2000) and are also present in many drugs, incorporated to 
increase potency and efficacy (Broom et al., 1995; Hagen et al., 2001; Press et al., 
1993) as well as enhancing pharmacokinetic properties (Broom et al., 1995; Hagen 
et al., 2001; Rodenhuis et al., 2000).  Thiophene rings have been shown to undergo 
P450 bioactivation by several mechanisms (Fig 1.2). The first consists of oxidation 
of the ring to form an epoxide intermediate (Dansette et al., 2005; O'Donnell et al., 
2003). This intermediate can then be detoxified by GSH conjugation, resulting in an 
hydroxyl GSH adduct (Dansette et al., 2005), or can undergo rearrangement to form 
an α,β-unsaturated aldehyde intermediate (O'Donnell et al., 2003) (Fig 1.2). Another 
mechanism consists of oxidation of the sulphur atom to form a thiophene S-oxide 
intermediate (Belghazi et al., 2001; Nishiya et al., 2008; Shimizu et al., 2009). These 
reactive metabolites can again be quenched by GSH conjugation (Fig 1.2). 
Epoxidation and S-oxidation of thiophene containing drugs has been linked with 
occurrences of toxicity. Tienilic acid, a diuretic, has been shown to form an S-oxide 
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metabolite (Belghazi et al., 2001), which can covalently bind to human CYP2C9 
(Lopez-Garcia et al., 1994). This mechanism is thought to lead to the autoimmune 
hepatitis brought on by tienilic acid therapy (Pons et al., 1991). Methapyrilene, a H1 
receptor antagonist, is a rat specific hepatotoxin. The periportal damage caused by 
methapyrilene is thought to be metabolism dependant (Ratra et al., 1998) and due to 
bioactivaction of the thiophene ring (Graham, 2007). Suprofen, a non-steroidal 
antiflammatory drug, has been shown to form a thiophene epoxide and consequently 
an α,β-unsaturated aldehyde intermediate (O'Donnell et al., 2003). Suprofen use has 
been associated with acute renal failure (Abreo et al., 1986). S-oxide metabolites of 
the anti-platelet agent ticlopidine have also been discovered in in vivo and in vitro 
systems (Lim et al., 2008; Shimizu et al., 2009). Ticlopidine has been associated 
with cases of acute hepatitis, (Pizarro et al., 2001), but more commonly causes 
aplastic anemia (Yeh et al., 1998).   
Ticlopidine belongs to a class of drugs for whom metabolism of the thiophene ring is 
essential for efficacy, which also includes clopidogrel and prasugrel. These 
thienopyridine drugs inhibit aggregation of platelets via their action as irreversible 
antagonists of the PY12 receptor. In order to covalently bind to this receptor, the 
thiophene ring must undergo bioactivation via a thiol acetone metabolite to the active 
thiol metabolites (Dansette et al., 2009; Nishiya et al., 2009a; Nishiya et al., 2009b) 
(Fig 1.3). These metabolic pathways have not been linked as a cause of off target 
toxicity. Clopiogrel is still used safely in patients, but there are some reports of 
similar adverse reactions as ticlopidine (Goyal et al., 2009). Prasugrel has only 
recently been introduced and there are currently no reports of off target adverse 
events (Huber et al., 2009).  
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Indeed, whilst some thiophene containing drugs have been associated with DILI as 
described above, thiophenes have also been safely incorporated in many widely used 
drugs, such as the estrogen receptor modulator, raloxifene, whose major metabolites 
in vivo are glucuronides (Trontelj et al., 2007), but has been shown to covalently 
bind to liver microsomes (Obach et al., 2008). The fused ring structure of raloxifene 
prevents formation of an epoxide intermediate, but S-oxidation would still be 
possible. However, protein adduct formation by raloxifene is postulated to be due to 
epoxidation of a benzene ring (Yukinaga et al., 2007). 
Another thiophene containing drug not associated with DILI is the opioid analgesic, 
sufentanil, which is subject to N-dealkylation in vivo (Thevis et al., 2005). The 
thiophene moiety in sufentanil is not fused, therefore both epoxidation and S-
oxidation are possible pathways of metabolism, however no such intermediates have 
been identified. Investigations in liver microsomes of human, rat and dog discovered 
similar metabolic pathways in all species, including oxidative N-dealkylation on the 
piperidine nitrogen, oxidative O-demethylation and aromatic hydroxylation 
(Lavrijsen et al., 1990).  
The alternative metabolic pathways may in these cases be favoured over formation 
of reactive metabolites, or in the case that reactive metabolites are formed, 
detoxification pathways are able to deal sufficiently with the electrophilic species, 
providing protection from potential hepatocyte damage.  It is therefore difficult for 
preclinical scientists to unravel the relationship between structure and toxicity. 
Whilst certain moieties may have a predilection for bioactivation, this does not 
always lead to the onset of DILI, whether this is due to other, more favoured 
pathways of metabolism, or effective detoxification pathways.  
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Figure 1.2.  Potential pathways of thiophene bioactivation and detoxification by 
nucleophiles such as GSH. Pathways shown are S-oxidation, epoxidation and 
epoxidation followed by rearrangement to an α,β unsaturated aldehyde. 
 
 
Figure 1.3. Formation of active metabolite of thienopyridine PY12 receptor 
antagonists, ticlopidine, clopidogrel and prasugrel via a thiolacetone intermediate. 
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1.6 Use of Model Hepatotoxins to Explore Mechanisms of DILI 
Several compounds can be used to further investigate DILI due to their actions as 
hepatotoxins in animal and cell models. The reliability of these models enables an 
understanding of idiosyncratic reactions which are difficult to reproduce. Such 
molecules include acetaminophen, bromobenzene, carbon tetrachloride, furosemide 
and methapyrilene. In each of these cases, the basis for injury appears to be 
metabolic. Acetaminophen (APAP) forms a quinine immine metabolite (Raucy et 
al., 1989), bromobenzene is metabolised to an epoxide and a quinone (Fisher et al., 
1993), carbon tetrachloride is converted into a free radical, and furosemide forms an 
epoxide of the furan ring (Williams et al., 2007). In the case of methapyrilene, 
bioactivation of the thiophene ring has been postulated (Graham, 2007), but the 
chemistry has not been defined. Use of model hepatotoxins in in vivo and in vitro 
experiments can begin to unravel some of the complex mechanisms involved. APAP 
overdose causes massive necrosis, and also results in an adaptive defence response in 
the hepatocyte (Copple et al., 2008). Bromobenzene is postulated to cause injury via 
GSH depletion, covalent binding, lipid peroxidation and disruption of mitochondria. 
The formation of a free radical from carbon tetrachloride leads to lipid peroxidation. 
Covalent binding has been observed with furosemide, which causes necrosis in the 
mouse. Methapyrilene is rat specific hepatotoxin, causing periportal hepatotoxicity. 
An understanding of the chemistry of bioactivation is essential in providing a full 
picture of how structure can influence the propensity of a molecule to illicit 
mechanisms resulting in liver injury. The mechanisms by which model hepatotoxins 
produce liver injury can provide us with more information regarding frequent targets 
of reactive metabolites, and therefore aid the design of new preclinical tests and 
biomarkers of DILI. 
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1.7 Methods for trapping, identifying and defining reactive metabolites 
In order to design safe drugs and elucidate how structure may affect toxicity due to 
propensity for bioactivation, it is imperative that companies are aware of the 
metabolism of any new chemical entity under investigation.  
Traditionally, metabolic products of xenobiotics have been assessed by microsomal 
incubation followed by analysis by liquid chromatography. Metabolites can also be 
identified in vivo, either in urine and faeces, or from the bile of cannulated animals. 
Both these studies are generally undertaken from a pharmacokinetic standing, to 
identify metabolic „soft spots‟ of compounds which have a low metabolic stability 
and therefore inform how structural alterations  could be directed. Prior to 
toxicological studies in animals, both these in vitro and in vivo methods can be used 
to determine metabolite exposure and identify which molecules to take forward 
(Baranczewski et al., 2006).  
As reactive metabolites are usually short lived, it is difficult to identify them directly, 
therefore it is by looking for the presence of conjugates that we can infer the 
structure of reactive intermediates. These conjugates can be found in the in vivo 
studies mentioned above, either as GSH or N-acetylcysteine conjugates, or as 
products of these, such as mercapturic acid conjugates (Pascoe et al., 1988). When 
using microsomal incubations to investigate bioactivation, it is necessary to 
supplement the incubation with a trapping agent due to the absence of co-factors 
restricting Phase II metabolism (Masubuchi et al., 2007). Both hard and soft 
electrophiles can be determined by the use of different trapping agents; cyanide for 
hard  electrophiles (Meneses-Lorente et al., 2006), and thiols such as GSH, N-acetyl-
cysteine and glutathione ethyl ester for soft electrophiles (Castro-Perez et al., 2005). 
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Use of radiolabelled compounds allows for quantitative analysis via radiomatic 
HPLC, but mass spectrometry is required in order to elucidate the chemistry of 
metabolites. Since the LC-MS technique was introduced in the 1990s (Bryant et al., 
1997), there have been several advances in technology and introduction of new 
techniques which have aided in the use of mass spectrometry to define structure of 
thiol conjugates, and therefore in the deduction of reactive metabolite chemistry. 
Tandem mass spectrometry has allowed more intricate investigation of the structure 
of metabolites, by enabling more information about fragmentation to be examined. 
Various types of instrument are currently available with different scan functions and 
use of different mass spectrometers in metabolite profiling has been reviewed 
(Zhang et al., 2009), along with their abilities in screening for GSH adducts.  
LC-MS methods of analysis do not always provide sufficient information to 
definitively determine a chemical structure, and therefore it is possible to 
complement these analyses with nuclear magnetic resonance (NMR). However, 
static NMR, whilst providing highly detailed information on the structure of 
molecules, requires an isolated sample of high purity. Sample and data processing 
techniques can therefore be introduced into LC-MS analysis to provide more 
information regarding the structure. These include hydrogen/deuterium exchange, in 
which labile hydrogen atoms are replaced with deuterium, enabling the number of 
labile hydrogen atoms to be deduced (Lam et al., 2002; Liu et al., 2001; Nassar, 
2003).  
Although formation of a reactive species does not necessarily translate into 
hepatocyte damage and onset of DILI, it is important to determine if a reactive 
metabolite is formed in order to not only provide evidence for careful safety 
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monitoring of that particular molecule, but also to provide information relevant when 
assessing other molecules containing similar structural qualities.  
 
1.8 Use of Hepatocytes in Metabolism and Toxicity Studies 
Although microsomes are a useful tool for studying Phase I metabolism and covalent 
binding, their use is restricted with regards to Phase II metabolism due to the lack of 
co-factors present in the fraction. Because of this, in vitro studies in metabolism are 
often carried out using whole isolated hepatocytes. Isolated human and animal 
hepatocytes are recognised as a useful and relevant model for studying not only 
metabolism, but also transporter interactions (Liu et al., 1999), and toxicological 
potential of molecules (Tirmenstein et al., 2002). Once isolated, if suspended under 
adequate conditions, hepatocytes will maintain the entire hepatic metabolising 
system for up to six hours, and if cultured, will express functional hepatocyte traits 
(Gomez-Lechon et al., 2004; Gomez-Lechon et al., 2003; O'Brien et al., 2005). 
Studies have shown that the results obtained in vitro using this system and results 
obtained in vivo are well correlated. Indeed, a study using hepatocytes prepared from 
human donors showed a similar metabolic profile for aceclofenac in vitro, as was 
identified in vivo when the same donors were administered with a dose of the same 
drug (Ponsoda et al., 2001). However, compared to human hepatoma cell lines such 
as HepG2, freshly human hepatocytes are not as readily available, and unlike 
isolated animal hepatocytes, are subject to marked inter-individual variability. 
Cryopreservation and pooling of isolated human hepatocytes has begun to address 
this problem, however, the use of isolated animal hepatocytes offers an easily 
controllable model. Fresh animal cells are straightforward to locate and the use of 
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inbred strains and controlled diets minimises variability. It is also possible to control 
the model further, by breeding for certain phenotypes, such as slow or fast 
metabolisers. By using suspensions, as opposed to culture, the enzymatic capability 
is maintained and allows investigation of both chemistry of metabolism and 
toxicological end points in the same incubation (O'Brien et al., 2004; O'Brien et al., 
2005). This would enable an integrated exploration of structure toxicity 
relationships.  
Despite being readily available and having simpler culture conditions, hepatoma cell 
lines do not represent a good model for studying hepatic metabolism. This is due to 
the limited expression of biotransformation enzymes, levels of which are low 
compared to those in the normal adult liver (Donato et al., 2008). These cell lines 
however have had a place in investigating the toxicological potential of molecules 
(Mersch-Sundermann et al., 2004). In order to try and understand the role of 
metabolism in hepatotoxicity, there has been a drive towards development of 
transfected enzyme systems in hepatoma derived cell lines.  These have included 
transfecting both human (HepG2) and murine cell lines with both stable and 
inducible cDNA encoding for both Phase I and Phase II metabolising enzymes and 
cell defence genes (Aoyama et al., 1990; Goldring et al., 2006; Puga et al., 1990), 
therefore potentially providing a good model for investigating DILI in a hepatoma 
cell line. However, the P450 expression in these cells is often transient and of low 
level when compared to hepatocytes. Recently, a human liver epithelial cell line 
(THLE-5b), has been stably transfected with cDNA of P450s using simian virus 40 
and a cytomegalovirus  promoter. Whilst these cells have a hepatocyte-like 
phenotype, expressing high levels of Phase 2 metabolising enzymes they do not 
express high levels of P450. When transfected as described above, the THLE-CYP 
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cell lines express comparable levels of P450 to human hepatocytes (Mace et al., 
1997). By engineering several cell lines expressing single human P450s, there is 
scope for investigating the role of discrete P450 enzymes in the metabolism and 
cytotoxicity of drugs.  
1.9 Glutathione Conjugation as a Detoxification Mechanism 
Formation of reactive intermediates leads to an adaptive defence response in the cell, 
involving nuclear translocation of transcription factors which orchestrate 
transcription of cellular defence genes (Copple et al., 2010; Kensler et al., 2007). 
Upregulated enzymes include phase II enzymes, heme oxygenase (Takakusa et al., 
2008), and those involved in the formation and conjugation of glutathione (GSH), 
such as glutamate cysteine ligase, the rate limiting enzyme in GSH synthesis (Randle 
et al., 2008).  Maintaining the pool of the protective tripeptide GSH is critical in 
preserving the balance of deactivation of reactive metabolites and onset of toxicity 
(Lu, 2009; Mercer et al., 2009). GSH is found at millimolar concentrations in the 
liver and is formed in a two step process. The first is catalysed by glutamate cysteine 
ligase and sees glutamate bound to cysteine, forming γ-glutamylcysteine. The second 
step is the addition of glycine to the cysteine residue, catalysed by glutathione 
synthetase. The synthesis and metabolism of GSH takes place as part of the γ-
glutamyl cycle (Fig 5.7) and it is the γ-glutamyl linkage and cysteine residue that 
allow GSH to carry out it‟s various cellular functions, from the detoxification of 
reactive metabolites (Srivastava et al., 2010) to protecting astrocytes from oxidative 
stress (Dringen et al., 2003). To prevent covalent binding of electrophilic metabolites 
in nucleophilic moieties in cellular proteins and halt the resultant onset of toxicity 
(Anderson et al., 1998), the reactive species can be quenched by reaction with the 
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thiol group of the cysteine residue of GSH, either by spontaneous Michael addition 
or by an enzymatic reaction catalysed by glutathione-S-transferases, resulting in a 
chemically stable metabolite. The resulting glutathione adduct can be excreted in 
bile, and exceptionally in urine (Johnson et al., 2005), or it can be cleaved by 
transpeptidase to a cysteinylglycine adduct (Josch et al., 1998),  leading to cysteine 
and mercapturate adducts which can also be excreted via these routes. (Hinchman et 
al., 1994; Hinchman et al., 1991). Because the linkage and balance of bioactivation 
and bioinactivation ultimately determines whether or not a reactive metabolite 
produces a cytotoxic effect, failure to maintain GSH content leads to cellular injury 
(Reed et al., 1984). Therefore, analysis of GSH depletion is a marker of DILI that 
can be used to understand mechanisms of injury. 
1.10 Development of Novel Biomarkers in DILI 
In order to prevent drug attrition and withdrawal of drugs from the market, and in the 
clinical diagnosis of DILI, biomarkers are an essential tool for assessment of drug 
safety and clinical injury. Biomarkers consist of proteins or molecules that can be 
measured in biofluids either quantitatively or qualitatively and give some reflection 
of the health of the organ or system being assessed. A biomarker can be defined as a 
measured change in DNA, protein or metabolite levels, reflective of either a normal 
or disrupted biological process, either inflicted by disease state or pharmacological 
agent. In terms of DILI, there are a set of classic biomarkers which can be measured 
in serum, which are used across the board, both in preclinical safety assessment, and 
also in patient diagnosis. As discussed earlier, these include proteins such as bilrubin 
and albumin, and a series of hepatic enzymes, whose level in serum is representative 
of hepatocyte disruption, or organelle damage. Alanine aminotransferase (ALT), 
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aspartate aminotransferase (AST) and sorbitol dehydrogenase (SDH) are all enzymes 
used as markers of cytotoxic hepatocyte injury (Amacher, 2010). However, these 
tests do not provide information on the mechanism of hepatic injury, and indeed, are 
not entirely liver specific. For example, measurement of total serum ALT takes into 
account both ALT1 and ALT2. Whilst ALT1 is expressed highly in human liver 
tissue (as well as skeletal muscle and kidney), ALT2 is found in heart and skeletal 
muscle tissue (Lindblom et al., 2007). Enzyme levels can also be elevated in other 
disease states, such as liver cancer, fatty liver disease and viral hepatitis (Ozer et al., 
2008). These classic biomarkers are also only diagnostic of damage, and are unable 
to detect early signs of injury. Histopathology is often required to fully diagnose the 
details of injury substained. There is therefore an effort to find novel biomarkers that 
improve upon the reflective, predictive and diagnostic value of currently used 
markers, as well as enhancing organ selectivity. An ideal biomarker would be 
present at low baseline level in a non-invasive media, and be subject to rapid assay. 
It would be predictive of the onset of injury and reflective of the type of injury and 
be transferable across in vitro, in vivo and clinical situations. When taking into 
account sampling times following administration of a potential toxin, it is also 
important to be aware of the kinetics of a biomarker, as this will enable more 
informed predictions and diagnosis of injury status. Investigations with serum 
tumour biomarkers have shown that a knowledge of half-life can inform when blood 
should be sampled, and optimise patient management (Bidart et al., 1999). 
Ideally, new biomarkers would also provide more information on the mechanisms 
behind liver injury spanning in vitro and in vivo safety testing, and translating into 
clinical practice. Many current studies are taking advantage of proteomics, 
metabolomics and mass spectrometry in order to elucidate potential new peptides as 
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biomarkers, analysing animal biofluids following exposure to toxic xenobiotics 
(Soga et al., 2006; Yamamoto et al., 2006). Previously, there has also been interest 
in exploiting biochemical pathways, such as sulphur amino acid metabolism, which 
may result in a biomarker reflective of the state of free thiol status within the cell, 
such as urinary taurine levels (Waterfield et al., 1993a; Waterfield et al., 1993b). A 
similar non-invasive biomarker of hepatic GSH status would clearly be useful in 
providing preclinical safety information and also potentially in the clinic. Currently, 
hepatic GSH can only be determined directly via liver tissue and requires biopsy. 
Recently a metabolomic study revealed a potential candidate for such a role (Soga et 
al., 2006). Following administration of APAP to mice, one metabolite was 
consistently elevated in serum, and was determined to be ophthalmic acid (OA). 
When serum and hepatic OA concentrations from the APAP treated mice were 
correlated to hepatic GSH, it was found that the expected depletion in hepatic GSH 
corresponded to an increase in OA concentrations. This suggested to the authors that 
in cases where cellular cysteine levels are low, 2-aminobutyrate will take its place, 
leading to the formation of OA as opposed to GSH. They also provided evidence for 
involvement of glutamate cysteine ligase (the rate limiting enzyme in the synthesis 
of glutathione) in the formation of OA. When the experiment was repeated with the 
inhibitor of glutamate cysteine ligase, buthionine sulfoximine, whilst levels of 
hepatic GSH were depleted, there was no simultaneous increase in the serum or 
hepatic levels of OA. However, when the experiment was repeated with the direct 
GSH depletor, diethylmaleate, a similar result was obtained; elevation of serum OA 
levels, corresponding to hepatic GSH depletion. This suggests that the observed 
phenomenon is not unique to APAP, and OA may have potential as a biomarker of 
hepatic GSH depletion. The authors suggest that as well as GSH depletion, OA may 
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prove useful as a biomarker of general oxidative stress, and be used in the detection 
and maintainance of several conditions where oxidative stress is indicated, such as 
Alzheimers, Parkinsons, cardiac infarction and diabetes (Soga et al., 2006). 
1.11 Aims of this work 
In order to further our understanding of the relationship between metabolism and 
toxicity, this work aims to employ some of the discussed techniques. In particular, 
the role of chemical structure in the onset of toxicity will be discussed, using 
thiophene containing molecules and their bioactivation to S-oxides and epoxides as a 
paradigm.  Two cell models will also be investigated, namely freshly isolated rat 
hepatocytes and single CYP expressing THLE cell lines, to review and reflect on 
their ability to provide an integrated system for the study of xenobiotic metabolism 
and toxicity. LC-MS/MS methods will be utlised to identify and define GSH 
adducts, as biomarkers of thiophene bioactivation in these systems. In vivo studies to 
assess the suitability of OA as a biomarker of the biochemical impact of GSH 
conjugation and ensuing depletion will be carried out, including investigations into 
the kinetics of OA. 
 
 
 
 The specific questions to be addressed are; 
1) How mass spectrometry (MS) can be used to provide information on the 
chemistry of thiophene bioactivation? 
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In order to investigate the role of MS in identification of reactive metabolites of 
thiophenes, several thiophene containing molecules will be incubated in in vitro 
metabolic systems, either rat liver microsomes, isolated rat hepatocyte suspensions 
or human liver epithelial cell cultures (THLE) stably transfected with single human 
P450 enzymes. Supernatant from these incubations will be analysed by liquid 
chromatography linked to various MS machines, including an LTQ-Orbitrap mass 
spectrometer (ThermoFisher Scientific, Hemel Hempstead, Hertfordshire, UK) and 
API 2000 and 3000 mass spectrometers (Applied Biosystems, Warrington, 
Cheshire, UK), and subjected to tandem MS examination and product ion scans. In 
order to distinguish between S-oxides and hydroxyl metabolites of methapyrilene 
using MS, the above discussed hydrogen deuterium exchange technique will be 
trialled.   
 
2) Are thiophene GSH adducts formed in certain animal and human in vitro 
models, and if so can they be linked to any observed toxicity? 
Use of the above MS techniques should enable identification of any GSH adducts 
formed in isolated rat hepatocyte suspensions and THLE cell incubations, where 
toxicological endpoints can also be examined. The importance of bioactivation and 
detoxification pathways in influencing cell viability will be further investigated by 
incubation with 1-aminobenzotriazole, a non-specific P450 inhibitor and with 
diethylmaleate, a know depletor of GSH. Any relationship between the chemistry of 
thiophene bioactivation and the level of cell death can then be discussed and 
evaluated, as well as the effects of removing both the bioactivation stage by 
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incubation with 1-aminobenzotriazole, and removing the detoxification process by 
using diethylmaleate to reduce the GSH levels within the cell. 
 
3) How well do these models serve as predictive tools for DILI due to 
bioactivation? 
The ability of both the isolated rat suspension model and the THLE cell model to 
provide data on bioactivation and on toxicological potential will be evaluated and 
discussed with regards to other published reports of metabolism and toxicity of the 
molecules investigated, as well as the frequency and severity of DILI induced by the 
thiophenes examined, i.e. MP, 2-PT, TA and TC. Predicting DILI has previously 
proved to be incredibly complex, but by focusing on the specific aspect of the 
influence of bioactivation, it may be possible to define a model that enables in depth 
evaluation of the chemistry of reactive metabolite formation, and the ability to link 
this to cytotoxcity. 
 
4) Can serum OA levels be exploited as a biomarker of hepatic GSH depletion? 
In order to improve both diagnostic and predictive tests for DILI both in research and 
clinical purposes, mechanistic biomarkers would prove to be an invaluable tool for 
unpicking the biochemical pathways involved in determining the final fate of a cell 
upon exposure to a potentially toxic xenobiotic. Hepatic GSH is vital in protecting 
from damage caused by reactive metabolites and any resultant oxidative stress, and 
from preventing reactive metabolites from covalently modifying cellular proteins by 
forming GSH adducts. Formation of these adducts can lead to decreased 
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concentration, leaving the cell unable to cope with any further reactive metabolite.  
In order to test the suitability of serum OA levels as a reflective and predicative 
biomarker of hepatic GSH depletion, in vivo investigations will expose animals to 
GSH depletory agents and subsequent analysis of tissue and biofluids for OA and 
GSH levels will enable a judgement to be made regarding the use of OA as such a 
biomarker. Kinetic studies of OA in rat serum, bile and urine will also be carried out 
to assess which of these media might provide most measurable levels of OA and to 
investigate how parameters such as half life might affect sampling times.  
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2.1 Introduction 
 
Thiophene derivatives are commonly found in nature. Exposure as a consequence of 
human activity occurs when thiophenes are released into the environment through fossil 
fuel combustion (Huffman et al., 2000) and generated in cooking processes (Bredie 
et al., 2002; Methven et al., 2007). Thiophene rings, acting as bioisosteres for benzo, 
phenyl, phenol and heterocyclic moieties (Broom et al., 1995; Kilbourn, 1989; Press 
et al., 1993; Rodenhuis et al., 2000) are also present in many drugs, incorporated to 
increase potency and efficacy (Broom et al., 1995; Hagen et al., 2001; Press et al., 
1993) and additionally to enhance pharmacokinetic properties (Broom et al., 1995; 
Hagen et al., 2001; Rodenhuis et al., 2000). Notwithstanding their occasional 
association with toxicity, thiophene drugs can display both excellent potency and 
low cytotoxicity in vitro (Hagen et al., 2001).  However, some thiophene containing 
drugs have been withdrawn due to adverse effects, such as the diuretic, tienilic acid, 
withdrawn due to cases of autoimmune hepatitis (Lecoeur et al., 1996), and the H1 
receptor antagonist, methapyrilene (MP), withdrawn following reports of hepatic 
carcinomas in the rat (Lijinsky et al., 1980). Metabolism to reactive moieties may be 
in part to blame for these adverse reactions but it is also important to note that a 
number of drugs rely on metabolic activation and covalent binding to proteins for 
their efficacy, and thus prevention of adverse covalent binding through chemical 
modification of the compound may inadvertently lead to loss of efficacy. For 
example, oxidative metabolic activation of the (fused) thiophene ring is a generic 
pharmacophoric characteristic of thienopyridine antiplatelet agents (Hagihara et al., 
2009).  
50 
 
 
While C-oxidation of the thiophene ring of tienilic acid yields a stable C-5 hydroxyl 
derivative (Mansuy et al., 1984), metabolic investigations with thiophene derivatives 
have provided evidence for the formation of both an S-oxide and epoxide of the 
thiophene ring (Dansette et al., 2005; Shimizu et al., 2009). Oxidation of thiophenes 
to thiolacetone (Hagihara et al., 2009; Shimizu et al., 2009), thiol (Hagihara et al., 
2009), sulphenic acid (Dansette et al., 2009)and γ-thioketo-α,β-unsaturated aldehyde 
(O'Donnell et al., 2003) intermediates is also known. The sulphenic acid and 
aldehyde intermediates are highly reactive species. S-oxidation seems to occur as the 
major in vivo pathway of thiophene-ring bioactivation in the rat; the main 
metabolites, as detected in bile and urine, being variously the sulphoxide dimer 
formed via the Diels-Alder reaction and the GSH adduct, or its mercapturate 
catabolite (Dansette et al., 1992; Shimizu et al., 2009; Valadon et al., 1996) formed 
from Michael addition of GSH to the S-oxide (Dansette et al., 1992; Mansuy et al., 
1984; Nishiya et al., 2008a; Nishiya et al., 2008b; Shimizu et al., 2009; Valadon et 
al., 1996).  
In vitro studies of the metabolic activation of drugs are usually carried out by using 
isolated hepatocytes or microsomal incubations supplemented with NADPH. In the 
case of the latter, the lack of co-factors restricts Phase II metabolism, and presence of 
reactive metabolites can be inferred from assessing irreversible binding of 
radiolablled substrate to the microsomes, or by addition of a trapping agent 
(Masubuchi et al., 2007). The trapping technique can be used to identify formation 
of hard electrophiles using cyanide, and for soft electrophiles using thiols such as 
glutathione (GSH), N-acetyl cysteine (NAC) and glutathione ethyl ester (Rousu et 
al., 2009).  
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Both in vitro and in vivo investigations rely on mass spectrometry as the main 
technique for elucidating which metabolites are formed (Ma et al., 2009), but often 
turn to nuclear magnetic resonance spectroscopy in order to fully determine chemical 
structure, by defining the number, location and interactions of hydrogen atoms in the 
molecule (Dear et al., 2000). Although powerful NMR spectrometers are 
increasingly available for metabolite analysis (Dansette et al., 2005; Shimizu et al., 
2009), extended isolation procedures are still required for minor metabolites 
(Srivastava et al., 2009) However, over the past ten years, hydrogen/deuterium 
exchange has become recognised as a valuable tool for studying fragmentation in 
mass spectrometry and thereby in differentiating alternate metabolite structures, by 
determining the number and (approximate) location of exchanged-in deuterium 
atoms within a metabolite (Chen et al., 2009; Lam et al., 2002; Liu et al., 2001; 
Medower et al., 2008; Nassar, 2003; Ohashi et al., 1998). 
 
MP was introduced in the 1950s and used commonly as a sleeping aid for 25 years 
until being withdrawn due to hepatocarcinogenicity in chronically dosed rats 
(Lijinsky et al., 1980). No carcinomas or hepatotoxic events were reported in 
humans.  Giving a negative result in the Ames test, MP is a non mutagenic 
carcinogen, and appears to be species selective, with no carcinomas reported in 
hamsters, guinea pigs and mice (Brennan et al., 1982; Reznik-Schuller et al., 1981). 
Dose dependent hepatotoxicity in rats has also been reported following both acute 
(Mercer et al., 2009; Ratra et al., 2000) and chronic (Cunningham et al., 1995) 
dosing and MP produces concentration dependent toxicity in isolated rat hepatocytes 
(Graham et al., 2008; Ratra et al., 1998b). Chronic dosing regimens of between 
100mg/kg/day to 300mg/kg/day for three days produce mild to moderate injury, 
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consisting of necrosis, inflammatory cell infiltration and bile duct proliferation. 
Structure toxicity studies with rat hepatocytes and MP analogues have identified the 
thiophene moiety as the toxicophore of MP (Graham et al., 2008). The mechanism of 
such toxicity has been investigated in some detail (Beekman et al., 2006; Craig et 
al., 2006; Methven et al., 2007; Ratra et al., 1998a; Ratra et al., 1998b; Ratra et al., 
2000) but the chemistry of any reactive metabolite formed was hitherto defined 
uncertainly (Kammerer et al., 1986; Kammerer et al., 1988; Kelly et al., 1992; 
Lampe et al., 1990; Singer et al., 1987; Ziegler et al., 1981) 
Metabolism of MP in the rat has been investigated previously, and several 
metabolites identified in vivo (Fig. 2.1) (Kammerer et al., 1988; Kelly et al., 1990; 
Ratra et al., 2000; Singer et al., 1987). MP has several structural alerts for 
bioactivation to reactive intermediates (Kalgutkar et al., 2005), via N-oxidation to 
iminium ions, S-oxidation and arene oxidation. Irreversible binding has been 
detected with radiolabelled MP in vivo and in vitro, providing evidence for 
bioactivation to an electrophilic metabolite able to form protein adducts (Lampe et 
al., 1990; Singer et al., 1987). The in vitro metabolism of MP has also been 
investigated using rat liver microsomes (RLM) and rat hepatocytes (Graham, 2007; 
Graham et al., 2008). Several metabolites have been identified as detailed in Figure 
2.1. A reactive metabolite has not yet been identified in rat systems, but an iminium 
ion was trapped using cyanide in rabbit liver microsomes (Ziegler et al., 1981). 
Recently, Graham (2007) investigated metabolism of MP in the rat using 
radiolabelled drug. The tritiated form of MP was administered to anesthetised male 
Wister rats and bile and urine were collected at various time points and then analysed 
by radiometric HPLC and LC-MS. Incubations were also carried out with 
hepatocytes and hepatic microsomes isolated from the same strain of rat. The major 
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metabolite in bile and hepatocytes, and in microsomal incubations supplemented 
with GSH, was defined as a mono-oxygenated (M+O+GSH) glutathione adduct. 
Fragmentation revealed by a process of elimination that the site of glutathione 
conjugation was the thiophene ring (Graham et al., 2008). However, whether the 
adduct was formed from an S-oxide or an epoxide (Dansette et al., 2005; Shimizu et 
al., 2009), or a -thioketo-α, β-unsaturated aldehyde (O'Donnell et al., 2003) of the 
heterocycle remained elusive.  
 
The investigations described in this chapter were intended to define the reactive 
metabolite of methapyrilene produced in rats by employing rat hepatic microsomes 
as the source of metabolic enzymes, and using glutathione as a trapping agent. In 
order to achieve definition of the chemistry of metabolites detected, LC-MS/MS/MS 
will be used to determine absolute mass and to observe fragmentation of metabolites, 
focusing on formation of glutathione adducts. Approximate position and number of 
labile hydrogen atoms can then be determined by H/D exchange followed by LC-
MS/MS.  
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Figure 2.1.  Schematic representation of the metabolism of methapyrilene (MP) in 
the rat, both in vivo and in vitro. (Kammerer et al., 1986; Kammerer et al., 1988; 
Kelly et al., 1990; Lampe et al., 1990; Ratra et al., 2000; Singer et al., 1987) 
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Figure 2.2 Alternative hypothetical pathways of bioactivation of MP to the 
intermediate trapped as a glutathione conjugate: to MP S-oxide, an epoxide that 
reacts with GSH without opening of the thiophene ring, and an epoxide that 
undergoes concerted opening of the epoxide and thiophene rings to produce a -
thioketo-,-unsaturated aldehyde. 
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2.2 Materials and Methods 
2.2.1 Materials.  
 
MP and monodeuteromethanol (MeOD; 99.5 atom % D) were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). Non-deuterated methanol was HPLC grade 
from Fisher Scientific UK (Loughborough, Leicestershire, UK). Unless otherwise 
stated all other reagents were obtained from Sigma-Aldrich. Organic solvents were 
products of VWR (Lutterworth, Leicestershire, UK) and were of chromatographic, 
analytical, or cell-culture grade. 
 
2.2.2 Animals.  
 
Adult male Wistar rats were obtained from Charles River Laboratories (Margate, 
Kent, UK). All experiments with live animals were undertaken in accordance with 
criteria outlined in a license granted under the Animals (Scientific Procedures) Act 
1986 and approved by the Animal Ethics Committee of the University of Liverpool. 
 
2.2.3 Preparation and Incubation of Rat Hepatic Microsomes.  
 
RLM were prepared from tissue minced in ice-cold 67 mM phosphate buffer, pH 7.5, 
containing KCl (1.15%, w/v). Homogenates were produced with a motor-driven 
homogenizer, and centrifuged (10,000g; 20 min; 4°C) to obtain supernatant from 
which microsomes were sedimented (105,000g; 60 min; 4°C). The microsomes were 
resuspended in KCl phosphate buffer, centrifuged (105,000g; 60 min; 4°C) and 
reconstituted in 67mM phosphate buffer, pH 7.5. Protein content measured by the 
Bradford assay (Bradford, 1976). Incubations were carried out in a final volume of 
1ml 0.2 M Tris-HCl buffer, pH 7.4, containing 1 g/ml microsomal protein, various 
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concentrations of MP (10-1000µM) and a NADPH regenerating system (0.4mM 
NADP, 7.5 mM glucose-6-phosphate, 1U/ml glucose-6-phosphate dehydrogenase, 
5.0mM MgCl2), supplemented with 1mM GSH.  The regenerating system was 
omitted from control incubations. After 60-min incubation at 37ºC, the reaction was 
terminated by the addition of an equal volume of ice-cold acetonitrile, centrifuged 
(18,400g, 5 min), and the final supernatant analyzed by liquid chromatography-
tandem mass spectrometry (LC-MS/MS/MS).  
 
2.2.4 LC-MS/MS/MS Analysis of Microsomal Incubations 
 
Supernatant (10µl) from microsomal incubations was injected onto a Gemini 250 x 2 
mm, 5µM column (Phenomenex, UK) and eluted with a gradient of MeOH 
(containing 10mM ammonium acetate) in 10mM aqueous ammonium acetate at a 
flow rate of 300µl/min. The gradient was as follows, 0% B for 3min, 100% B at 
13min to 15min, and 0% B from 15.1min to 20min. The column eluent was analysed 
by an LTQ-Orbitrap mass spectrometer (ThermoFisher Scientific, Hemel 
Hempstead, Hertfordshire, UK). The capillary and spray voltages were 4 V and 3.8 
kV, respectively, and the capillary temperature was 275°C. Full-scanning (m/z 100-
900) and selected MS/MS/MS acquisitions in positive-ion mode were performed at 
100,000 resolution through Xcaliber 2.0 SR2. The instrument was calibrated for 
accurate mass measurements on the day of analysis. 
 
2.2.5 Characterization of glutathione adduct by deuterium exchange. 
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MP (100µM) was incubated at 37ºC with RLM (protein concentration, 1mg/ml) in a 
final volume of 1ml 0.2M Tris-HCl buffer, pH 7.4, containing NADPH regenerating 
system and GSH (1mM). After 60 min, an equal volume of ice-cold acetonitrile was 
added to the single incubation and the mixture was stored at -20ºC until further use. 
Following centrifugation at 870g for 10min, the supernatant was evaporated to 
dryness under nitrogen and the residue was reconstituted immediately in either 
MeOH or MeOD (200µl) at room temperature. The solution was clarified by 
centrifugation at 10,000g for 5 min, and immediately thereafter infused (20µl/min) 
directly into the electrospray ionisation source of an LTQ Orbitrap mass 
spectrometer (ThermoFisher Scientific, Hemel Hempstead, Hertfordshire, UK). The 
capillary and spray voltages were 4 V and 3.8 kV, respectively, and the capillary 
temperature was 275°C. Full-scanning (m/z 100-900) and selected MS/MS 
acquisitions (MS
2
 and MS
3
 product ion scans) in positive-ion mode were performed 
at 100,000 resolution through Xcaliber 2.0 SR2. The instrument was calibrated for 
accurate mass measurements on the day of analysis. 
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2.3 Results 
 
2.3.1 Determination of metabolism by MS/MS/MS 
 
Previous work had indicated that RLM supplemented with 1mM GSH produce 
hydroxymethapyrilene, methapyrilene N-oxide, desmethylmethapyrilene and a 
glutathione adduct. The presence of these metabolites was confirmed by LC-
MS/MS/MS. Figure 2.3 shows extracted ion chromatograms for the following m/z 
values of [M+1]
+
 species; 262 (parent drug), 278 (monoxygenated MP, MP[O]), 248 
(desmethyl MP) and 585 (GSH adduct of monoxygenated MP, MP[O]SG). A single 
peak was detected for m/z 262. MS/MS yielded a major fragment at m/z 217, 
corresponding to neutral loss of the dialkylamine group (HN(CH3)2). MS/MS/MS, 
i.e. fragmentation of m/z 217, yielded peaks at m/z 119 and 97, representing the 
pyridine and thiophene rings, respectively (Fig 2.4).  
Two peaks were detected in the chromatogram for m/z 278, at retention times 11.75 
min and 13.19 min. The peak at 11.75 min was attributed to a hydroxylated 
metabolite. Fragmentation revealed the pyridine ring as the location of 
hydroxylation, due to the presence of m/z 135 in the MS/MS/MS scan (Fig. 2.5). The 
peak at retention time 13.19min, eluting characteristically after MP, yielded a 
diagnostic [M+1-O]
+
 fragment in the full scan spectrum (Ramanathan et al., 2000), 
and was therefore defined as MP N-oxide (Fig. 2.6). Desmethylmethapyrilene 
exhibited a similar fragmentation pattern to the parent drug (Fig. 2.7). The peak at 
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m/z 585 was defined as an oxygenated glutathione adduct. MS/MS analysis revealed 
fragments at m/z 540 [585-HN(CH3)2]
+
, m/z 278 [585-GSH]
+
 (retro-Michael 
elimination of GSH) and m/z 456 [585-129]
+ 
(neutral loss of pyroglutamate from the 
GSH residue) In addition, m/z 522 ([540-H2O]
+
), 411 ([540-129]
+
), 393 ([411-
H2O]
+
), 267 ([233+S+2H]
+
) and 233 ([540-GSH]
+
) were obtained as fragments of 
m/z 540 in an MS/MS/MS product-ion scan (Fig. 2.8). 
 
2.3.2 Characterization of glutathione adduct by deuterium exchange. 
 
The mass spectral identification of the glutathione adduct (m/z 585) having been 
confirmed using the LTQ Orbitrap, it was next established that GSH dissolved in 
MeOD exchanged all seven of its labile amine, amide, carboxyl and sulphydryl 
protons, with a consequential increase in the mass of the protonated molecule from 
308.0917 ([M+H]
+
; +0.1 ppm) to 316.1419 ([MD+D]
+
; +0.1 ppm); where MD 
represents the weight of the fully deuterated analyte and ± ppm represents the 
deviation of the measured m/z from the calculated m/z. . The mass of the protonated 
microsomal metabolite increased from 585.2173 (C24H37N6O7S2; +0.8 ppm) to 
592.2618 (C24H30D7N6O7S2; ([MD+D]
+
; +1.4 ppm) when the compound was 
deuterated under the same conditions (Fig. 2.9 B and C). This was interpreted as 
representing exchange of the six amine, amide and carboxyl protons on the 
glutathionyl residue of an S-oxide adduct (Fig. 2.10). The ion at m/z 593.2648 was 
identified as [MD+D]
+
 for the mono-
13
C isotopomer of hexadeutero-MP[O]SG by 
comparison of the measured mass with the calculated mass: 593.2648 (Fig. 2.11). 
The ions at m/z 590.2491 and 591.2553 were due to incomplete deuteration of 
MP[O]SG. An isomeric dihydrohydroxythiophenyl-S-glutathionyl adduct derived 
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from a thiophene epoxide of MP would be expected to exchange seven protons, 
including an hydroxyl proton on the thiophene ring, and yield a monoisotopic 
[MD+D]+ ion at m/z 593.2662 (calculated) (Fig. 2.11). 
The abundant MS/MS product ions of MP[O]SG, namely [M+1-307]
+
 and [M+1-
HN(CH3)2]
+
, underwent mass shifts upon deuteration of the metabolite that were 
consistent with the six proton exchanges being confined to the glutathionyl residue 
(Fig. 2.10 A, B and C).  
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Figure 2.3. LC/MS chromatograms showing metabolites of MP in rat hepatic 
microsomal incubations as analysed on a LTQ-orbitrap mass spectrometer 
(ThermoFischer, UK). A) Extracted chromatogram of m/z 248 showing single peak 
representing desmethylMP. B) Extracted chromatogram of m/z 262. Single peak 
represents parent drug. C) Chromatogram showing m/z 248. Peak at retention time 
11.75min corresponds to hydroxyMP and peak at retention time 13.19min 
corresponds to MP N-oxide. D) Extracted chromatogram showing mono-oxygenated 
GSH adduct of MP (MP[O]SG) at m/z 585. E) Total diode array scan of incubation. 
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Figure 2.4.  MS
1
, MS
2
 and MS
3
 spectra representative of parent drug as recovered 
from incubation of RLM supplemented with 100µM MP, 1mM GSH and NADPH 
regenerating system. Analysis was carried out on a LTQ-Orbitrap mass spectrometer. 
MS
2
 and MS
3
 spectra are product ion spectra of the base peak in the preceding 
spectrum. 
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Figure 2.5. MS
1
, MS
2
 and MS
3
 spectra representative of metabolite with retention 
time 11.75min as detected in extracted chromatogram of for m/z 278. Metabolites 
were generated by RLM supplemented with 100µM MP, 1mM GSH and NADPH 
regenerating system. Analysis was carried out on a LTQ-Orbitrap mass spectrometer. 
Fragmentation suggests that site of hydroxylation is the pyridine ring, although exact 
position of the hydroxyl group has not been determined. MS
2
 and MS
3
 spectra are 
product ion spectra of the base peak in the preceding spectrum. 
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Figure 2.6. MS
1
, MS
2
 and MS
3
 spectra representative of metabolite with retention 
time 13.19  as detected in extracted chromatogram of  m/z 278. Metabolites were 
generated by RLM supplemented with 100µM MP, 1mM GSH and NADPH 
regenerating system. Analysis was carried out on a LTQ-Orbitrap mass spectrometer. 
Fragmentation is consistent with MP N-oxide, due to lack of hydroxylation of either 
the thiophene or pyridine ring. MS
2
 and MS
3
 spectra are product ion spectra of the 
base peak in the preceding spectrum. 
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Figure 2.7. MS
1
, MS
2
 and MS
3
 spectra representative of metabolite with retention 
time 12.35  as detected with selective monitoring for m/z 248. Metabolites were 
generated by RLM supplemented with 100µM MP, 1mM GSH and NADPH 
regenerating system. Analysis was carried out on a LTQ-Orbitrap mass spectrometer. 
Parent ion mass and fragmentation are indicative of desmethyl methapyrilene. 
Fragmentation confirms no alteration to thiophene or pyridine rings. MS
2
 and MS
3
 
spectra are product ion spectra of the base peak in the preceding spectrum. 
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Figure 2.8. MS
1
, MS
2
 and MS
3
 spectra representative of metabolite with retention 
time 9.12  as detected with selective monitoring for m/z 585. Metabolites were 
generated by RLM supplemented with 100µM MP, 1mM GSH and NADPH 
regenerating system. Analysis was carried out on a LTQ-Orbitrap mass spectrometer. 
MS
1
 mass is indicative of a glutathione adduct [262 +307]
+
. This is confirmed 
presence of fragments m/z 456 [M+1-129]
+ 
representing loss of pyroglutamate and 
m/z 278 [M+1-308]
+ 
representing loss of GSH in the MS2 spectra. 
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Figure 2.9.  Full-scan and partial electrospray mass spectra of glutathione adduct 
(MP[O]SG) produced by an incubation of MP with RLM and GSH. (A) Full-scan spectrum 
of MP[O]SG dissolved in MeOD, showing at m/z 592 ([MD+D]
+
) the deuteronated 
hexadeuterated derivative ([O]MP.D6-SG) attributed to exchange of the six labile protons on 
the glutathionyl residue. (B) Parent-ion region of the spectrum of MP[O]SG ([O]MP.SG) 
dissolved in methanol showing [M+H]
+
 at m/z 585.2173. (C) Parent-ion region of spectrum 
of (A) showing [MD+D]
+
 at m/z 592.2618 and the mono-
13
C isotopomer of hexadeutero-
MP[O]SG at m/z 593.2648.  
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Figure 2.10. Interpretations of mass spectral fragmentation of (A) MP[O]SG ([M+H]
+
 at m/z 
585) recovered from an incubation of RLM with MP and GSH, represented as the 
glutathione adduct of MP S-oxide (position of glutathionylation not determined), and (B) 
and (C) hexadeuterated MP[O]SG ([MD+D]
+
 at m/z 592) obtained by H/D exchange of the 
metabolite in MeOD. The mass shifts of fragments [M+1-HN(CH3)2]
+
 (m/z 540 to m/z 546), 
[M+1-pyroglutamate]
+
 (m/z 456 to m/z 461) and [M+1-GSH]
+
 (m/z 278 to m/z 280) produced 
by deuteration are consistent with the six H/D exchanges being confined to the glutathionyl 
residue and thereby with the proposed S-oxide structure of MP[O]SG. The mass shift of 
[M+1-GSH]
+
 from m/z 278 to m/z 280 rather than to m/z 279 implies H/D exchange between 
the thiophene ring and a hexadeuterated glutathionyl residue (mass, 312) during 
fragmentation. 
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Figure 2.11. Calculated MS spectra (parent ion region) obtained in Xcaliber 2.0 SR2 
representing spectra expected following H/D exchange of (A) a glutathione adduct 
formed from an S-oxide of MP and (B) a glutathione adduct formed via an epoxide 
of MP resulting in a hydroxyl glutathione adduct.  
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2.4 Discussion. 
 
The purpose of the work described in this chapter was to define the chemistry of the 
toxicophoric reactive metabolite of MP formed in the rat. In order to do this, 
incubations were carried out using RLM supplemented with a 10-fold molar excess 
of GSH (1mM) in order to trap any electrophilic metabolite formed. It has been 
shown that GSH does not inhibit any major CYP450 isoforms at concentrations up to 
10mM (Zhang et al., 2009). Incubations were firstly analysed by LC-MS/MS/MS in 
order to confirm turnover to a glutathione adduct had been achieved and to 
investigate which other metabolites were identifiable. A mono-oxygenated 
glutathione adduct (MP[O]SG) of the M+O+GSH type was found, and its 
fragmentation corresponded with that previously reported (Graham, 2007). An 
incubation of liver microsomes and GSH or a GSH derivative is now the standard 
preparation used in screens for reactive drug metabolites that are soft electrophiles 
(Gan et al., 2009). However,  it can yield more (Bu et al., 2007; Rousu et al., 2009) 
or fewer (Srivastava et al., 2009) conjugates than can be accounted for in vitro, 
thereby giving a false impression of the bioactivation pathways that operate in vivo. 
This was not the case with MP, only one GSH adduct being found in hepatic 
microsomal incubations, rat hepatocytes and rats (Graham et al., 2008). Also 
detected in the incubations were other previously reported metabolites, namely 
desmethyl MP, MP N-oxide and mono-oxygenated MP (Graham et al., 2008). 
Whilst the pyridine ring is suggested as the site of hydroxylation, the exact position 
of the hydroxyl group was not determined. Therefore it was confirmed that 
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microsomal bioactivation occurred in the context of the established pathways of 
MP‟s transformation to stable metabolites. 
 
Passive hydrogen/deuterium exchange (H/D exchange) was then used to define the 
structure of the GSH adduct and thence to derive the chemistry of the reactive 
intermediate, be it an S-oxide or epoxide of the thiophene ring, or a ring opened α,β-
unsaturated aldehyde. H/D exchange has previously been found to be effective in 
distinguishing between S-oxides or N-oxides and isomeric hydroxyl metabolites due 
to the difference between the number of labile hydrogen atoms, hydroxyl metabolites 
having an extra hydrogen atom available to exchange (Chen et al., 2009; Liu et al., 
2001).  Liu et al. (2001) used online H/D exchange to identify an S-oxide metabolite 
of an investigational compound. Having characterised a mono-oxygenated 
metabolite due to a mass increase of 16Da, and having shown that the parent 
compound had two exchangeable hydrogen atoms, they used a D2O/acetonitrile LC 
gradient to effect online H/D exchange that revealed a mass increase of 2Da on the 
mono-oxygenated metabolite, therefore ruling out the hydroxyl metabolite and 
supporting formation of an S-oxide (Chen et al., 2009; Liu et al., 2001). Other 
groups used this technique successfully to aid definition of metabolic structures 
(Gianelli et al., 2000; Miao et al., 2005; Ohashi et al., 1998). It would appear from 
our findings and those of other groups, that using H/D exchange is an effective way 
of deducing the structures of reactive intermediates of thiophene rings.  
Following the H/D exchange experiment described in this chapter, it is proposed that 
the toxicophore of MP is the S-oxide of the thiophene ring. As mentioned previously, 
S-oxidation appears to be the major route of bioactivation of thiophene molecules in 
the rat (Dansette et al., 1992; Shimizu et al., 2009), and has also been detected 
73 
 
previously in in vitro investigations (Belghazi et al., 2001; Dansette et al., 2005; 
Joshi et al., 2004). However, it should be noted that the metabolic activation of 
thiophene compounds with more than one bioactivatable moiety is not necessarily 
restricted to the thiophene ring (Lim et al., 2008).  Isomeric thioether adducts formed 
by addition of GSH to MP S-oxide and the α,β-unsaturated aldehyde intermediate 
(Fig. 2.2) would both have structures consistent with the observed six H/D 
exchanges in MeOD: H/D exchange on the MP-derived moiety would not be 
expected in either case. Nevertheless, there are several factors suggesting that a 
thioketo aldehyde is an improbable precursor of MP[O]SG. Firstly, in microsomal 
incubations of suprofen, a 2-aroylthiophene, the putative 4,5-epoxide precursor of 
the γ-thioketo-α,β-unsaturated aldehyde intermediate, and not the aldehyde, was 
trapped with GSH as a thioether adduct. The aldehyde itself was stabilized 
separately, as a pyridazine derivative, with semicarbazide (O‟Donnell et al., 2003). 
Secondly, investigations with methapyrilene and semicarbazide found neither 
inhibition of the irreversible binding of [
3
H]MP to liver microsomes nor yielded an 
additional metabolite, and specifically no pyridazine derivative (Graham et al., 
2008). Finally,  furans and pyrroles are also metabolized to GSH adducts without 
apparent opening of the heterocycle (Kalgutkar et al., 2005; Williams et al., 2007), 
and, in general, it seems that α,β-unsaturated aldehydes derived from heteroarene 
epoxides by ring opening are not trapped in ring-opened forms by GSH. 
Recyclization requires dehydration, yielding a M-2+GSH type adduct. The 
glutathione adduct of a γ-thioketo-α,β-unsaturated aldehyde, as implied by Medower 
et al. (2008), might also be formed from a thiophene epoxide by concerted addition 
of GSH and ring opening, but no published precedent for such a reaction has been 
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found. Therefore, the available data are most readily understood in terms of 
MP[O]SG being a glutathione adduct of MP S-oxide. 
These findings represent the first detailed structural definition of an electrophilic 
metabolite of MP modified in the toxicophore moiety. Whilst iminium ions have 
previously been trapped using cyanide (Ziegler et al., 1981), this was in rabbit liver 
microsomes, so it is not apparent how this relates to the in vivo hepatotoxic rat 
model. The metabolic activation of MP appears to play a role in the toxicity of MP. 
Irreversible binding of tritiated MP in both RLM and isolated rat hepatocytes has 
previously been investigated parallel to cytotoxicity (Graham, 2007). Irreversible 
binding in hepatocytes was 4.56nmol/mg protein at 200µM MP, but was 
significantly reduced following preincubations with non specific P450 inhibitors 
aminobenzotriazole and SKF-525A (Graham, 2007; Graham et al., 2008). These 
inhibitors also attenuated the cytotoxicity caused by 200µM MP. Incubations with 
RLM exhibited 0.7nmol/mg protein irreversible binding, but following 
supplementation with glutathione, this decreased to 0.1nmol/mg and a glutathione 
adduct was formed. It can therefore be asserted that the S-oxide metabolite described 
in this chapter is responsible for the hepatotoxic effects of MP in the rat.  
This chapter adds to the convincing and substantial evidence that metabolic 
activation can be a mechanism involved in drug induced liver injury (Park et al., 
2005). There is therefore a serious need for preclinical systems in which to 
investigate the potential of compounds to undergo metabolism to reactive metabolic 
and to investigate structure metabolism and toxicity relationships (Groneberg et al., 
2002).  
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3.1 Introduction 
The metabolism of methapyrilene (MP) to a glutathione adduct, via formation of an 
S-oxide intermediate, was described in chapter two. Much evidence exists to back up 
the proposition that bioactivation of molecules in this way can lead to adverse drug 
reactions, in particular drug-induced liver injury (DILI) (Park et al., 2005; Srivastava 
et al., 2010). A major physiological purpose of the liver is to transform low 
molecular weight lipophilic compounds into hydrophilic derivatives to facilitate 
excretion. The liver has a high capacity for phase I and phase II biotransformations. 
Although generally these pathways produce non-toxic, inert, readily excretable 
compounds, reactions catalysed by P450 isozymes can sometimes produce a 
metabolite that is chemically much more reactive than the parent drug, usually short 
lived and electrophilic in nature. These electrophilic or free radical species (if not 
deactivated) can cause chemical modification of cellular proteins, potentially 
eliciting hepatotoxicity, e.g. acetaminophen quinone imine (Park et al., 2005); 
hypersensitivity, e.g. sulphamethoxazole nitrosoarene (Callan et al., 2009); or 
carcinogenicity, e.g. aflatoxin oxidation products (Guengerich et al., 2002). 
Formation of these potentially damaging species leads to an adaptive defence 
response in the cell, involving nuclear translocation of transcription factors which 
orchestrate transcription of cellular defence genes (Kensler et al., 2007). The 
upregulated hepatic enzymes include phase II enzymes, heme oxygenase (Takakusa 
et al., 2008), and those involved in the formation and conjugation of glutathione 
(GSH), such as glutamate cysteine ligase, the rate limiting enzyme in GSH synthesis 
(Randle et al., 2008).  Synthesis and depletion of GSH is a critical mechanism in the 
balance of deactivation of reactive metabolites and onset of toxicity (Lu, 2009; 
Mercer et al., 2009). Electrophilic metabolites can be quenched by reaction with the 
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thiol group of the cysteine residue of GSH, either by spontaneous Michael addition 
or by an enzymatic reaction catalysed by glutathione-S-transferases. If the thioether 
adduct is chemically stable – which is not invariably the case (Boots et al., 2005) – 
this prevents the electrophilic metabolites from covalently binding to cellular 
proteins, and hence prevents toxicity from proceeding (Anderson et al., 1998).  The 
resulting glutathione adduct can be excreted in bile, and exceptionally in urine 
(Johnson et al., 2005), or it can be cleaved by transpeptidase to a cysteinylglycine 
adduct (Josch et al., 1998) which yields variously cysteine and mercapturate adducts 
that are excreted in a similar way (Hinchman et al., 1994; Hinchman et al., 1991). It 
is the linkage and balance of bioactivation and bioinactivation which ultimately 
determines whether or not a reactive metabolite produces a cytotoxic effect.  
The propensity of a molecule to undergo bioactivation is a function of its chemistry. 
Certain moieties are considered to be more susceptible than others and are labelled 
as structural alerts for bioactivation (Kalgutkar et al., 2009). The thiophene ring has 
been designated as a structural alert as it can form unstable, reactive epoxides and S-
oxides (Kalgutkar et al., 2005). As mentioned in the previous chapter, several 
thiophene-containing drugs have been associated with DILI. The types of reactions 
vary from autoimmune hepatitis, caused by the now withdrawn diuretic tienilic acid 
(Eugene et al., 1980), to raised serum transaminase levels seen with zileuton 
treatment during asthma (Watkins et al., 2007). In several cases, an S-oxide or 
epoxide metabolite has been identified or inferred through in vitro or in vivo 
laboratory studies, and are thought to be responsible for the liver injury associated 
with the investigated drug (Graham et al., 2008; Nishiya et al., 2008a; O'Donnell et 
al., 2003; Shimizu et al., 2009). The in vitro systems investigated have included 
human (Dansette et al., 1991) and rat (Dansette et al., 1990) microsomes, 
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Supersomes (O'Donnell et al., 2003), S9 fractions (Shimizu et al., 2009) and cultured 
primary hepatocytes (Lopez-Garcia et al., 2005). In vivo investigations comprise 
administration of test compounds to live animals, and collection of bile and urine 
(Dansette et al., 1992; Nishiya et al., 2008a; Shimizu et al., 2009).  
The strength of the associative link between formation of reactive drug metabolites 
and onset of an adverse reaction in patients is difficult to predict preclinically. 
Screens for irreversible protein binding and trapping of reactive intermediates can be 
performed, but positive results do not necessarily translate into an accurate 
prediction of hepatotoxicity (Kalgutkar et al., 2009; Obach et al., 2008). The balance 
between bioactivation and bioinactivation can depend on many factors, such as 
patient biology and genetics, dosage and co-administered drugs.  
This chapter aims to elicit a link between thiophene bioactivation and an endpoint of 
liver cell toxicity, using suspensions of freshly isolated rat hepatocytes. These 
hepatocytes retain good metabolic capacity and their susceptibilities to toxins have 
been shown to correlate well with in vivo models in predicting hepatotoxicity 
(O'Brien et al., 2004). The formation of GSH adducts was taken as a biomarker for 
thiophene-compound bioactivation (Gan et al., 2009), and loss of cell membrane 
integrity as a measured hepatotoxicity endpoint.  
The following questions were addressed: 
 Are thiophene molecules bioactivated by isolated rat hepatocytes? 
 Do thiophene molecules elicit cytotoxicity in isolated rat hepatocytes? 
 Does modulation of bioactivation or bioinactivation attenuate or enhance 
toxicity? 
Investigated compounds are detailed in table 3.1. 
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Table 3.1. Details of compounds investigated. 
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3.2 Materials and Methods. 
 
3.2.1 Materials 
 
Methapyrilene (MP), ticlopidine (TC) and 2-phenylthiophene (2-PT) were purchased from 
Sigma-Aldrich (Poole, Dorset, UK). Tienilic acid (TA) was a gift from Molecular 
Toxicology, AstraZeneca (Alderley Park, Cheshire, UK).  Collegenase A was purchased 
from Roche (Mannheim, Germany). Bradford reagent was purchased from Bio-Rad 
(Germany). Solvents were purchased from either VWR (Lutterworth, Leicestershire, UK) or 
Fischer Scientific (Loughborough, Leicestershire, UK). Unless otherwise stated, all the other 
reagents were purchased from Sigma-Aldrich. 
 
3.2.2 Animals 
 
Adult male Wistar rats were obtained from Charles River Laboratories (Margate, Kent, UK). 
All experiments were undertaken in accordance with criteria outlined in a license granted 
under the Animals (Scientific Procedures) Act of 1986 and approved by the Animal Ethics 
Committee of the University of Liverpool.  
 
3.2.3 Hepatocyte isolation procedure 
 
Rat hepatocytes were isolated using a modified two-step collagenase procedure based on 
Seglen et al. (1976).  The rats (150 g – 300 g) were anaesthetized with sodium pentobarbital 
(Euthanal, 200 mg/ml, 1 µl/g, i.p.). The liver was first perfused via the hepatic portal vein 
for 9 min with wash buffer consisting of Hank‟s buffered salt solution containing 5.8 mM 
HEPES and 4.5 mM NaHCO3 but containing no calcium chloride, magnesium chloride, 
magnesium sulphate, sodium hydrogencarbonate, or phenol red (Invitrogen, Paisley, UK). 
This was followed by a perfusion with 200 ml of wash buffer supplemented with 5 mM 
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CaCl2 and 100 mg of collagenase until the liver interstitium had been digested. The flow rate 
was maintained at 30 ml/min and all solutions were kept at 37°C. After in situ digestion the 
liver was excised and the liver capsule was broken. The cells were combed and stirred out of 
the capsule. The cells were suspended in 100 ml wash buffer supplemented with DNase I 
(0.1 mg/ml) to prevent cell clusters and filtered through a 125-m mesh (Lockertex, 
Warrington, Cheshire, UK). They were allowed to settle for 10 min at 4°C.  Cells were 
centrifuged at 50g for 2 min, supernatant removed, and the cells resuspended in wash buffer 
containing DNase I. This was repeated twice with wash buffer, with final resuspension in 
wash buffer supplemented with 1 mM MgSO47H2O (incubation buffer). Viability was 
assessed by trypan blue exclusion with 20 μl of 0.4% trypan blue solution (Sigma-Aldrich) 
combined with 100 μl of cell suspension. The proportion of viable, i.e. dye-excluding, cells 
was determined by microscopic observation of stained cell suspension in a haemocytometer. 
At least 500 cells were counted for each determination. Hepatocytes were only used when 
viability was greater than 75%. Typically, initial viability was 85-90%. Cells were incubated 
with thiophene compound approximately 1h after the start of the liver perfusion.  
 
3.2.4 Hepatocyte incubations for assessment of cytotoxicity and metabolism of 
thiophene compounds  
 
Rat hepatocytes from individual isolations were incubated in suspensions (2 × 10
6
 cells/ml, 
final volume 6 ml) with between 10-1000 M thiophene, dissolved in either incubation 
buffer (MP; for buffer composition, see 3.2.3) or MeOH (TC, 2-PT, TA). The thiophene was 
added in a volume of 60 µl. Control incubations contained either 60 µl incubation buffer or 
60 µl MeOH. Incubations were performed in 20 ml glass vials, with tops loosely screwed. 
Vials were placed in an orbital shaker at 37°C for 6 h, gently stirring to ensure the cells did 
not settle throughout the incubation. Hepatocytes were also pre-incubated with either 1-
aminobenzotriazole (ABT) to inhibit P450 non-specifically or diethyl maleate (DEM) to 
deplete GSH.  
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3.2.5 Determination of thiophene cytotoxicity  
 
Following the incubation, an aliquot of the cell suspension (100 l) was used to assess 
trypan blue exclusion as detailed in 3.2.2. Thiophene incubations were assessed only in the 
case that control viability was at least 65%. The IC50 value given in the results was the 
concentration of test compound that resulted in a proportion of viable cells half the 
level found in the vehicle-control incubations. 
 
3.2.6 Preparation of samples for assessment of metabolism by LC-MS 
 
The incubation was terminated with an equal volume of ice-cold acetonitrile (ACN) and 
transferred to a 12 ml glass tube (LSL, Rochdale, UK). The mixture was stored at -20˚C 
overnight in order to fully precipitate the proteins. It was then centrifuged (2200rpm, 10min) 
and the supernatant was evaporated to dryness under a vacuum. The resulting residue was 
reconstituted in 500µl H2O. The reconstituted residue was clarified by centrifugation 
(14000rpm, 5min), and was stored at -20˚C until analysis. 
 
3.2.7 Assessment of metabolism of thiophene compounds by LC-MS/MS 
analysis  
 
Aliquots of the solutions derived from hepatocyte incubations (30 l or 50 l) were 
chromatographed at room temperature on a Prodigy 5-m ODS-2 (C-18) column (150  4.6 
mm i.d.; Phenomenex, Macclesfield, Cheshire, UK) or a Gemini 5-µm C-18 column (250  
4.6mm i.d.; Phenomenex, Maccelesfield, Cheshire, UK), using the chromatographic 
conditions outlined in Table 3.2.  In the case of 2-PT, the LC system consisted of two Jasco 
PU980 pumps (Jasco UK, Great Dunmow, Essex, U.K.) and a Jasco HG-980-30 mixing 
module. The eluent flow rate was 0.9 ml/min. Eluted compounds were monitored at 254 nm 
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(max. range, 0.0005 AUFS; adjusted as required) with a Jasco UV-975 spectrophotometer. 
Eluate split-flow to the LC-MS interface was ca. 40 l/min. A Quattro II mass spectrometer 
(Waters Corp, Manchester, UK) fitted with the standard co-axial electrospray source was 
operated using nitrogen as the nebulizing and drying gas. The interface temperature 
was 80 C; electrospray capillary voltage, 3.8 kV; standard cone voltage, 30 V; and 
fragmenting cone voltage, 60 V. The instrument was set up for full-scanning 
acquisitions in the positive-ion mode as follows: scan range, m/z 50-1050, with a 
scan time of 5s and an inter-scan delay of 100 ms. Instrument management and data 
processing were accomplished through MassLynx 3.5 software. For MP, TC and TA 
the LC system consisted of a PerkinElmer Series 200 pump and autosampler 
(PerkinElmer Life and Analytical Sciences, Boston, MA, USA). 
Table 3.2. Chromatographic conditions used for LC-MS/MS analysis of  2-PT, MP, TA 
and TC. 
Drug Column Eluent A Eluent B Flow 
rate 
Gradient 
MP Gemini 10mM ammonium 
acetate 
100% ACN 1ml/min 0min 100% A,  
5min 100% A,  
25min 30% A 
30min 30% A 
33min 100% A 
34min 100% A 
2PT Prodigy 0.1% formic acid 100% MeOH 1ml/min 0min 100% A 
5min 100% A 
25min 20% A 
30min 20% A 
31min 100% A 
32min 100% A 
TA Prodigy 0.1% formic acid 100% MeOH 1ml/min 0min 95% A 
5min 95% A 
20min 5% A 
25min 5% A 
26min 95%A 
27min 95% A 
TC Prodigy 0.1% formic acid 100% MeOH 1ml/min 0min 90% A 
5min 90% A 
23min 25%A 
29min 25%A 
30min 90% A 
35min 90% A 
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Eluate split-flow to the LC-MS interface was ca. 160 l/min. Analyses were carried 
out on an API 2000 mass spectrometer (Applied Biosystems, Warrington, Cheshire, 
UK) fitted with a TurboIonSpray source and operated in the positive mode. Q1 scans 
were acquired using the following conditions; curtain gas (CUR) setting, 20; 
ionspray voltage (IS), 5.5 kV; source temperature (TEM), 400˚C; ion source gas 1 
(GS1) setting, 20; ion source gas 2 (GS2) setting, 75; declustering potential (DP), 20 
V; focusing potential (FP), 200 V; and entrance potential (EP), 10 V. Product ion 
scans were carried out to assess the fragmentation of detected glutathione adducts 
using parent ions m/z 585 for MP, m/z 636 for TA and m/z 587 for TC. Conditions 
for these scans were as above except for the following changes and additions; DP, 71 
V; FP, 370 V; EP, 11 V; collision energy, 31 eV and collision cell exit potential, 14 
V. Instrument management and data processing were accomplished through Analyst 
1.4 software. 
 
3.2.8. Statistics 
 
All results are expressed as mean ± standard error of the mean (SEM).  Values to be 
compared were analysed for non-normality using a Shapiro-Wilk test.  A Students 
unpaired t-test was used for comparing two groups when normality was indicated 
and a Mann-Whitney U test was used for non-parametric data.  All calculations were 
performed using StatsDirect statistical software (Research Solutions, Cambridge, 
U.K.), results were considered to be significant when P values were less than 0.05. 
IC50 calculations were carried out using GraFit 3.01 software (Erithacus Software 
Ltd., Surrey, UK.). 
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3.3. Results 
3.3.1 Cytotoxicity of thiophene-containing compounds in rat hepatocytes 
suspensions 
 
 Methapyrilene 
 
Methapyrilene (MP) exhibited dose-dependant toxicity as assessed by trypan blue 
exclusion, with a significant decrease in cell viability observed at 50µM (Fig. 3.2A). 
Cell viability was decreased to 21% by a concentration of 500µM MP, with an IC50 
value of 152µM (Table 3.3.). Preincubation with 1mM ABT for 60min attenuated 
the toxicity, with a significant increase in IC50 to 646µM. A significant attenuation 
was observed at 500µM MP, when addition of ABT produced an increase in cell 
viability form 21% to 75% (Fig. 3.3A). Depletion of GSH by a 30-min preincubation 
with 1mM DEM reduced the IC50 to 88µM, but no significant decrease in cell 
viability was observed (Fig. 3.3A). 
 
2-Phenylthiophene 
 
Significant toxicity was only observed at higher concentrations (500µM and 1mM) 
of 2-PT, which exhibited an IC50 value of 553µM (Fig 3.2B). Preincubation with 
1mM ABT produced a significant rise in cell viability at these two concentrations 
but overall, preincubation with ABT had little effect, producing a non significant fall 
in the IC50 to 478µM (Table 3.2). However, pre-incubation with DEM produced a 
significant decrease in IC50 compared to drug alone, from 553µM to 153µM (Table 
3.3).   
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Tienilic Acid 
 
TA was the least toxic compound in this system, with the highest IC50 value of 
563µM. Significant toxicity was observed at 500µM and 1mM (Fig. 3.2D). Neither 
preincubation with ABT or DEM had any significant effect on toxicity (Fig. 3.3D). 
However, whilst ABT had little effect on the IC50 of TA (598µM), preincubation 
with DEM produced a reduction to 316µM (Table 3.3) 
 
Ticlopidine 
 
Like 2-PT, TC was only significantly toxic to hepatocytes at 500µM and 1mM (Fig 
3.2C). Preincubation with ABT seemed to attenuate toxicity at lower drug 
concentrations, but at higher concentrations actually produced a significant decrease 
in toxicity (Fig. 3.3C), resulting in a reduction in IC50 values from 352µM for TC 
alone to 278µM for TC plus ABT (Table 3.2). DEM produced no significant fall in 
cell viability, but did reduce the IC50 value for TC to 226M.  
 
 
 
 
 
 
 
 
 
 
 
94 
 
 
Table 3.3. IC50 values for MP, 2-PT, TC and TA from incubation with male rat 
hepatocytes: thiophene alone and in the presence of 1mM ABT or 1mM DEM. 
 
† Concentration of test compound that resulted in a proportion of viable cells half the 
level found in the vehicle-control incubations. The IC50 was determined used Graph 
Pad Prism Software (GraphPad Software, La Jolla, CA, USA.). 
* 95% Confidence interval indicates significant difference in IC50 value compared to 
drug alone.  
 
 
 
IC50 Value (µM) † 
Compound 
(95% 
Confidence 
Interval)  
Alone  +ABT  +DEM  
MP  
152  646*  88  
(111 to 206)  (552 to 755)  (55 to 138)  
2-PT  
553  478  153*  
(392 to 777)  (347 to 657)  (91 to 255)  
TC  
352 287*  226 
(226 to 546)  (239 to 345)  (169 to 302)  
TA  
563 598 316 
(485 to 651)  (458 to 779)  (167 to 594)  
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Figure 3.2. Cytotoxicity of (A) MP (■); (B) 2-PT (♦); (C) TC (▲) and (D) TA (●) in 
isolated male rat hepatocytes following a 6h incubation at 37˚C in a shaking water 
bath. Data points indicate mean of 3-8 separate isolations. Error bars represent 
standard error of the mean. Control viabilities at the end of incubation time were at 
least 65%.  
 * P <0.05, ** P<0.005,  *** P<0.0005.  
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Figure 3.3. Graphs showing effects of preincubation with 1mM ABT (non-specific 
cytochrome P450 inhibitor) and 1mM DEM (glutathione depletor) on toxicity of (A) 
MP; (B) 2-PT; (C) TC and (D) TA in isolated male rat hepatocytes. Data points 
indicate mean of 3-8 separate isolations. Error bars represent standard error of the 
mean. *P < 0.05 for 1mM ABT preincubation versus drug alone. † P < 0.05 for 
1mM DEM preincubation versus drug alone.  
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3.3.2 Formation of Thiophene Glutathione Adducts in Rat Hepatocyte 
Suspensions 
 
 
Methapyrilene 
 
A full Q1 scan (Fig 3.4A) did not immediately reveal any metabolites of MP 
following incubation with rat hepatocytes. Extracting the mass chromatogram for 
[M+1]
+
 (m/z 585) of the MP glutathione adduct described in chapter two 
(MP[O]SG), revealed a small peak at retention time 13.89min (Fig 3.4B). A product 
ion scan of m/z 585 did not produce any obvious peaks (Fig 3.4C), but evaluation of 
the spectrum between 15.071 and 17.912min, revealed an MS/MS fragmentation 
pattern indicative of MP[O]SG: m/z 540 [585-HN(CH3)2]
+
, m/z 277.8 [585-GSH]
+
 
(retro-Michael elimination of GSH), m/z 456 [585-129]
+ 
(neutral loss of 
pyroglutamate from the GSH residue) and m/z 233 ([540-GSH]
+
) (Fig 3.4C).  
 
2-Phenylthiophene 
 
Chromatographic analysis at 254nm revealed that 2-PT (1mM) was extensively 
metabolised in rat hepatocytes suspensions (Fig 3.5A). The three definitely identified 
metabolites were two GSH adducts of monoxygenated 2PT (2PT[O]SG) ([M+1]
+
 at 
m/z 484), one major (retention time 11.76min) and one minor (retention time 
10.4min), and appreciable quantities of the S-oxide dimer (m/z 353, retention time 
16.69min) (Fig 3.5B & C). The MS fragmentation pattern of the minor adduct (rt 
10.4) suggested a GSH adduct of 2-PT thiophene S-oxide due to the presence of the 
following fragments: m/z 436 [484-S=O]
+
, m/z 366 [484-129]
+
 (neutral loss of 
pyroglutamate from the GSH residue), m/z 307 [436-129]
+
, m/z 177 [484-GSH]
+
 
(Fig 3.5E). The major adduct was therefore assigned to a GSH adduct of 2-PT 
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thiophene epoxide, as evidenced by the following fragments: m/z 466 [484-H2O]
+
, 
m/z 391 [466-75]
+
 (loss of glycine from the GSH residue), m/z 391 [466-129]
+
 
(neutral loss of pyroglutamate from the GSH residue), m/z 308 [GSH]
+
, m/z 177 
[484-GSH]
+
 (Fig 3.5D). These assignments were based on those made by (Dansette et 
al., 2005), which were founded on a combination of data from mass spectrometry and NMR 
spectroscopy. 
 
Tienilic Acid 
 
Several peaks were visible in the Q1 scan of an incubation of tienilic acid and rat 
hepatocytes (Fig 3.6A). The most prominent peak, at retention time 20.41min, was 
identified as the parent drug ([M+1]
+
 at m/z 331). A monoxygenated metabolite (m/z 
347) was also found at retention time 21.5min. The MS spectrum of the peak with 
retention time 18.69min demonstrated an abundant ion at m/z 636. This 
corresponded to a non-oxygenated glutathione adduct of tienilic acid in rat bile 
(Nishiya et al., 2008a). A product ion scan of m/z 636 gave a single peak with 
retention time 19.57min (Fig 3.6B). The MS/MS spectrum of this peak had the 
following fragments, suggestive of a glutathione adduct (Fig 3.6C); m/z 618.8 [636-
H2O]
+
,
 
 m/z 561.0 [636-72]
+
 (loss of glycine from the GSH residue), m/z 506.9 [636-
129]
+
 (neutral loss of pyroglutamate from the GSH residue), m/z 489.9 [636-
COOH(CH2)2CH2NH2CONH]
+
, m/z 360.9  
[636-COOH(CH2)2CH2NH2CONHCH2CH3CONHCH2COOH]
+
 and m/z 246.6 [636-
COOHCH2OC6H2(Cl2)2CO]
+
. 
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Ticlopidine 
 
TC was extensively metabolised in the rat hepatocytes suspension (Fig 3.7A). The 
largest peak in the total ion chromatogram of the Q1 scan, with retention time 
30.66min, was assigned to parent drug ([M+1]
+
 at m/z 264). Peaks attributable to TC 
metabolites were found. The peak with retention time 23.19min was assigned to an 
oxygenated metabolite (m/z 278), but whether this was the lactam reported by 
Shimizu et al. (2009) was not investigated. A peak of m/z 296 was also seen, with a 
retention time of 21.90min. A thiophene ring-opened thioketone carboxylate 
metabolite yielding an ion at m/z 296 has been described previously (Shimizu et al., 
2009). The two adjacent peaks with retention times 12.8min and 13.77min both 
displayed m/z 587 in their MS spectra. This m/z value is equal to that of a 
glutathione adduct of monoxygenated TC (TC[O]SG). A product ion scan for m/z 
587 produced two distinct adjacent peaks with retention times 14.26min and 
14.85min (Fig 3.7B). The MS/MS spectrum for the first peak (rt 14.26min) 
displayed a fragmentation pattern corresponding to a glutathione adduct formed via 
an S-oxide of TC. This was surmised from the presence of a fragment with m/z 
539.2, [587-S=O]
+
 ((Dansette et al., 2005). Other fragments in the spectrum were 
indicative of a glutathione adduct: m/z 569.3 [587-H2O]
+
, m/z 458 [587-129]
+
 
(neutral loss of pyroglutamate from the GSH residue), m/z 409 [539-S=O]
+
 and m/z 
280 [587-GSH]
+
  (Fig 3.7C). The MS/MS spectrum of the second peak (rt 14.85min) 
did not display a fragment concordant with loss of sulphoxide, instead only the 
fragments at m/z 457.8 [587-129]
+
 and m/z 308 [GSH]
+
, were indicative of a 
glutathione adduct (Fig 3.7D). It is possible that this adduct was formed via an 
epoxide of the thiophene ring.  
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Figure 3.4. Mass chromatograms and spectrum from incubations of 100µM MP with freshly 
isolated rat hepatocytes (6h, 37˚C). Figure shows (A) Total ion current chromatogram with 
parent drug peak at retention time 18.43 min; (B) Extracted ion chromatogram of m/z 585. 
The peak at 13.89min represents an oxygenated glutathione adduct of MP; (C) Product ion 
spectrum of m/z 585 showing fragmentation pattern concordant with previously reported S-
oxide GSH adduct of MP (Chapter 2). 
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Figure 3.5 UV chromatogram and mass chromatograms and spectra from incubations of 
1mM 2-PT with freshly isolated rat hepatocytes (6h, 37˚C). (A) UV chromatogram showing 
two GSH adducts highlighted in red and S-oxide dimer highlighted in blue; (B) Extracted 
ion chromatogram of m/z 484. Peaks at 10.4min and 11.76min represent oxygenated 
glutathione adducts of 2-PT. (C) Extracted ion chromatogram of m/z 353. Single peak 
represents 2-PT S-oxide dimer. (D) MS spectrum of peak rt 11.79 exhibiting fragmentation 
consistent with an hydroxyl GSH adduct of 2-PT formed via an epoxide of the thiophene 
ring. (E) MS spectrum of peak rt 10.40min exhibiting fragmentation consistent with an S-
oxide GSH adduct of 2-PT. Assignments were based on those made by Dansette et al. 
(2005). 
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Figure 3.6 Mass chromatograms and spectrum from incubations of 100µM TA with freshly 
isolated rat hepatocytes (6h, 37˚C). Figure shows (A) Total ion current chromatogram 
annotated to show parent drug, a GSH adduct and a hydroxy TA metabolite (B) Product ion 
chromatogram of m/z 636. The peak at 19.57min represents  a glutathione adduct of TA; (C) 
Product ion of spectrum of m/z 636. Fragmentation pattern is in agreement with a non-
oxygenated GSH adduct of TA. 
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Figure 3.7 Mass chromatograms and spectra from incubations of 100µM TC with freshly 
isolated rat hepatocytes (6h, 37˚C). Figure shows (A) Total ion current chromatogram 
annotated to show parent drug and two oxygenated GSH adducts. (B) Product ion 
chromatogram of m/z 587. The two major peaks represent glutathione adducts of TC; (C) 
Product ion spectrum of peak with rt 14.26. Fragmentation pattern is in agreement with a 
GSH adduct of TC S-oxide. (D)  Product ion spectrum of peak with rt 14.26. Fragmentation 
pattern consistent with a GSH adduct of hydroxy TA. 
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3.4 Discussion 
 
The work described in this chapter aimed to address several questions. The first of 
these concerned the bioactivation of the thiophene moieties in isolated rat 
hepatocytes. This model has been used successfully in many investigations of the 
relationships between drug metabolism/bioactivation and hepatotoxicity (Castell et 
al., 1997; Graham et al., 2008; Lauer et al., 2009; Williams et al., 2007). GSH 
adducts of all four compounds were detected, suggesting that reactive intermediates 
were formed from each. Although glutathione conjugates can be converted to 
mercapturates via an entirely intrahepatic pathway (Hinchman et al., 1994; 
Srivastava et al., 2010), the relatively low hepatic -glutamyltranspeptidase activity 
in rats will tend to limit degradation of the conjugates by these isolated hepatocytes 
(Josch et al., 1998), and particularly perhaps at high drug concentrations (Hinchman 
et al., 1991). In addition, further metabolism by dipeptidase of any cysteinylglycine 
intermediate produced by -glutamyltranspeptidase, a cell surface enzyme, would 
require uptake into the hepatocytes (Josch et al., 1998); a process that might be 
compromised in suspensions of isolated cells. Therefore it is probable that GSH 
adduct recovered from a rat hepatocyte incubation is representative of the total 
amount formed.  Chen et al. (2002) noted that raloxifene, a fully substituted 
benzothiophene, was eliminated in rat bile and urine as a GSH adduct and 
mercapturate, respectively, but they found only the GSH adduct in rat hepatocytes.  
 
A thiophene S-oxide glutathione adduct of MP with a similar fragmentation pattern 
to the one portrayed in this chapter was produced in rat liver microsomes (Chapter 
two). The same metabolite has also been found in rat bile (Graham, 2007). Two 
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oxygenated glutathione adducts of 2-PT are described in this chapter. The more 
abundant adduct appears to have been formed via an epoxide of the thiophene ring, 
and the minor adduct via an S-oxide. Work by Dansette et al. (2005) using rat liver 
microsomes from -naphthoflavone induced rats and human CYP1A1 Supersomes 
has previously detected similar metabolites. This was the first evidence that P450 
could catalyse both S-oxidation and epoxidation of a single thiophene. In the isolated 
rat hepatocyte model used here, TC was also metabolised to two glutathione adducts 
via an epoxide and S-oxide. Both adducts have been reported previously in 
experiments with human liver microsomes and GSH supplementation (Lim et al., 
2008). The thiophene S-oxide GSH adduct of TC has also been found in rat hepatic 
S9 fraction and was identified as the main biliary adduct in rats following TC 
administration (Shimizu et al., 2009). TA produced a non-oxygenated GSH adduct 
as detected previously in the bile and urine of TA-treated rats (Nishiya et al., 2008a). 
TA has previously been reported as being oxidised by P450. Investigations using 
deuterated TA in CYP2C9 Supersomes and rat liver microsomes from clofibrate-
treated rats detected a mono-oxygenated GSH TA adduct with [M+1]
+
 at m/z 654 
(Belghazi et al., 2001). Both formation of an S-oxide and epoxide intermediate were 
postulated as possible routes of GSH adduct formation. The authors also reported 
finding a GSH adduct similar to that reported in this chapter (m/z 636) and surmised 
that is had been formed via dehydration and rearomatisation of the mono-oxygenated 
GSH adduct. This deduction may provide an explanation for the non-oxygenated 
GSH adduct of TA described here.  
 
The metabolism of all the compounds described in this chapter have been reported 
previously either in vivo and ex vivo (MP, TA and MP) or in vitro alone (2-PT). The 
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findings reported here represent the first comprehensive ex vivo study of how 
bioactivation and bioinactivation of thiophene compounds is linked to cytotoxicity. 
When incubated in the absence of ABT or DEM, MP exhibited the highest 
cytotoxicity. Both TC and TA displayed IC50 values of over 500µM. Addition of 
ABT (1 mM) and DEM (1 mM) to incubations produced varied responses. ABT is a 
mechanism-based inactivator of P450 (Ortiz de Montellano et al., 1981) that is 
generally regarded as a non-specific inhibitor of P450 isoforms but it nevertheless 
demonstrates considerable selectivity for inhibition of the major human isoforms 
(Emoto et al., 2005; Linder et al., 2009). Thus 1 mM ABT effectively destroys 
CYP2A6 and CYP3A4 in human liver microsomes but eliminates only 
approximately 40% of CYP2C9 activity (Emoto et al., 2005; Linder et al., 2009). 
Selective inhibition by ABT of the isoforms in rat liver microsomes has not been 
reported – CYP4F1 and CYP4F4 are equally susceptible (Xu et al., 2004)– but is a 
reasonable expectation. There is some evidence of selective inhibition in the livers of 
rats dosed chronically with ABT (Isayama et al., 2003) but the relevance of these 
findings to isolated hepatocytes is uncertain. While ABT is invaluable for identifying 
a P450-mediated contribution to metabolism and hepatocytotoxicity in vitro 
(Graham et al., 2008; Martin et al., 2009; Williams et al., 2007), it cannot be 
assumed that any remaining enzymatic activity or biological effect after ABT 
pretreatment is non-P450 mediated. DEM is an avid substrate for glutathione S-
transferase in rat liver (Boyland et al., 1967), and 1 mM DEM depletes the GSH in 
isolated male rat hepatocytes by approximately75-90% after 30-60 min (Dicker et 
al., 1986; Larrauri et al., 1987). DEM enhances the cytotoxicity of diverse chemicals 
that are bioactivated in rat hepatocytes (Jurima-Romet et al., 1991; Nakagawa et al., 
2009; Nakagawa et al., 1992). Higher concentrations (2-5 mM) are hepatocytotoxic 
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(Miccadei et al., 1988; Tirmenstein et al., 2000) but not even 90% depletion of GSH 
by 1 mM DEM is sufficient in itself to cause ATP depletion (Nakagawa et al., 2009), 
lipid peroxidation (Tirmenstein et al., 2000) or cell injury as measured either by 
release of lactate dehydrogenase (Tirmenstein et al., 2000) or trypan blue exclusion 
(Nakagawa et al., 1992). Therefore it is unlikely the toxicity of MP (Graham et al., 
2008) and TA (Takagi et al., 1991) in rat hepatocytes is caused directly by the GSH 
depletion produced by these drugs. 
 
The most striking difference in toxicity was exhibited in MP incubations, where a 
significant attenuation of toxicity was observed at 200µM and 500µM following 
general inhibition of P450 by ABT, suggesting that bioactivation is a vital step in the 
hepatotoxicity of MP. This was also evident in incubations of MP and DEM. Pre-
depletion of GSH significantly reduced the IC50 of MP from 152µM to 88µM. This 
implies that the balance between bioactivation and bioinactivation is vital to 
protection from MP-induced hepatotoxicity. The P450 isoform responsible for 
bioactivation of MP is not yet known. Enzyme inhibition and induction work 
proposed a role for CYP2C11 (Ratra et al., 1998), but this has not been corroborated. 
The hepatotoxic potential of MP in the rat is well established, and the toxicological 
consequences of metabolic activation of MP have been described previously (Mercer 
et al., 2009). Chronic (150m/kg/day) dosing of MP leads to zonal GSH depletion in 
the periportal region, and elevated levels of serum ALT, GLDH, AST and ALP. 
Downstream functional effects included the induction of heme-oxygenase and 
glutamate cysteine ligase, both proteins associated with cell defence. The findings 
reported in this chapter conform with the published work on the metabolism and 
toxicity of MP in rat models (Graham et al., 2008; Mercer et al., 2009).  
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Inhibition of P450 by ABT had little effect on the IC50 of 2-PT, but did produce a 
significant increase in viability at higher concentrations. Pre-depletion of GSH with 
DEM significantly decreased the IC50 of 2-PT to 153µM. The toxicity of 2-PT has 
not previously been described, either in animal or human models. If we use 2-PT as a 
paradigm compound for thiophene drugs, these results imply that oxidation of the 
thiophene ring to an S-oxide or epoxide have toxicological consequences. Whilst 
both metabolites are described in rat hepatocytes in this chapter and previously in rat 
liver microsomes (Dansette et al., 2005), metabolism by human CYP1A1 
Supersomes altered the ratio of adduct formation in favour of the S-oxide GSH 
adduct (Dansette et al., 2005), suggesting a role for CYP1A1 in thiophene S-oxide 
formation. The results from incubations with DEM highlight the crucial role of GSH 
in detoxification and cell protection.  
 
The hepatotoxicity of TC has not been investigated extensively; the focus tends to lie 
on the potential for TC to cause agranulocytosis and thrombocytopenia (Liu et al., 
2000; Nishiya et al., 2009), or the ability to inhibit CYP2C19 by mechanism-based 
inhibition (Nishiya et al., 2009). The findings in this chapter therefore present the 
first investigation into TC hepatotoxicity in a rat model. Concentration-dependant 
toxicity was observed with a IC50 of 352µM. The presence of ABT actually 
aggravated the toxicity, suggesting that either parent drug or a metabolite not 
produced by an inhibited enzyme may be responsible for toxicity. For example, if 
metabolism to lactam or hydroxyl metabolites is favoured under normal conditions, 
and addition of 1mM ABT selectively inhibits this route of metabolism, then 
oxidation to S-oxide or epoxide may instead become favoured, producing more 
reactive metabolite. Depletion of GSH with DEM also caused a greater decrease in 
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cell viability compared to TC alone. These results suggest that in these conditions, 
TC is successfully detoxified by GSH conjugation, therefore inhibition of P450 does 
not attenuate toxicity, whereas depletion of GSH enhances toxicity by removing a 
route of detoxification. This proposition is supported by the presence of two GSH 
adducts observed in incubations of rat hepatocytes with TC alone as described in this 
chapter.  
The results of incubations of TA presented here suggest it was the least 
hepatocytotoxic compound tested, with the highest IC50. Inhibition of P450 by 
preincubation with ABT had little effect on the toxicity, perhaps because the 
particular isoenzyme responsible for bioactivation was not inhibited, or because all 
reactive intermediate formed in incubations of TA alone is successfully detoxified 
under incubation conditions. This explanation would satisfy the resultant 
enhancement of TA toxicity observed in incubations containing DEM. Notably, 
Acosta et al. (1982) reported that TA at concentrations between 1 µM and 1 mM was 
“minimally toxic” in hepatocytes isolated from neonatal rats; in which basal hepatic 
P450 activities are lower than those in adult rats (Acosta et al., 1982; Lupp et al., 
2008). Pre-depletion of GSH caused an increase in toxicity compared to TA alone, as 
exhibited by the reduction in IC50 from 563µM to 316µM. The data suggests a 
similar picture to that observed in TC incubations in that inhibition of P450 does not 
attenuate the toxicity, but depletion of GSH causes a greater decrease in cell viability 
than drug alone. This indicates a functioning route of detoxification via GSH 
conjugation, which is disrupted by predepletion of GSH, leaving the cell vulnerable 
to damage by reactive intermediates. The toxicity of TA has been investigated 
previously in isolated rat hepatocyte suspensions using LDH leakage as an endpoint 
(Higaki et al., 1989). TA (3mM) was incubated with hepatocytes and found to 
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reduce cell viability to 0% after 60min incubation time. When compared to three 
other diuretics not containing the thiophene moiety, it was found to be the most toxic 
in the model. TA hepatotoxicity has also been assessed in vivo (Nishiya et al., 
2008b). TA was administered to Sprague-Dawley rats both alone and in combination 
with the glutamate cysteine ligase inhibitor, buthionine sulphoximine (BSO). When 
administered alone, the effects of TA were limited to gene expression changes and 
variations in bilirubin and bile acid concentrations observed at the highest dose of 
TA (1g/kg) from 3h to 24h following dose. In combination with BSO, striking 
elevations in serum alanine aminotransferase and alkaline phosphatise were 
observed, as well as centrilobular necrosis. This in vivo data correlates well with the 
ex vivo data presented here: high concentrations of TA are required to produce 
evident hepatotoxicity, however depletion of GSH markedly increases the toxicity by 
removing the ability for deactivation/detoxification of the reactive intermediate.  
 
 
The findings described in this chapter suggest that the combination of isolated rat 
hepatocytes and LC-MS is an excellent methodology for assessing the formation of 
GSH adducts from thiophene-containing compounds. Gan et al. (2009) have shown 
using human liver microsomes that there appears to be a general trend between the 
extent of thiol adduct formation from drugs and the potential for drug-induced 
toxicity when dose and total daily reactive metabolite burdens are considered. The 
rat hepatocyte model could be improved in terms of elucidating hepatotoxic potential 
by assessing earlier end points of cytotoxicity other than loss of membrane integrity 
as is indicated by the trypan blue exclusion assay. However, the cell membrane of a 
rat hepatocyte can be rendered 93-100% permeable to trypan blue by toxin treatment 
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which does not produce gross damage to the cell surface and causes only low 
(22%) leakage of lactate dehydrogenase and minimal disruption of intracellular 
morphology (McEwen et al., 1985).  Whilst this model proves useful as an animal ex 
vivo model for assessing bioactivation and hepatotoxic potential, prediction of drug-
induced liver injury in the patient population is still incredibly difficult (Obach et al., 
2008; Kalgutkar et al., 2009). Parallel investigations in different animal and human 
systems should be used to complement each other and produce a broader picture of 
hepatotoxic potential. The following chapter looks at the consequences of thiophene 
bioactivation by P450 isoenzymes for toxicity in a human liver endothelial cell line.  
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CHEMICAL AND BIOCHEMICAL ASPECTS OF DRUG INDUCED LIVER INJURY 
CHAPTER FOUR 
AN INVESTIGATION OF 
BIOACTIVATION AND TOXICITY OF 
THIOPHENES IN THLE-CYP CELL LINES 
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4.1 Introduction 
 
The previous chapter described a rat hepatocyte model for assessment of thiophene 
bioactivation and toxicity which could potentially be used in preclinical investigations of 
drug-induced liver injury (DILI).  However, the complexity of DILI calls for a battery of 
complimentary assays and models in order to assess the many different aspects involved, 
such as mitochondrial dysfunction (Labbe et al., 2008), drug metabolism (Park et al., 2005), 
P450 inhibition (Fowler et al., 2008), cell defence systems (Copple et al., 2010) and 
involvement of the immune system (Lavergne et al., 2008). The model described in the 
previous chapter and many other cell-based models use short-term cytotoxicity as a predictor 
for hepatotoxic potential (Dambach et al., 2005). An approach that exploits this indicator 
uses cultured cells, whether immortalised cell lines or primary cultures from isolated 
hepatocytes. The use of human cells has obvious benefits over animal cell models as they 
are potentially more reflective of patients (Gomez-Lechon et al., 2007). Whereas 
immortalised cell lines lose their metabolic capacity to a greater or lesser extent, primary 
cultured hepatocytes maintain many physiological functions when cultured under 
appropriate conditions, including expression of drug metabolising enzymes (Hewitt et al., 
2007).  
In order to overcome the loss of metabolic enzyme expression in immortalised cell lines and 
in order to develop a viable alternative to isolated hepatocytes several cell lines have been 
transfected with cDNA encoding drug metabolising enzymes. Cell lines used have included 
human HepG2 cells (Goldring et al., 2006), murine hepatoma cells (Puga et al., 1990) and 
Chinese hamster V97 lung cells  (Doehmer, 1993). However, the P450 expression in these 
cells is often transient and of low level when compared to hepatocytes. Recently, a human 
liver epithelial cell line (THLE-5b), has been stably transfected with cDNA of P450s using 
simian virus 40 and a cytomegalovirus  promoter. Whilst these cells have a hepatocyte-like 
phenotype, expressing high levels of Phase 2 metabolising enzymes they do not express high 
levels of P450. When transfected as described above, the THLE-CYP cell lines express 
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comparable levels of P450 to human hepatocytes (Mace et al., 1997). By engineering several 
cell lines expressing single human P450s, there is scope for investigating the role of discrete 
P450 enzymes in the metabolism and cytotoxicity of drugs.  
 
Investigations have found that 90% of all drugs are metabolised by human P450 enzymes 
(Watkins, 1990). Six isoforms are responsible for 95% of this metabolism (CYP3A4, 
CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP1A1/2) with CYP3A4 being responsible 
for 65% of this total (Zimmerman, 1999). In terms of their involvement in DILI, several 
P450‟s have been linked to formation of reactive metabolites. For example, CYP2E1 has 
been implicated in the formation of N-acetyl benzoquinone imine from paracetamol (Lee et 
al., 1996), along with CYP3A4 and CYP1A2 (Laine et al., 2009).  
 
Investigations into the role of specific P450 enzymes in the bioactivation of thiophene drugs 
and non-drug xenobiotics have shown the involvement of several isoforms. Monoxygenated 
GSH adducts of 2-phenylthiophene (2-PT; Table 3.1) formed via both a thiophene S-oxide 
and thiophene epoxide have been observed in incubations of 2-PT with CYP1A1 
Supersomes (Dansette et al., 2005). Significant toxicity was only observed in freshly 
isolated rat hepatocytes at higher concentrations (500µM and 1mM) of 2-PT (chapter 3). 
Tienilic acid (TA) has been shown to be metabolized by recombinant CYP2C9 to a 
thiophene S-oxide (Belghazi et al., 2001), and CYP2C9 has been shown to be inactivated by 
reactive metabolites of TA (Lopez-Garcia et al., 2005; Lopez-Garcia et al., 1994). In many 
patients suffering from TA-induced hepatitis, anti-LKM2 antibodies directed against 
CYP2C9 were observed (Beaune et al., 1987; Homberg et al., 1984); which suggested a role 
for CYP2C9 in the hepatotoxicity associated with TA. Suprofen, a thiophene-containing 
anti-inflammatory drug associated with nephrotoxicity, has also been shown to be a suicide 
inhibitor of CYP2C9, due to the formation of a thiophene epoxide intermediate (O'Donnell 
122 
 
et al., 2003). TA was the least toxic thiophene examined in isolated rat hepatocytes. 
Significant toxicity was observed at 500µM and 1mM (chapter 3). 
Suicide inhibition of P450 enzymes has also been observed with ticlopidine, clopidogrel and 
prasugrel, thiophene-containing PY212 antagonists. Ticlopidine and clopidogrel are 
mechanism-based inhibitors of CYP2C19, whereas their thiolactone metabolites inhibit 
CYP2C19 only in a concentration-dependent manner (Nishiya et al., 2009b). CYP2B6 was 
inactivated by ticlopidine and clopidogrel and the thiolactone metabolites of ticlopidine, 
clopidogrel and prasugrel (Nishiya et al., 2009a). A thiophene S-oxide dimer metabolite of 
ticlopidine has also been observed in incubations with CYP2C19 (Ha-Duong et al., 2001), 
indicating that this enzyme is responsible for bioactivation of ticlopidine.  
The P450 enzyme responsible for bioactivation of methapyrilene remains elusive. Previous 
investigations in the rat (Ratra et al., 1998a; Wrighton et al., 1991) have suggested a role for 
CYP2C11, the male rat ortholog of human CYP2C9, but this has not been confirmed. 
Methapyrilene is toxic to freshly isolated rat hepatocytes (chapter 3) and cultured primary rat 
hepatocytes (Beekman et al., 2006) but not to mouse hepatocytes (Graham et al., 2008). 
The use of a panel of THLE cell lines expressing single P450 representing some of the most 
prevalent isoforms involved in drug metabolism presents an opportunity to address the role 
of human P450 isoforms in the metabolism and cytotoxicity of thiophene compounds, and to 
evaluate the place of such an assay in preclinical DILI investigations.  
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4.2 Materials and Methods 
 
4.2.1 Materials 
 
PMFR-4 medium was purchased from Millipore (Watford, UK). GlutaMAX (dipeptide 
substitute for L-glutamine), G418 (geneticin), foetal bovine serum (FBS) and trypsin-EDTA 
were purchased from Invitrogen (Paisley, UK). Methapyrilene (MP), and 2-phenylthiophene 
(2-PT) were purchased from Sigma-Aldrich (Poole, Dorset, UK). Tienilic acid (TA) was a 
gift from Molecular Toxicology, AstraZeneca, (Alderley Park, Cheshire, UK).  Solvents 
were purchased from either VWR (Lutterworth, Leicestershire, UK) or Fischer Scientific 
(Loughborough, Leicestershire, UK). Unless otherwise stated, all reagents were purchased 
from Sigma-Aldrich. THLE-CYP cell lines were obtained by AstraZeneca under license 
from Nestec Ltd., Switzerland. 
 
4.2.2 THLE-CYP Cell Culture 
PMFR-4 medium was supplemented with the following reagents, values in parentheses refer 
to final concentration: GlutaMAX (2mM), ITS liquid media supplement (1.75µM), 
hydrocortisone (0.2µM), epidermal growth factor (5ng/ml), bovine pituitary extract 
(15µg/ml), retinoic acid (0.33nM), FBS (3%) and G418 (150µg/ml). 
Cells were thawed from a vial contained 1 x 10
6
 cells, and seeded in a BioCoat T75 flask 
(BD Biosciences, San Jose, CA, USA) in freezing medium (10% DMSO in 1:1 PMFR-4: 
FBS). Cells were left to attach for 4 hours at 37˚C in 5% CO2, and medium was removed and 
replaced with fresh FBS-containing medium. Cells were then incubated at 37˚C in 5% CO2 
and medium was replaced every 2-3 days until a confluent monolayer was formed.  
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4.2.3 THLE-CYP Cell Incubation Regime 
 
To perform the toxicity assay, cells (15x10
3
 cells per 200µl well), were firstly plated in 96-
well plates using the following procedure. Medium was removed and cells were washed 
thoroughly with Hank‟s balanced salt solution (HBSS) (without magnesium, calcium or 
Phenol Red; Invitrogen, UK). HBSS was then removed by aspiration and 1ml 0.025% 
trypsin-EDTA was added. Cell detachment usually took place after 2 min and was 
confirmed under a microscope. Medium (8ml) was added to harvest the cells. An aliquot 
(50µl) of cells was combined with 50µl 0.4% trypan blue solution and the cell number per 
millilitre was determined. Cells were diluted to a concentration of 75 x 10
3
 cells/ml and 
200µl was added to each well (15000 cells per well). Cells were left to adhere for 24h (37˚C, 
5% CO2). 
Stock solutions of compounds (MP, TA, 2-PT, chlorpromazine) were made up in 0.4% 
DMSO at a concentration of 250mM. Serial dilutions were performed using PMFR-4 
medium (without FBS supplement) to achieve required concentrations. DMSO concentration 
was maintained throughout at 0.4%. Following cell adherement, the medium was removed 
and replaced with drug-containing medium. Incubations were performed in triplicate. 
Assessment of toxicity was performed at either 24h or 72h. In the case of 72-h exposure, 
medium was replaced with fresh drug-containing medium at 48h. Chlorpromazine was used 
as a positive control for toxicity measurements (Greer et al., 2010).  
 
4.2.4 Assessment of Toxicity of Thiophenes in THLE-CYP Cell Lines 
 
Toxicity was determined using the CellTiter 96
®
 Aqueous One Cell Proliferation Assay Kit 
(Promega, Southampton, UK). Medium was combined with 3-(4,5-dimethylthiazol-2-yl)-5-
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(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) solution at a ratio of 
5:1 (v/v). Following the drug exposure period, drug-containing medium was removed 
(retained for LC-MS analysis), and replaced with 120µl of medium:MTS mixture. MTS was 
added to 3 three empty wells to act as blanks. Following 1-h incubation, 100µl of medium 
was removed and pipetted into a non-collagen coated 96-well plate, ensuring no bubbles 
were formed. Absorbance was read at 490nm on a Wallac EnVision Spectrophotometer 
(PerkinElmer).  
 
4.2.5 Preparation of Samples for LC-MS Analysis 
 
An equal volume of ice-cold ACN was added to the cell supernatant from 500-µM 
incubations of each thiophene compound removed prior to MTS assay. Samples were kept at 
-80˚C until needed. Prior to LC-MS analysis, samples were centrifuged at 14000rpm for 
5min and the supernatant was retained for analysis.  
4.2.6 Analysis of Thiophene Metabolism in THLE-CYP Cell Lines 
 
Aliquots of the solution (20-100µl) were chromatographed at room temperature on either a 
Prodigy 5-m ODS-2 (C-18) column (150  4.6 mm i.d.; Phenomenex, Macclesfield, 
Cheshire, UK) or a Gemini 5-µm C-18 column (250 x 4.6mm i.d.; Phenomenex, 
Macclesfield, Cheshire, UK), using the chromatographic conditions outlined in table 4.1. 
Analyses were carried out on an API 2000 mass spectrometer (Applied Biosystems, 
Warrington, Cheshire, UK) operated in the positive mode. Q1 scans were acquired using the 
following conditions: curtain gas (CUR) setting, 20; ionspray voltage (IS), 5.5 kV; 
temperature (TEM), 400˚C; ion source gas 1 (GS1) setting, 20; ion source gas 2 (GS2) 
setting, 75; declustering potential (DP), 20 V; focusing potential (FP), 200 V and entrance 
potential (EP), 10 V.  
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Table 4.1. Chromatographic conditions used for LC-MS analysis of  MP, 2-PT and TA. 
Thiophene Column Eluent A Eluent B Flow 
rate 
Gradient 
MP Gemini 10mM ammonium 
acetate 
100% ACN 1ml/min 0min 100% A,  
5min 100% A,  
25min 30% A 
30min 30% A 
33min 100% A 
34min 100% A 
2-PT Prodigy 0.1% formic acid 100% MeOH 1ml/min 0min 100% A 
5min 100% A 
25min 20% A 
30min 20% A 
31min 100% A 
TA Prodigy 0.1% formic acid 100% MeOH 1ml/min 0min 90% A 
5min 90% A 
23min 25%A 
29min 25%A 
30min 90% A 
35min 90% A 
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4.3 Results 
 
4.3.1 Toxicity of Thiophene Compounds in THLE-CYP Cell Lines 
 
Following a 24-hr exposure period, only TA produced any decrease in viability in any cell 
line: approximately a 50% reduction in viability was observed in all cell lines, including the 
NULL cell line (no P450 expressed), at 500µM. No P450-dependent toxicity was observed 
for any of the thiophene compounds, although the CYP3A4 cell line appears to show 
consistently lower viability for all four compounds (including the positive control, 
chlorpromazine) (Fig 4.1). Elongating the exposure period to 72hr did not affect the toxicity 
of 2-PT in any cell lines (Fig 4.2A). Cell viability of CYP3A4, CYP2D6 and CYP1A2 cell 
lines was reduced by 500µM MP following 72-hr exposure, hinting at possible slow 
developing, P450-dependant, toxicity at high doses of MP (Fig 4.2B). The toxicity of TA 
was exacerbated in all cell lines by prolonged exposure (72hr) (Fig 4.2C). As reported by 
Greer et al. (2010), chlorpromazine was toxic to NULL cells and all of the THLE-CYP cell 
lines. 
 
4.3.2 Bioactivation of Thiophene Compounds in THLE-CYP Cell Lines 
 
Details of metabolites observed can be seen in table 4.2. Incubations of 500µM 2-PT in the 
CYP1A2 cell line produced the only detected GSH adduct after both 24-h and 72-h 
incubations (Fig 4.3A & B). This adduct (m/z 484) was previously described in this work 
(chapter 3) and in incubations of human CYP1A1 Supersomes and rat liver microsomes 
(Dansette et al., 2005), where an S-oxide dimer was also reported. The same S-oxide dimer 
(m/z 353) was only observed following a 24-hr incubation of 500µM 2-PT with THLE cells 
expressing CYP2C9 (Fig 4.3C). Conversely, the S-oxide dimer was not observed in 72-h 
incubations with the CYP2C9 cell line (Fig 4.3D). Incubations of all cell lines with TA (both 
24h and 72h) failed to produce a GSH adduct, neither an oxygenated (m/z 652) nor a non-
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oxygenated adduct (m/z 636) as reported in chapter 3. Hydroxyl TA (OH-TA, m/z 347) was 
not observed in any incubation. A previously reported oxygenated GSH adduct of 
methapyrilene (chapter 2 and 3) (Graham et al., 2008) was not identified in 24-h or 72-h 
incubations of MP in any THLE-CYP cell line. However, both hydroxyl MP (m/z 278) (Fig 
4.4) and desmethyl MP (m/z 248) (Fig 4.5) were found in all cell lines, after either 24h, 72h 
or both (Table 4.2).  
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Figure 4.1 Dose response curves showing % cell viability compared to control in five 
THLE-CYP cell lines (NULL, CYP1A2, CYP2C9, CYP2D6 and CYP3A4) following 24-
hr exposure to (A) 2-PT, (B) MP, (C) TA and (D) chlorpromazine. Cell viability was 
assessed using the CellTiter 96® Aqueous One Cell Proliferation Assay Kit (Promega, 
Southampton, UK). Data points show mean of at least three triplicate assays and error bars 
indicate standard error of the mean.  
A B
C D
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Figure 4.2 Dose response curves showing % cell viability compared to control in five 
THLE-CYP cell lines (NULL, CYP1A2, CYP2C9, CYP2D6 and CYP3A4) following 72-
hr exposure to (A) 2-PT, (B) MP, (C) TA and (D) chlorpromazine. Cell viability was 
assessed using the CellTiter 96® Aqueous One Cell Proliferation Assay Kit (Promega, 
Southampton, UK). Data points show mean of at least three triplicate assays and error bars 
indicate standard error of the mean.  
 
 
 
 
A B
C D
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Table 4.2. Metabolites found in 24-h and 72-h incubations of 500µM MP, 2-PT and TA (in 
0.4% DMSO) with five THLE-CYP cell lines: NULL (no P450 expressed), CYP1A2, 
CYP2C9, CYP2D6 and CYP3A4. „x‟ indicates that the metabolite was observed in an LC-
MS analysis of the corresponding incubation. The stated m/z values refer to [M+1]
+
 ions of 
the following metabolites: for TA, m/z 347, OH-TA; m/z 636, TA-SG; m/z 652, TA[O]SG;; 
for 2-PT, m/z 484, 2-PT[O]SG; m/z 353, 2-PT S-oxide dimer; for MP, m/z 585, MP[O]SG; 
m/z 278, OH-MP; m/z 248, desmethyl MP.  
 NULL CYP1A2 CYP2C9 CYP2D6 CYP3A4 
TIENILIC ACID 24h 72h 24h 72h 24h 72h 24h 72h 24h 72h 
m/z 347                      
m/z 636                      
m/z 652                      
                      
  NULL CYP1A2 CYP2C9 CYP2D6 CYP3A4 
2-PHENYLTHIOPHENE 24h 72h 24h 72h 24h 72h 24h 72h 24h 72h 
m/z 484     x x             
m/z 353         x           
                      
  NULL CYP1A2 CYP2C9 CYP2D6 CYP3A4 
METHAPYRILENE 24h 72h 24h 72h 24h 72h 24h 72h 24h 72h 
m/z 585                     
m/z 278 x  x x x x x x x x x 
m/z 248 x x x x x x x x x x 
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Figure 4.3 Extracted mass chromatograms from incubations of 500µM 2-PT with THLE-
CYP cell lines. (A) Extracted mass chromatogram of m/z 484 from 24-h incubation of 
500µM 2-PT with THLE-CYP1A2 cell line showing presence of GSH adduct with rt 
4.73min; (B) Extracted mass chromatogram of m/z 484 from 72-h incubation of 500µM 2-
PT with THLE-CYP1A2 cell line showing presence of GSH adduct with rt 4.84min; (C) 
Extracted mass chromatogram of m/z 353 from 24-h incubation of 500µM 2-PT with THLE-
CYP2C9 cell line showing presence of S-oxide dimer with rt 6.25min; (D) Extracted mass 
chromatogram of m/z  353 from 72-h incubation of 500µM 2-PT with THLE-CYP2C9 cell 
line showing lack of S-oxide dimer.  
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Figure 4.4 Extracted mass chromatograms of m/z 278 (hydroxyl MP) from incubations (24h 
and 72h) of 500µM MP with five THLE-CYP cell lines: NULL (no P450 expressed), 
CYP1A2, CYP2C9, CYP2D6 and CYP3A4. Hydroxyl MP was observed in all cell lines 
with an rt of between 7.25min – 7.35min. 
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Figure 4.5 Extracted mass chromatograms of m/z 248 (desmethyl MP) from incubations 
(24h and 72h) of 500µM MP with five THLE-CYP cell lines: NULL (no P450 expressed), 
CYP1A2, CYP2C9, CYP2D6 and CYP3A4. Desmethyl MP was observed in all cell lines 
with an rt of between 7.29min – 7.37min. 
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4.4 Discussion 
 
 
The work described in this chapter aimed to evaluate the role of several P450 enzymes in the 
metabolism and toxicity of thiophene-containing drugs and non-drug xenobiotics. A panel of 
THLE cell lines expressing single human P450s or none (NULL, CYP1A2, CYP2C9, 
CYP2D6 and CYP3A4) were exposed to either MP, 2PT or TA for a period of 24h or 72h 
and the cytotoxicity and metabolism of those compounds was assessed.  
Following 24-h exposure, only TA showed any cytotoxicity. In all cell lines, 250µM TA 
reduced cell viability by approximately 25% compared to control. However, the observed 
toxicity was not accompanied by the formation of any of the drug‟s known metabolites. 
Although a 72-h exposure to TA increased the susceptibility of the cells to cytotoxicity, 
again, no metabolites were observed in any cell line. The sensitivity of the NULL cell line to 
TA suggests that the toxicity observed was not due to formation of metabolites The lack of 
TA metabolism in the CYP2C9 cell line is puzzling. As mentioned previously, CYP2C9 has 
been implicated in the bioactivation of TA (Belghazi et al., 2001),  so the presence of GSH 
adducts would be expected in the THLE-CYP2C9 cell line. It may be the case that the MS 
methods were not sensitive enough to detect GSH adducts. It could also be possible that the 
majority of reactive metabolites formed were bound to cellular proteins and therefore not 
detected as GSH adducts, reactive metabolites of TA have previously been shown to bind to 
and inactivate human CYP2C9 (Lopez-Garcia et al., 2005), however, as this did not appear 
to be the case in the rat hepatocyte incubations described in chapter 3. GSH adducts of TA 
have successfully been identified previously (Lim et al., 2008), so such a phenomenon is 
only likely to occur due to lack of GSH or GST enzymes in these cell lines, which has not 
been explored. However, an investigation into the role of Phase 2 metabolising enzymes on 
MDMA detoxification successfully defined a role for COMT and GST enzymes using 
THLE cells (Antolino Lobo et al., 2010).  
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No toxicity was observed following 24-h exposure to MP. Longer exposure (72h) lead to a 
decrease in cell viability in CYP1A2, CYP2D6 and CYP3A4 cell lines at the highest 
concentration of MP (500µM). As with TA, this toxicity was not accompanied by the 
formation of any reactive intermediates stabilized as GSH adducts. However, unlike TA, two 
metabolites of methapyrilene, desmethyl MP and hydroxyl MP, were observed in all cell 
lines at both 24h and 72h. These metabolites are formed by rat hepatocytes (Graham et al., 
2008). The lack of toxicity of MP in the NULL cell line suggests a role for certain P450 
enzymes in the reduction of cell viability that was observed. It may be the case that human 
P450 enzymes do not bioactivate MP to a reactive metabolite. Through its years in clinical 
use, no human adverse events were reported, and investigations into MP‟s hepatotoxicity 
and carcinogenicity have mainly been performed in the rat (Craig et al., 2006; Graham et al., 
2008; Kammerer et al., 1986; Lijinsky et al., 1980; Ratra et al., 1998b; Ratra et al., 2000). 
The toxicity seen in these THLE-CYP cell lines could be due to parent drug effects. As with 
TA, it may be the case that any reactive metabolite formed favoured protein covalent 
binding as opposed to GSH adduct formation. MP has previously been shown to form 
covalent adducts with cellular proteins (Graham, 2007).  
 
The least cytotoxic compound tested was 2-PT. No decrease in cell viability was observed in 
any cell line, following either 24-h or 72-h exposure. Despite this, 2-PT was the only 
thiophene to produce a detectable GSH adduct in this system, in the CYP1A2 cell line. 
Following both 24- and 72-h exposure, an oxygenated GSH adduct of 2-PT (m/z 484) was 
observed. An S-oxide dimer was also v visible in the mass chromatographic analysis of a 24-
h incubation of CYP1A2 cell line with 2-PT. Previous work with human Supersomes has 
shown a role for human CYP1A1 in formation of GSH adducts of 2-PT via both thiophene 
S-oxide and thiophene epoxide intermediates (Dansette et al., 2005). Human CYP1A1 and 
CYP1A2 share 72% amino acid sequence identity (Goldstone et al., 2006), and have 
previously been shown to metabolise similar substrates (Arlt et al., 2004; Stiborova et al., 
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2005). The lack of toxicity in the THLE-CYP1A2 cell line associated with formation of 
thiophene S-oxide and epoxide intermediates could be due to a number of factors. Although, 
as described in the previous chapter, 2-PT cytotoxicity was detected in incubations with 
freshly isolated rat hepatocytes, there were many differences between the conditions and 
methods used in that work and the procedures described in this chapter. The cytotoxicity 
„end point‟ used for the work reported in chapter three was a loss of membrane integrity as 
assessed by the trypan blue assay, whereas in this investigation, mitochondrial viability was 
assessed using a tetrazolium dye assay (Promega, Southampton, UK). A comparison of cell 
viability assays showed that use of tetrazolium dye assay can overestimate the number of 
viable cells compared with trypan blue determination (Wang et al., 2010). It could also be 
that formation of GSH adducts conferred protection from reactive metabolites, and that in 
the case of 2-PT, any thiophene S-oxide or epoxide intermediate formed was successfully 
detoxified and that the GSH adducts detected represent a portion of reactive intermediate, 
large enough that damage from any residual intermediate does not result in observable 
cytotoxicity.  
Comparisons between metabolic and toxicological results obtained in this chapter and the 
previous chapter is difficult for several reasons. Method, length of exposure and the end 
point of the experiment were different in both cases. It is however interesting to note the 
homology of the human enzymes investigated in this chapter and their rat counterparts. Rat 
CYP1A2 is 88% homologous to the human form. The rat form of human CYP2C9 is know n 
as CYP2C11 and is 87% homologous. Rat CYP2D4 is 75% homologous with human 
CYP2D6 and the rat counterpart of human CYP3A4 is called and CYP3A9 and is 88% 
homologous. 
The results gained with these cell lines do not enable extrapolation to link a single P450 
enzyme with the bioactivation and toxicity of any of the compounds investigated. Single-
P450 cells have an obvious potential limitation in respect of investigating the metabolic 
origins of toxicity: cells expressing single P450 will not reveal a cytotoxicity that depends 
on bioactivation by two or more P450 acting sequentially. The extent to which this is a 
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significant limitation on use of THLE-CYP cells for metabolism/toxicity screening is 
unknown, however carbamazepine has been shown to undergo sequential P450-catalyzed 
bioactivation reactions in HLM incubations (Bu et al., 2007), but the number and operational 
sequence of the P450s involved are unknown. The lack of detection of GSH adducts might 
have been a result of intracellular covalent binding as mentioned above, or because the 
amount of adduct formed was too small to be detected by the MS methods described in this 
chapter. It could also have been due to low metabolic capacity of the cells, either in phase 1 
or phase 2 metabolism. However, the phase 1 metabolic capacity of the THLE-CYP cells 
was assessed by Molecular Toxicology (AstraZeneca, UK) using probe substrates and the 
P450-Glo™ luminescence assay (Promega, Southampton, UK).  The probe substrates used 
were phenacetin (CYP1A2), diclofenac (CYP2C9), bufurarol (CYP2D6) and verapamil 
(CYP3A4), and confirmed P450 activity in all cell lines. Phase 2 enzyme activity has also 
been described in THLE cell lines (Antolino Lobo et al., 2010). 
Despite the low cytotoxicity of thiophene compounds observed here, THLE-CYP cells have 
previously been shown to display cytotoxicity with chlorpromazine (Greer et al., 2010). 
Chlorpromazine was found to be toxic to THLE-1A2, -2C9, -2D6, -3A4 and –null cells at 
following 24h exposure, but it was much more toxic to THLE-3A4 cells than the other cell 
types over 72h.  
 
The findings reported in this chapter have indicated that a detailed assessment of the 
toxicological usefulness of THLE-CYP cells will require, firstly, an understanding of the 
role of their GSH and GST in detoxification of reactive metabolites. GSH depletion is an 
important factor in hepatotoxicity (Comporti et al., 1991) and has been observed in 
investigations into mechanisms of several hepatotoxins (Kitteringham et al., 2000), and 
detection of GSH depletion may be key in to the diagnosis of an altered redox state or of 
formation of reactive metabolites. Serum biomarkers to assess tissue GSH levels and help to 
reveal the effects of drug administration on GSH biochemistry would be an excellent tool in 
preclinical evaluation, and could potentially be extrapolated to the clinic. 
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CHAPTER FIVE 
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5.1 Introduction 
 
The previous two chapters have focused on formation of glutathione (GSH) adducts as a 
marker of bioactivation of thiophene molecules. The potential of GSH adducts and their 
metabolites to serve as biomarkers of exogenously and endogenously derived electrophilic 
intermediates, and thereby as disease and toxin-exposure biomarkers, has been reviewed  
(Blair, 2010). Bioactivation to reactive metabolites is often, though not invariably, 
associated with drug-induced liver injury (DILI) in patients (Srivastava et al., 2010), usually, 
it is thought, by initiating primary changes within the cell from which damage and cell death 
can lead. These primary changes may be oxidative stress – characterised typically by lipid 
peroxidation and changes in thiol status – and covalent binding to macromolecules, with 
immediate consequences that include enzyme inhibition and mitochondrial damage 
(Timbrell, 2000). Although some reactive oxygen species play a physiological role in 
intracellular signalling (Forman et al., 2010), the appearance of excessive reactive oxygen 
species and of organic electrophiles such as reactive drug metabolites provokes a defensive 
response from the cell (Nguyen et al., 2009; Copple et al., 2010). This response is centred on 
the upregulation of phase-II metabolism enzymes and those responsible for production and 
maintenance of GSH, enabling the cell to restore its redox and electrophile status. GSH is 
critical to maintenance of a cell‟s redox and electrophile status (Forman et al., 2009), 
playing a protective role via three mechanisms: conjugation to reactive species by 
glutathione-S-transferases, non-enzymic reaction to form GSH adducts and donation of 
protons to reactive metabolites or free radicals. GSH is found at high concentrations (5mM) 
in the liver and in addition to performing a variety of other functions (Cho et al., 1984; 
Pallardo et al., 2009) must be available within a cell to quench excessive electrophilic 
species and prevent oxidative stress; thereby averting covalent modifications – adduction 
and oxidation – of critical cellular proteins (Park et al., 2005).  
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GSH arises within the cell via synthesis from its precursor L-amino acids (Bloch et al., 
1947): glutamate, cysteine and glycine. It is formed in a two-step process catalysed by two 
discrete enzymes. The first and rate-limiting step involves the conjugation of glutamate and 
cysteine to form γ-glutamylcysteine by glutamate cysteine ligase (GCL) (Meister et al., 
1983). This enzyme is regulated by feedback inhibition from GSH. The second step, 
catalysed by glutathione synthetase, is the addition of glycine to the cysteine residue forming 
GSH (See fig 5.6 for an overview of GSH metabolism). The free sulphydryl group on the 
cysteine residue is the crucial moiety in GSH biochemistry. It can act as an electron donor, a 
reductant and as a scavenger of free radicals. Nucleophilic addition or substitution reactions 
of the GS
- 
thiolate ion (Graminski et al., 1989), catalysed by glutathione transferases, lead to 
formation of glutathione S-conjugates, excreted principally in bile but also in urine (Johnson 
et al., 2005), whereas reactions involving reduction catalysed by enzymes such as GSH 
peroxidase give rise to glutathione disulphide. The use of N-acetylcystein-S-yl 
(mercapturate) metabolites of GSH adducts as non-invasive biomarkers of electrophile 
exposure has been reviewed (Jian et al., 2009). GSH peroxidase enzymes utilise reduced 
GSH to reduce hydrogen peroxide, lipid peroxides and organic hydroperoxides, protecting 
DNA, proteins and lipids from oxidative damage (Awasthi et al., 1975; Hou et al., 1996; 
Sies et al., 1997). To maintain a reducing environment within the cell, glutathione reductase 
utilises NADPH to convert glutathione disulphide back to the reduced form.  
For a number of drugs for which glutathione conjugate formation takes place, the reactive 
metabolites do not appear to exert toxicity as long as the cellular pool of glutathione is not 
depleted. Toxicity occurs when the cellular pool of GSH is depleted to below a critical 
threshold, due to overdose or saturation of other clearance pathways, as is the case with the 
analgesic, acetaminophen (APAP). 
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There is a lack of an accurate and convenient preclinical test for this toxicity threshold. A 
serum biomarker reflective or indeed predictive of hepatic GSH depletion would be an ideal 
tool both in drug safety studies and potentially in the clinic. The potential of biomarkers to 
improve the progress of clinical research and to reduce attrition in drug development is 
becoming widely acknowledged. Biomarkers, in this context, can be defined as changes in 
DNA, mRNA, protein or metabolite levels that correlate with particular disease states or are 
reflective of drug treatment. An ideal biomarker would be detected in biological material 
obtainable by non-invasive or minimally invasive procedures, such as saliva, blood or urine, 
and be amenable to rapid, specific and sensitive assay, as well as being proportionately 
reflective of the tissue injury sustained. Ideally, it should be predictive of toxicity, and 
therefore, in human subjects, allow avoidance of the onset of any irreversible injury. In order 
to be useful when bridging studies in basic science, drug development and in the clinic, the 
ideal biomarker should be transferable across in vitro, in vivo and clinical systems.  
 
A recent metabolomic study identified a potential biomarker of hepatic GSH depletion in 
mouse serum by capillary electrophoresis and mass spectrometry (Soga et al., 2006). Male 
C57BL6 mice were fasted overnight prior to anaesthetising with pentobarbital sodium and 
administration of 150mg/kg APAP (i.p.). The authors detected a significant increase in the 
abundance of an unknown ion at m/z 290.135 in the serum and liver of the APAP-treated 
animals. Through tandem mass spectrometry, they defined this ion as ophthalmic acid (OA), 
an analogue of GSH. The mass deficit between the unknown ion and GSH was 17.958Da, 
concordant with replacement of the sulphydryl group on the cysteine residue with the methyl 
group of 2-aminobutyrate (2-AB). The authors suggest that this increase in the serum 
concentration of OA is due, firstly, to depletion of the GSH pool, removing the feedback 
inhibition on GCL and increasing the activity of this enzyme. They then propose that due to 
a decreased cysteine pool, GCL instead recruits 2-AB and forms γ-glutamylaminobutyrate, 
the precursor for OA, which is then effluxed out of the hepatocyte (Fig 5.6). Through the use 
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of diethylmaleate (DEM), they were able to reproduce this effect, i.e. a rise in serum OA 
reflective of a hepatic GSH decrease. Administration of the GCL inhibitor buthionine 
sulphoximine depleted hepatic GSH, but was not accompanied by an increase in hepatic OA, 
implying that GCL is also the crucial enzyme in formation of the latter. They concluded that 
monitoring serum OA levels could facilitate the detection of several pathologies  – not just 
DILI –  such as Alzheimer‟s, Parkinson‟s, cardiac infarction and diabetes, in which 
oxidative stress is thought to play an important role. 
 
OA was first isolated from calf lens in 1956 (Waley, 1956) and was discovered to be 
synthesised via a two-step process that is similar to the biosynthesis of  GSH (Cliffe et al., 
1958; Cliffe et al., 1961). Subsequent studies detected OA in the lens of several other 
species (Tsuboi et al., 1984) and later in rat liver (Kasai et al., 1989). Little research has 
been conducted into the physiological role of OA in the liver, with the majority of 
investigations focusing on GSH transport processes. OA has been shown to stimulate GSH 
efflux from freshly isolated rat hepatocytes (Garcia-Ruiz et al., 1992) and to both stimulate 
and inhibit GSH transport across bile canalicular membranes (Ballatori et al., 1994). As 
mentioned previously, GSH and OA are synthesised in a two-step process from glutamate, 
either cysteine or 2-AB, and glycine (Meister, 1989). Glutamate is synthesised from 
glutamine and 2-ketoglutarate, and is recycled via the γ-glutamyl cycle. Glycine is formed 
from serine and tetrahydrofolate. Cysteine is synthesised from the essential amino acid 
methionine via homocysteine and cystathionine. 2-AB is also formed from methionine, via 
excision of 2-ketobutyrate from cystathionine. This is then transaminated with either serine 
or threonine to create 2-aminobutyrate. Both OA and GSH are reliant on the activity of GCL 
and glutathione synthetase. The Km values of the rate-limiting enzyme, GCL, towards 2-AB 
and cysteine are 1.0mM and 0.3mM, respectively (Seelig et al., 1985).  
The aim of the work described in this chapter was to evaluate the usefulness and 
limitations of serum OA concentration as a biomarker of hepatic GSH consumption 
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using models of hepatic GSH depletion and OA stability. Serum OA and hepatic OA 
were measured, and where possible, compared to hepatic GSH and a classic 
biomarker of liver injury, serum alanine transaminase (ALT) activity. In kinetic and 
stability studies, 2-AB concentrations were also monitored.  
The following models were used: 
 
 Acute APAP exposure in male C57BL6 mice 
 Chronic APAP exposure in male Wistar rats using an infusion pump 
 
 Acute exposure of anaesthetised male Wistar rats to DEM 
 
 Definition of serum kinetics of OA in male Wistar rats following a single 
intravenous dose 
 
 Stability of OA in serum and tissue homogenates from untreated male Wistar rats. 
 
The GSH depleting agents used were APAP and DEM. APAP is often used as a model 
hepatotoxin. It is bioactivated by P450 enzymes to a reactive metabolite, N-acetyl p-
benzoquinone imine, which is detoxified via GSH conjugation (Mitchell et al., 1973a). In 
overdose, this route of elimination results in depletion of hepatic GSH, which may herald the 
onset of APAP-induced injury (Mitchell et al., 1973b). Indeed, treating APAP overdose with 
N-acetylcysteine to replace cysteine and therefore restore GSH concentrations can prevent 
liver injury from proceeding (Prescott et al., 1977). Acute dosing of APAP to mice has 
classically been used as a model to study DILI. Rats are more resistant to APAP-induced 
liver injury (Moldeus, 1978), and therefore require chronic or very high dosing to produce 
an effect useful for studying the consequences of APAP-induced GSH depletion. DEM is 
also a model hepatotoxin, used mainly for its ability to deplete hepatic GSH rapidly and 
extensively following acute dosing (Gerard-Monnier et al., 1992). 
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5.2 Materials and Methods 
 
 
5.2.1 Materials 
 
Ophthalmic acid (OA) was purchased from Bachem (Rhein, Germany). 2-Aminobutyrate (2-
AB), acetaminophen (APAP), urethane, [remove] and diethylmaleate (DEM) were 
purchased from Sigma-Aldrich (Poole, Dorset, UK). Bradford reagent was purchased from 
Bio-Rad (Germany). Solvents were purchased from either VWR (Lutterworth, 
Leicestershire, UK) or Fischer Scientific (Loughborough, Leicestershire, UK). Unless 
otherwise stated, all the other reagents were purchased from Sigma-Aldrich. 
 
5.2.2 Animals 
 
Adult male Wistar rats and adult male C57BL6 mice were obtained from Charles River 
Laboratories (Margate, Kent, UK). All experiments were undertaken in accordance with 
criteria outlined in a license granted under the Animals (Scientific Procedures) Act of 1986 
and approved by the Animal Ethics Committee of the University of Liverpool.  
 
 
5.2.3 Investigation into the effects of acute APAP dosing on serum OA levels in 
male C57BL6 mice 
 
At time-point zero, male C57BL6 (20-25g) mice were dosed intraperitoneally (i.p.) with 
either 530mg/kg APAP or with saline vehicle (control). Table 5.1 details the dosing regime. 
At various time points upto 6h, animals were euthanised with rising levels of CO2. Blood 
was sampled via cardiac puncture, and livers were removed and snap frozen in liquid 
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nitrogen and then stored at -80˚C until analysis. Blood samples were stored overnight at 2-
4˚C to allow clotting to take place. Serum was then removed and stored at -80˚C until 
analysis. 
 
Table 5.1. Regime for acute APAP dosing in male C57BL6 mice 
Group 
Number of 
Animals 
Dose Euthanised 
0h 4 530mg/kg APAP 0h 
0h control 4 0.9% Saline 0h 
1h 4 530mg/kg APAP 1h 
1h control 4 0.9% Saline 1h 
2h 4 530mg/kg APAP 2h 
2h control 4 0.9% Saline 2h 
6h 4 530mg/kg APAP 6h 
6h control 4 0.9% Saline 6h 
 
 
5.2.4. Investigation into the effects of chronic APAP dosing on serum OA levels 
in male Han Wistar rats using chronic infusion.  
(The study described here was carried out in conjunction with AstraZeneca, Alderley Park, 
UK) 
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Adult male Han Wistar rats were anethetised and cannulated via the femoral vein. Following 
recovery (seven days was allowed for animals to recover from surgery), vehicle (saline) 
(n=3) or APAP (6mg/ml) (n=3) was infused into the femoral vein cannula at a constant rate 
(3ml/kg/hr) for 48hr.  Blood samples (300µl) were taken via the tail vein at 3h, 5h, 24h, 30h 
and 36h. Plasma was extracted via centrifugation (1300g, 10min) and stored at -80°C until 
analysis. Following termination of infusion, animals were euthanized by administration of 
halothane, and approximately 2ml of blood removed via the vena cava. Approximately 3mm 
thick slices will be taken from the left,median and caudate lobes. In addition a 3mm sample 
will be removed from the left lobe, frozen in liquid nitrogen, then stored at approximately -
80°C for analysis of GSH. 
5.2.5. Investigation into the effects of acute DEM dosing on serum OA levels 
and hepatic GSH levels in male Wistar rats using plasma sampling and 
liver biopsy. 
 
Adult male Wistar rats (200-300g) were anesthetised with urethane (1.4g/ml in 
saline; 1.0ml/kg i.p.) and cannulated via the trachea and carotid artery. A 3-cm 
incision was made in the abdomen and covered with saline-soaked gauze to allow 
access to the liver when required. The carotid artery cannula was filled with heparin-
containing saline (250U/ml). A predose blood sample (100µl, via carotid artery) and 
liver sample were taken 5min before administration of DEM. DEM (1ml/kg; 1.064 
g/kg) (n = 4) was administered i.p. Blood samples (100µl)  were taken via the carotid 
artery cannula simultaneously with liver biopsy at 15min, 30min 45min and then 
every 15min until 2h when animals were euthanized. Liver biopsy samples (20-
40mg) were snipped from the left lateral lobe and were snap frozen in liquid nitrogen 
and then stored at -80˚C until analysed for OA and GSH levels. Plasma was 
extracted via centrifugation (1300g, 10min) and stored at -80˚C until analysed. 
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5.2.6. Investigation into the serum kinetics of OA in vivo in the rat 
Adult male Wistar rats (200-300g) were anesthetised with urethane (1.4g/ml in 
saline; 1.0ml/kg i.p.) and cannulated via the trachea, common bile duct, femoral vein 
and carotid artery. Carotid artery cannula was filled with heparin-containing saline 
(250U/ml). A predose blood sample (100µl) was taken via the carotid artery cannula 
10min prior to dosing. Bile was sampled for 10min prior to dose OA (100mg/kg in 
0.9% saline) (n = 4) was administered i.v. via the femoral vein. Volume of 
administration was kept between 200-300µl and was administered over 5min. Blood 
samples (100µl) were taken via the carotid artery cannula at 5min, 10min, 20min, 
30min and then every 30min until 3h when animals were euthanized. The penis was 
ligated and bladder contents removed for analysis at the termination of study. . 
Plasma was extracted via centrifugation (1300g, 10min). Plasma, bile and urine were 
then stored at -80˚C until analysed.  
 
5.2.7 Determination of stability of OA in rat serum and tissue homogenates 
 
OA (10mM in dH2O) was spiked into serum, whole liver homogenate and whole kidney 
homogenate from untreated male Wistar rats to give a final concentration of 100µM OA and 
kept at room temperature. Homogenates were obtained by homogenising approximately 
40mg of tissue in cold phosphate buffer (pH 7.4, 1:4 w/v). The homogenate was then briefly 
sonicated (6min in three 2min blasts) before being subject to centrifugation (2200 rpm, 
5min). Supernatants were retained for analysis. At various time intervals up to 24h, 10µl was 
removed and subjected to analysis of OA and 2-AB concentration as outlined below Spiking 
of OA was performed in triplicate. 
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5.2.8  Determination of OA and 2-AB concentrations via LC-MS/MRM.  
 
Sample preparation 
 
Sample (10µl) was diluted with 30µl H2O and 200µl acetone to precipitate proteins. S-
hexylglutathione (S-hex) was used as an internal standard: 10µl of 12.5µM aqueous S-hex 
was added, to give a final concentration of 0.5µM. Standards (OA or 2-AB) were prepared 
for analysis in a similar way. An aqueous solution of standard (10µl) at 25-fold the final 
concentration was added to 20µl H2O and 10µl 20mg/ml bovine serum albumin. Acetone 
(200µl) was added to precipitate protein. Standards and samples were kept at -20˚C for 1h, 
before centrifugation at 14, 000rpm for 10min. Supernatant was retained and acetone was 
removed under a vacuum. Finally, 200µl 0.1% aqueous formic acid was added to all 
standards and samples.  
 
LC-MS/MRM Conditions 
Aliquots of the standards and samples (50µl) were chromatographed on an Uptisphere ODB 
120Å 5µm column (100 × 2mm) (Interchim, Montluçon, France), using a gradient of 0-80% 
MeOH in 0.1% formic acid over 30min at a flow rate of 0.2ml/min (PerkinElmer 200 series 
LC pump and autosampler, PerkinElmer, UK). Column temperature was maintained at 40˚C. 
Analyses were carried out on an API 3000 mass spectrometer (Applied Biosystems, 
Warrington, Cheshire, UK) operated in the positive-ion mode. Multiple reaction monitoring 
(MRM) acquisitions were performed using the optimized conditions outlined in table 5.2 and 
the following unoptimized conditions: nebuliser gas setting, 20; curtain gas (CUR) setting, 
10; collision gas setting, 8; ionspray voltage (IS), 5.5 kV; source temperature (TEM), 350˚C.  
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Table 5.2. MRM conditions for detection of OA, 2-AB and S-hex 
Analyte Q1 m/z  Q3 m/z  Declustering 
potential 
(V) 
Focusing 
potential 
(V) 
Collision 
cell 
entrance 
potential 
(V) 
Collision 
cell exit 
potential 
(V) 
OA 290.440 58.00 61 280 47 16 
S-hex 392.093 246.5 36 200 23 16 
2-AB 104.45 58.00 76 370 15 16 
 
 
 
 
Instrument operation and data processing were performed through Analyst 1.4 software 
(Applied Biosystems). To determine either the OA or 2-AB concentration, peak areas of 
samples and standards were first normalised against the S-hex peak area. A standard curve 
was then constructed and used to determine OA and 2-AB concentrations in the biological 
samples.  
 
5.3.9 Determination of hepatic GSH concentrations 
 
Hepatic GSH levels were determined using a microtitre plate assay (Vandeputte et 
al., 1994). Briefly, approximately 50 mg of tissue was homogenised in 5-
sulphosalicyclic acid (200 l; 6.5 % w/v) and GSH stock buffer (800 l; 143 mM 
NaH2PO4, 6.3mM EDTA, pH 7.4) and the protein was allowed to precipitate on ice 
for 10 min prior to centrifugation (18400g for 5 min).  The supernatants were used to 
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determine the total GSH and GSSG content.  Total GSH (GSH + GSSG) was 
determined spectrophotometrically using 5,5'-dithio-bis(2-nitrobenzoic acid), 
NADPH and GSH reductase at 412 nm.  The results were compared to GSH 
standards (0-40 nmol/ml).  Protein pellets were solubilised in 1M NaOH for 1h at 
60C before the protein concentration was determined (Bradford, 1976).  
 
5.3.10 Determination of serum alanine transferase (ALT) activity 
 
Plasma was prepared by centrifugation (10000rpm, 5min) after the blood was allowed to clot 
at room temperature for 1 hr. ALT was measured using the ThermoTrace Infinity ALT 
Liquid stable reagent (Alpha Labs, Eastleigh, Hampshire, UK) according to the 
manufacturer‟s instructions. 
 
 
5.3.11. Statistical Analysis 
 
All statistical analyses were carried out using StatsDirect software (StatsDirect Ltd., 
Altrincham, UK). Data were first assessed for normality using the Shapiro-Wilk test. Normal 
data were subjected to analysis of variance and Bonferroni comparison. Non-normal results 
were compared using the Mann-Whitney test. A value of p≤0.05 was taken as significant in 
all cases. 
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5.3. Results 
 
5.3.1.Investigation into the effects of acute APAP dosing on serum OA levels in 
male C57BL6 mice 
 
Animals were treated in groups of four, receiving one intraperitoneal dose of either 
530mg/kg APAP (in saline) or an equivalent volume of saline. Following euthanasia at 
either 0h, 1h, 2h or 6h, serum was analysed for ALT activity and OA concentrations. Liver 
was analysed for total GSH concentration. Results from the ALT analyses show a significant 
elevation above control only at the 6-h time point for APAP-treated animals (Fig 5.1A). 
However, hepatic GSH levels in APAP-treated animals were significantly depleted 
immediately to 41% of the mean time-matched control value (18.50nmol/mg protein vs. 
7.63nmol/mg protein), dropping to only 5% of the time-matched control value 
(23.15nmol/mg protein vs. 1.36nmol/mg protein) at 2h following dosing (Fig 5.1B). Serum 
OA concentrations in APAP-treated animals were increased in a similar pattern to serum 
ALT levels: only at 6h following APAP dosing were OA concentrations increased 
significantly compared to time-matched controls (0.6034µM vs. 0.0834µM) (Fig 5.1C). 
 
5.3.2. Investigation into the effects of chronic APAP dosing on serum OA levels 
in male Wistar rats using chronic infusion 
During the infusion period (6mg/ml APAP at 3ml/kg/hr; 18mg/kg/hr) blood samples were 
taken at 3h, 5h, 24h, 30h, 36h and 48h and analysed for OA concentration. Following 
termination at 48h, blood was removed from the vena cava and analysed for ATL activity. 
Hepatic GSH concentration was also determined. Serum concentrations of OA remained 
within a 10nM for the first 5h of infusion. From 24h to 36h, serum OA concentrations rose 
from 178nM to 689nM, an increase of 387%. Following 48h of infusion, serum OA had 
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increased sharply from predose levels (101nM) to 6.8µM. Terminal serum ALT activity was 
also determined and compared to that of control animals (Fig 5.2). ALT activity in animals 
receiving APAP infusion was 689.33U/L compared to 24.5U/L in control animals. Terminal 
hepatic GSH in APAP-treated animals was depleted by 50% compared to controls (19.46 vs. 
38.87nmol/mg protein) (Fig 5.2). 
 
5.3.3 Investigation into the effects of acute DEM dosing on serum OA levels and 
hepatic GSH levels in male Wistar rats using plasma sampling and liver 
biopsy. 
Male Wistar rats were anaesthetised (1ml/100g 14% urethane i.p.) followed by cannulation 
via the trachea and carotid artery which allowed for frequent blood sampling from the same 
animal. Blood samples and liver biopsies were taken simultaneously to enable time-matched 
comparisons of serum OA concentrations and hepatic total GSH concentrations. Predose 
samples and liver biopsies were taken before animals were dosed intraperitoneally with 
1ml/kg DEM. Samples and biopsies were then taken every 15min until 2h. Serum samples 
were analysed for OA concentration. Liver biopsies were analysed for both GSH and OA. 
Hepatic GSH was depleted significantly to a mean of 29% of predose value at 15min post 
dose and continued to stay significantly depleted over the 2h study (Fig 5.3). No significant 
rise was observed in either serum OA or hepatic OA concentrations over the course of the 2h 
study. However, hepatic OA concentrations did appear to increase over the time period from 
a mean of 58% of predose value at 15min to a mean of 134% of predose value at 2h (Fig 
5.3). 
5.3.4. Investigation into the serum kinetics of OA in vivo in the rat 
 
Following induction of anaesthesia, male Wistar rats were cannulated via the trachea, carotid 
artery, common bile duct and femoral vein. Animals received one dose of 100mg/kg OA via 
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the femoral vein to force an exaggerated increase in serum OA concentrations analogous 
though not necessarily proportionate to one that may potentially follow extensive hepatic 
GSH depletion. Blood and bile samples were then taken over 3h, as well as collection of 
urine. Serum, bile and urine were analysed to determine OA concentrations. Concentrations 
of 2-AB were also determined in serum samples. The greater part of the OA dose was found 
in serum, with a smaller fraction detected in bile (Fig 5.4). The levels of 2-AB were elevated 
above the predose concentration in serum, possibly due to metabolism of OA. OA and 2-AB 
were not detected in the urine. 
Several values for the distribution, elimination and clearance of OA can be calculated (Table 
5.3). Assuming the Cmax to be the value obtained at 5-min sampling (238.46µM), the half-life 
of OA in rat serum is 26.18min. This allows calculation of the elimination rate constant 
using the formula Kel = In2/t1/2. The value for „Kel‟ in this instance would therefore be 
0.026min. Volume of distribution (Vd) can also be estimated. Taking the average weight of 
the male Wistar rats in the study to be 300g, then the average dose given would be 30mg. 
Cmax (238.46µM) can be expressed as 0.069mg/ml, and if Vd = total dose/plasma 
concentration, then in this instance Vd = 30mg / 0.069mg/ml = 434.8ml, or 0.43L.  These 
values allow calculation of initial clearance using the formula Clp = Vd x Kel, which yields an 
estimate for the clearance of OA from plasma of 11.30ml/min.  
5.3.5 Determination of stability of OA in rat serum and tissue homogenates 
Stability of OA was assessed by „spiking‟ synthetic OA into serum, liver homogenate and 
kidney homogenate from untreated male Wistar rats. At various time points, an aliquot was 
analysed for OA and a constituent amino acid, 2-AB. The levels of OA in serum remained 
relatively stable, within a 14.2µM range (19.03 – 33.23µM), for 24h. Concentrations in liver 
homogenate remained stable until 6h (range = 13.3 µM), and then decreased at 24h to 36% 
of the initial value. OA was degraded very quickly in kidney homogenate even at room 
temperature, decreasing to 0.004% of the initial concentration within 30min of spiking (Fig 
accompanied by an increase in the concentration of 2-AB. Whilst the concentration of 2-AB 
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in the serum rose slightly (8.59 – 14.22µM over 24h), the concentration in liver homogenate 
rose steadily to 114% initial value (4.63 – 40.51µM). In kidney homogenate, the steep 
decline in OA concentrations was mirrored by a fast rise in 2-AB concentration, which 
increased from 1.13µM to 13.65µM over 30min, and then to 61.65µM at 24h (Fig 5.5B).  
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Figure 5.1. Effect of APAP dosing on (A) serum ALT activity; (B) total hepatic GSH 
concentration and (C) serum OA concentration in male C57BL6 mice. Mice were treated in 
groups of four, receiving either one i.p. dose of 530mg/kg APAP or equivalent volume of 
saline vehicle. Following euthanasia at the indicated time point, analyses were carried out on 
serum (ALT, OA) and liver (GSH). * p ≤0.05 versus 0h control value, † p ≤ 0.05 versus 
time-matched control. Columns represent mean of n = 4; error bars indicate standard error of 
the mean. 
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Figure 5.2.   Effect of APAP infusion on serum OA concentration, serum ALT activity and 
hepatic GSH concentration in male Han Wistar rats. Animals were treated in groups of three, 
receiving either infusion at 3ml/kg/hr of 6mg/ml APAP or saline vehicle. Blood samples 
were taken and analysed for OA at the indicated time points. Following termination at 48h, 
analyses were carried out on serum (ALT, OA) and liver (GSH). Columns represent mean of 
n ≤ 2; error bars indicate standard error of the mean. 
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Figure 5.3. Effect of 1ml/kg DEM (i.p.) on serum OA, and hepatic OA and hepatic GSH 
levels in anaesthetised male Wistar rats. Animals were anaesthetised with an i.p dose of 
1ml/100g 14% (w/v) urethane and cannulated via the trachea and carotid artery. Blood 
samples (100µl) were taken via the carotid artery cannula simultaneously with liver biopsy. 
Mean predose value (15min prior to dose) for each metabolite was taken as 100% and data 
are presented as percentages of this value. Columns represent mean of four separate 
determinations. Error bars indicate standard error of the mean. *p≤0.05 versus predose 
value. 
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Figure 5.4. Concentrations of OA and 2-AB in serum and bile of male Wistar rats pre 
(10min prior to dose) and post administration of a 100mg/kg i.v. dose of OA. Animals were 
anaesthetised with an i.p dose of 1ml/100g 14% (w/v) urethane and cannulated via the 
trachea, carotid artery, common bile duct and femoral vein. Data points indicate mean of at 
least four separate determinations. Error bars indicate standard error of the mean. * p ≤ 0.05 
compared to 5-min value.  
Table 5.3. Kinetics of OA in serum following 100mg/kg i.v. dose (based on Fig. 5.5) 
Half-life (t1/2) 
(minutes) 
Elimination rate 
constant (Kel) 
(minutes) 
Volume of 
distribution (Vd) 
(ml) 
Clearance (Clp) 
(ml/min) 
26.18 0.026 434.8 11.30 
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Figure 5.5. Concentrations of (A) OA and (B) 2-AB in serum, liver homogenate and kidney 
homogenate that were prepared from untreated male Wistar rats and spiked with Serum and 
homogenates were spiked with 10mM OA to give a final concentration of 100µM OA. OA-
spiked preparations were kept in sealed containers at room temperature and aliquots (10µl) 
removed for analysis at various time points upto 24h. Data points represent mean of three 
separate determinations. Error bars indicate standard error of the mean. * p ≤ 0.05, ** p ≤ 
0.001, compared to 0-min value.  
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5.4. Discussion 
 
 
The results presented in this chapter enable an evaluation of the usefulness of serum OA 
concentration as a biomarker of the GSH depletion associated with DILI. In vivo models 
were used to produce hepatic GSH depletion and serum OA concentrations were monitored 
for consequential perturbations. 
The first of these models was acute dosing of C57BL6 male mice with 530mg/kg APAP. 
Hepatic GSH levels were depleted rapidly, however a significant increase in serum OA was 
only seen at the 6h time point, indicating poor concurrency with GSH depletion. Serum 
transaminase levels were also increased only at 6h following dosing. In this case, whilst 
serum OA levels were increased by a significant amount in animals exposed to APAP, the 
usefulness of this increase as a biomarker is questionable due to the delay after the 
immediate depletion of GSH. These results contrast with those of Soga (Soga et al., 2006). 
Whilst an increase in serum OA levels was observed in both studies, the results presented in 
this chapter show a delay between initial depletion of GSH in APAP-treated mice and 
elevation of serum OA whereas those presented by Soga et al. (2006) show a maximal 
increase in serum OA at 1h post dosing. There are differences in study design which may go 
some way to providing a rational for this difference. Whilst the same strain of mouse was 
studied, the dose level was markedly different: 150mg/kg (Soga et al., 2006) vs. 530mg/kg. 
Mice in the previous study were also starved overnight prior to dosing and were anesthetised 
before APAP administration with pentobarbital (Soga et al., 2006) Neither of these methods 
was used in the work reported here. Starvation of the animals may have influenced the level 
of OA, as OA synthesis relies on methionine, an amino acid which must be obtained from 
the diet (Fig 5.6). Indeed, in rats fed with an excess of methionine (8% casein plus 3% 
methionine), although plasma OA was not detected, liver OA concentrations were shown to 
decrease compared to animals fed 8% casein alone, despite an increase in the plasma levels 
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of the precursor 2-AB. Liver glycine was also reduced and plasma levels of glutamate 
decreased (Kasai T et al., 1989). Starvation has also been shown to influence α-ketobutyrate 
dehydrogenase, leading to a loss of activity of this enzyme in the liver (Steele et al., 1984). 
The authors suggest that inhibition of this enzyme would therefore favour the transamination 
of α-ketobutyrate to 2-AB. The increase in 2-AB caused by fasting may go some way to 
explaining the immediate increase in OA observed by Soga et al. (2006). High levels of 2-
AB caused by fasting and increased activity of GCL through depletion of GSH due to APAP 
administration could have led to the fast formation of OA observed in that case. Presumably, 
the animals in this work would have had lower levels of 2-AB due to having access to food 
prior to dosing. This may mean that OA would take longer to accumulate, therefore 
clarifying the delayed increase in serum OA levels compared to the work published 
previously (Soga et al., 2006). 
  
The second part of the investigations presented here was a monitoring of OA in the serum of 
rats receiving a chronic infusion of APAP. In this case, it was not possible to analyse the 
results statistically. This was because the small blood sample collected at each time point 
meant that quantification of OA could not be carried out on all samples at each time point, 
leaving insufficient data for analysis. However, it is clear that the APAP infusion process 
caused a huge increase in serum OA levels at the later time points, despite the relatively low 
dose of APAP received over the course of the study. This was reflective of the terminal 
hepatic GSH value, which was depleted by 50% in APAP-treated animals versus control. 
Nevertheless, this method did not allow an assessment of how serum OA compared to 
hepatic GSH over the course of the study. Therefore, although the increase in serum OA 
observed is interesting, conclusions cannot be drawn as to how indicative OA serum values 
were of hepatic GSH levels throughout the course of the study.  
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To address this problem, a liver biopsy was taken simultaneously with each blood sample 
after the rats were anesthetised and exposed to the classic GSH depletor, DEM. However, 
although hepatic GSH was depleted to 25% of the predose value by 15min, neither serum 
nor hepatic OA levels reflected this decrease within the 2h study time, wherein hepatic GSH 
remained below 25% of the predose value. It may be, however, as in the C57BL6 mice 
administered APAP, that an elevation of serum OA levels is not seen until more than 2h 
following administration of DEM.  
 
The last section of the work described in this chapter was concerned with kinetics and 
stability of OA. Understanding the routes of elimination and kinetics of OA in serum are 
essential if it is to be a viable biomarker, as this knowledge enables more intelligent 
sampling times as well as going some way to gaining information about the metabolism of 
OA. To mimic an increase in serum OA that might occur following extensive hepatic GSH 
consumption, a large intravenous dose of OA was administered to anesthetised male rats. 
The concentration of OA was monitored in bile, serum and urine. The majority of the dose 
appeared in serum, with a small amount observed in bile. OA was not detected in urine. 
Employing the single-compartment model used in pharmacokinetic studies, values of some 
kinetic parameters were calculated. OA was found to have a half-life in serum of 26.18min. 
This gives a relatively short window of time in which serum samples would be reflective of 
an initial increase in OA. The absence of OA from bile and urine suggests that OA is 
metabolised into constituent parts during transport into these biofluids. Serum and urine 
were also analysed for 2-AB, a constituent amino acid of OA. Whilst small amounts of 2-AB 
were found in the serum, presumably due to catabolism of OA in solid tissues. No 2-AB was 
found in the urine. This is predictable due to the fact that the amino acids filtered by the 
kidney are near completely reabsorbed by the proximal tubule (Verrey et al., 2009). Ex-vivo 
stability studies reported in this chapter show fast metabolism of OA to 2-AB in rat kidney 
homogenate, as well as slower breakdown in rat liver homogenate, suggesting that OA is 
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subject to a metabolic fate similar to that of GSH.  Whereas synthesis of GSH is 
intracellular, its catabolism takes place in the extracellular environment as part of the γ-
glutamyl cycle (Fig 5.6). GSH and presumably OA are transported out of the cell and the 
first stage of metabolism is carried out by the membrane-bound enzyme, γ-
glutamyltranspeptidase, which recruits an amino acid and conjugates it to the glutamate 
residue, releasing cysteinylglycine. γ-Glutamyltranspeptidase is expressed on the apical 
surfaces of transporting epithelia, such as liver canalicular or bile ductular membranes, but 
activity varies from organ to organ, with kidney activity being the highest (DeLap et al., 
1977; Meister et al., 1976). This high kidney activity would account for the absence of OA 
from the urine. This enzyme has very low specificity for the γ-glutamyl donor and it is 
therefore likely that it will also catalyse the release of glutamate from OA to form 
aminobutyrylglycine (Fig 5.6). These dipeptides are then broken down by peptidase 
enzymes and the amino acids are actively reabsorbed into the cell and recycled. The γ-
glutamylaminoacid is then converted to 5-oxoproline (the cyclic form of glutamate) by γ-
glutamylcyclotransferase. 5-oxoproline is converted into glutamate by 5-oxoprolinease, and 
the glutamate can then be recycled (Fig 5.6).  
 
The observations from all the studies reported in this chapter suggest that whilst elevated 
serum OA levels may be an interesting by-product of hepatic GSH consumption, they are 
not consistently reflective of it. OA also does not conform to certain defining characteristics 
for a reliable biomarker of DILI: it is not predictive of liver injury and has proved not to be 
transferable across all animal models of hepatotoxicity. However, it could potentially be 
usual as a reflective biomarker specific to hepatic GSH depletion. The kinetic data presented 
here provides information which could be exploited to calculate optimal sampling times in 
rats. Human parameters can be predicted with good accuracy from animal studies), 
suggesting that OA could be used in both preclinical and clinical safety studies to assess a 
compounds potential to deplete hepatic GSH levels.  
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Figure 5.6. The synthesis and metabolism of GSH and OA 
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6.1. Discussion 
 
The work described in this thesis aimed to investigate if various animal and human 
liver models and analysis by mass spectrometry can be used to establish a link 
between bioactivation and toxicity of thiophene drugs, and how useful these models 
would be as preclinical drug safety tools. This includes the potential use of thiophene 
molecules with well defined chemistry as model hepatotoxins, and whether by 
obtaining integrated metabolic and toxicological data in these models aids in 
exploring structure toxicity relationships. The usefulness of ophthalmic acid (OA) as 
a potential biomarker of hepatic glutathione (GSH) depletion was investigated, with 
a view to exploring biochemical mechanism of DILI, including beginning to define 
the kinetics of OA in serum. 
 
6.2 Development of Methapyrilene as a Model Hepatotoxin 
 
Methapyrilene (MP) is H1 receptor antagonist and was introduced in the 1950s and 
used commonly as a sleeping aid for 25 years until being withdrawn due to 
hepatocarcinogenicity in chronically dosed rats (Lijinsky et al., 1980). The 
carcinogenic effect appears to be non-mutagenic – a negative result is obtained in the 
Ames test – and species specific, with no carcinomas reported in humans, hamsters, 
guinea pigs and mice (Brennan et al., 1982; Reznik-Schuller et al., 1981). As well as 
having carcinogenic effects, dose dependent hepatotoxicity in rats has also been 
reported following both acute (Cunningham et al., 1995; Mercer et al., 2009; Ratra 
et al., 2000) and chronic (Cunningham et al., 1995) dosing in vivo. Being rat 
specific, MP has been used as a model hepatotoxin in both in vivo and in vitro rat 
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models.  Chronic in vivo dosing regimens of between 100mg/kg/day to 
300mg/kg/day for three days produce mild to moderate injury, consisting of necrosis, 
inflammatory cell infiltration and bile duct proliferation. In vitro, MP produces 
concentration dependent toxicity in isolated rat hepatocytes (Graham et al., 2008; 
Ratra et al., 1998b). MP has also been used as model hepatotoxin in systems biology 
studies (Craig et al., 2006; Man et al., 2002). Despite the common use of MP in this 
way, any chemical basis behind the hepatotoxicity associated with MP had yet to be 
defined. MP has several structural alerts with the potential to act as a substrate for 
metabolic bioactivation (Kalgutkar et al., 2005). Previous in vitro studies using 
rabbit liver microsomes and cyanide as a trapping agent, have identified an iminium 
ion as a reactive intermediate of MP (Ziegler et al., 1981), but hepatotoxicity has not 
been noted in the rabbit, and it is unclear how this relates to the use of MP as a 
model hepatotoxin in the rat. Subsequent investigation showed MP toxicity to 
depend upon both bioactivation and presence of the thiophene ring (Graham, 2007; 
Graham et al., 2008; Ratra et al., 1998a). Whilst a GSH adduct had previously been 
reported in in vivo and in vitro investigations, and that the site of GSH conjugation 
was the thiophene ring (Graham, 2007), whether the reactive intermediate involved 
was an epoxide, S-oxide or α,β-unsaturated aldehyde had not been determined. 
Previously, the α,β-unsaturated aldehyde intermediate has only been postulated 
following detection of pyrazine adduct of suprofen following use of semicarbazide 
as a trapping agent (O'Donnell et al., 2003). Epoxide and S-oxide intermediates are 
more widely reported both in vivo and in vitro, in investigations with TA (Belghazi 
et al., 2001; Dansette et al., 1990; Mansuy et al., 1984; Nishiya et al., 2008a) and its 
isomer (Dansette et al., 1991), 2-PT (Dansette et al., 2005) and TC (Lim et al., 2008; 
Shimizu et al., 2009; Wen et al., 2008). The use of LC-MS/MS analysis following 
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incubation of MP with rat liver microsomes allowed us to confirm the site of 
oxidation as the thiophene ring (Fig 2.8). In order to elucidate if the GSH adduct 
detected in this system was the product of an epoxide or S-oxide intermediate, 
hydrogen/deuterium exchange was utilised. A similar method has successfully been 
used in other investigations to determine S-oxides and N-oxides from their hydroxyl 
counterparts (Chen et al., 2009; Liu et al., 2001; Medower et al., 2008). Described in 
chapter 2, the use of hydrogen/deuterium (H/D) exchange and mass spectrometry 
allowed exploitation of  the mass difference between the non-deuterated and 
deuterated GSH adduct of MP formed by rat liver microsomes to determine that the 
reactive intermediate was an S-oxide of the thiophene ring (Fig 2.9, Fig 2.10, Fig 
2.11). Having defined the chemistry of MP bioactivation, this enables a fuller 
understanding of the mechanisms of MP induced hepatotoxicity, and the use of MP 
as a model hepatotoxin. The consequences of the bioactivation of MP to MP S-oxide 
have been investigated (Mercer et al., 2009). Male Wistar rats receiving 
150mg/kg/day for three days experienced zonal GSH depletion in the periportal 
region of the liver and significant increases in serum transaminase levels. Expression 
of proteins associated with cell defence, glutamate cysteine ligase and heme-
oxygenase 1 were also increased (Mercer et al., 2009).  Histology also confirmed the 
presence of apoptotic bodies and necrotic activity as early as 3h. Apoptosis was also 
determined in vitro by assessing cytochrome c release and procaspase activation 
using isolated rat hepatocytes (Mercer et al., 2009). Taken together, the chemical and 
biological evidence inform studies using MP as a model, and provide information 
about the potential of other thiophene containing molecules to illicit a similar 
response. 
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6.3 Thiophene Bioactivation and Toxicity in Hepatic Cell Models 
 
Whilst microsomal incubations can provide information regarding metabolism, their 
use is restricted to this purpose, and indeed is limited due to the lack of co-factors 
present in incubations, which require addition in order to generate metabolites, e.g. 
NADPH and GSH. The use of whole hepatocyte incubations can overcome this 
problem and produce information regarding both Phase I and Phase II metabolism 
without the addition of co-factors. Isolated hepatocytes are recognised as a relevant 
model for studying metabolism, but also transporter interactions (Liu et al., 1999), 
and toxicological potential of molecules (Tirmenstein et al., 2002). Suspension or 
culture of isolated hepatocytes, will, under certain conditions, maintain the entire 
hepatic metabolising system and functional hepatocyte traits (Gomez-Lechon et al., 
2004; Gomez-Lechon et al., 2003; O'Brien et al., 2005). Correlation between human 
hepatocyte metabolic studies and human in vivo outcomes has been shown to be 
good (Ponsoda et al., 2001), but this is not always the case (Fig 2.1). However, 
freshly isolated human hepatocytes are not readily available, and unlike isolated 
animal hepatocytes, are subject to marked inter-individual variability. Although 
cryopreservation and pooling of isolated human hepatocytes has begun to address 
this problem, the use of isolated animal hepatocytes offers an alternative, as fresh 
animal hepatocytes are more straightforward to obtain. By using suspensions, as 
opposed to culture, the incubation can be started soon after isolation when enzymatic 
capability will be highest. This competency will be maintained for up to six hours 
under correct suspension conditions and allows acute investigation of both chemistry 
of metabolism and toxicological endpoints in the same incubation (O'Brien et al., 
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2004; O'Brien et al., 2005). This would enable an integrated exploration of structure 
toxicity relationships.  
Despite presenting simpler culture conditions, hepatoma cell lines represent a limited 
model for studying hepatic metabolism, due to the low expression of metabolic 
enzymes (Donato et al., 2008). However, cell lines such as these have previously 
been used to investigate toxicological potential of molecules (Mersch-Sundermann et 
al., 2004). However, the lack of metabolic competency in hepatoma cell lines means 
that any toxicity due to metabolism could be missed, and therefore development of 
transfected metabolic enzyme systems in hepatoma derived cell lines would provide 
a useful tool for study of the role of metabolism in hepatotoxicity.  Transfected 
human (HepG2) and murine cell lines have been developed with both stable and 
inducible cDNA encoding for both Phase I and Phase II metabolising enzymes and 
cell defence genes (Aoyama et al., 1990; Goldring et al., 2006; Puga et al., 1990), 
however, the P450 expression in these cells is often transient and of low level when 
compared to hepatocytes. A stable transfection with cDNA of P450s using simian 
virus 40 and a cytomegalovirus promoter has recently been developed using a human 
liver epithelial cell line (THLE-5b). These cells have a hepatocyte-like phenotype, 
expressing high levels of Phase 2 metabolising enzymes and when transfected, the 
THLE-CYP cell lines express comparable levels of P450 to human hepatocytes 
(Mace et al., 1997). By engineering several cell lines expressing single human 
P450s, there is scope for investigating the role of discrete P450 enzymes in the 
metabolism and cytotoxicity of drugs.  
 
Both freshly isolated rat hepatocyte suspensions and THLE-CYP cell lines were used 
in this work, both with the aim of evaluating them as models to investigate 
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metabolism dependent toxicity, but also to enhance knowledge of thiophene induced 
hepatotoxicity. Several thiophene containing drugs have been linked with some kind 
of adverse effect in the liver, including, but not limited to, those studied in this work. 
From the same family of platelet aggregation inhibitors as TC, clopidogrel has also 
been associated with hepatotoxicity in patients (Hollmuller et al., 2006), as well as 
inhibition of certain P450 enzymes (Nishiya et al., 2009a; Nishiya et al., 2009b). 
Zileuton, used in asthma therapy, has been shown to cause an increase in serum 
transaminase levels in clinical practice (Watkins et al., 2007).  For both of these 
drugs, there is evidence that bioactivation may be involved. Clopidogrel has been 
shown to form sulfenic acid intermediates (Dansette et al., 2009) and also to inhibit 
CYP2B6 and CYP2C19 via metabolic mechanisms (Nishiya et al., 2009a; Nishiya et 
al., 2009b). Zileuton is thought to form a 2-acetylthiophene S-oxide metabolite, 
capable of alkylating human serum albumin (Joshi et al., 2004; Li et al., 2007). The 
bioactivation of MP, 2-phenylthiophene (2-PT), ticlopidine (TC) and tienilc acid 
(TA) will be discussed in more detail below.  
 
6.3.1 The Use of Isolated Hepatocyte Suspensions to Study Thiophene 
Bioactivation and Toxicity  
 
Chapter three dealt with the use of freshly isolated rat hepatocytes as a model for 
providing integrated information regarding bioactivation and toxicity of xenobiotics, 
using thiophene containing molecules as a paradigm. Freshly isolated rat hepatocytes 
have previously been successfully used as a model for studying bioactivation and 
toxicity (O'Brien et al., 2005; Regan, 2009). The aim of the chapter was not only to 
evaluate this model, but also to provide evidence of a link between metabolism of 
the thiophene ring and onset of hepatocyte damage. The model was further extended 
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to investigate the effect of metabolism on toxicity and of GSH conjugation as a 
detoxification method by pre incubation with 1-aminobenzotrizole (ABT), a P450 
inhibitor, and diethylmaleate, a depletor of GSH.  ABT is a mechanism-based 
inactivator of P450 (Ortiz de Montellano et al., 1981) that is regarded as a non-
specific inhibitor of P450 isoforms, and while ABT is invaluable for identifying a 
P450-mediated contribution to metabolism and hepatocytotoxicity in vitro (Boyland 
et al., 1967; Graham et al., 2008; Martin et al., 2009; Williams et al., 2007), it 
cannot be assumed that any remaining enzymatic activity or biological effect after 
ABT pretreatment is non-P450 mediated. DEM (1mM) depletes the GSH in isolated 
male rat hepatocytes by approximately 75-90% after 30-60 min (Dicker et al., 1986; 
Larrauri et al., 1987). 
The decision to choose to study 2-PT, despite it not being a therapeutic molecule was 
taken due to the evidence that 2-PT is bioactivated in vitro to both an epoxide and S-
oxide intermediate. Analysis by LC-MS and NMR of incubation of 2-PT with both 
rat liver microsomes from β-napthoflavone induced rats and human CYP1A1 
supersomes confirmed presence of two oxygenated GSH adducts of 2-PT, formed 
via a thiophene epoxide and a thiophene S-oxide intermediate (Dansette et al., 2005). 
The results obtained here from incubations of 2-PT with freshly isolated rat 
hepatocytes produced a similar metabolic profile (Fig 3.5). No previous studies have 
been carried out to investigate whether 2-PT induces hepatocytotoxicity, and 
whether this toxicity is metabolism dependent. Pre-depletion of GSH with DEM 
significantly reduced the IC50 of 2-PT, bringing to light the importance of 
detoxification pathways in thiophene toxicity. If we use 2-PT as a paradigm 
compound for thiophene drugs, these results imply that oxidation of the thiophene 
ring to an S-oxide or epoxide have toxicological consequences. 
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 As previously discussed, TA was withdrawn for the market following cases of 
autoimmune hepatitis, characterised by circulation of anti-LKM2 antibodies 
(Homberg et al., 1984). Although the bioactivation of TA to a thiophene S-oxide 
intermediate has been extensively studied (Belghazi et al., 2001; Dansette et al., 
1991; Mansuy et al., 1984), as well its ability to inhibit CYP2C9 (Lopez-Garcia et 
al., 2005; Lopez-Garcia et al., 1994), linking this bioactivation to toxicity has proved 
more difficult.  Recently, GSH was shown to be a critical component in TA 
hepatotoxicity in vivo (Nishiya et al., 2008b). Male Sprague-Dawley rats were 
administered either buthionine-sulfoximine (BSO) - a glutamate cysteine ligase 
inhibitor, and therefore depletor of GSH - prior to TA administration, or were treated 
with TA alone. In groups receiving BSO, serum transaminases, bilirubin and bile 
acids were significantly increased over the animals receiving TA alone. A similar, 
although not significant, effect was also observed in ex vivo investigations in chapter 
three of this work. Cytotoxicity of TA to freshly isolated rat hepatocyte suspensions 
was increased when hepatocytes were co-incubated with the GSH depletor, 
diethylmaleate (DEM) (Fig 3.3 D), suggesting GSH is involved in protection from 
TA hepatotoxicity. This is backed up by the observation of GSH adducts in the 
freshly isolated rat hepatocyte model (Fig 3.6). This report is the first to describe a 
decrease in cell viability and to detect GSH adducts of TA in the same ex vivo 
incubation, therefore providing evidence of a link between TA bioactivation and 
hepatocyte damage, and a crucial role for GSH in protection from this injury. 
MP was withdrawn from the market due to reports of rat hepatic carcinomas 
(Lijinsky et al., 1980). The hepatotoxic effects in rats have been investigated, 
including its potential to cause oxidative stress and disrupt mitochondrial function 
(Ratra et al., 1998b) and to cause zonal depletion of GSH (Mercer et al., 2009). The 
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connection between bioactivation of MP in the rat and cytotoxicity is substantiated 
by several studies. Inhibition of P450 by cobalt protoporphyrin IX afforded 
protection against MP induced liver injury in vivo (Ratra et al., 1998a). Pre-
incubation with the P450 inhibitor 2-aminobenzotriazole (ABT) attenuated 
hepatotoxicity in freshly isolated hepatocytes incubated with MP (Graham, 2007). 
The results obtained in this work from suspensions of freshly isolated hepatocytes 
incubated with MP are in keeping with previously reported findings, both alone and 
following pre-incubation with both ABT and DEM (Graham, 2007; Mercer et al., 
2009). 
The data presented on the hepatotoxicity of TC in chapter three is a novel 
demonstration of the cytotoxic effects of TC in a rat liver model. It is also the first 
report describing both hepatotoxicity of TC and formation of GSH adducts in the 
same model, as well as the first observation of simultaneous formation of two GSH 
adducts formed via both epoxidation and S-oxidation of the thiophene ring (Fig.3.7). 
The hepatotoxicity observed in freshly isolated hepatocytes was not attenuated by 
pre-incubation with ABT, but was increased by pre-incubation with DEM (Fig. 
3.3D). This suggests that GSH is vital to protection from TC induced hepatotoxicity, 
presumably by conjugation to reactive metabolites. It also suggests that addition of 
ABT may inhibit an alternative, non-reactive route of metabolism, therefore 
increasing the proportion of TC being converted to a reactive metabolite to over a 
threshold that can be coped with by detoxification processes. 
In terms of thiophene metabolism, the aim in chapter three was to determine if the 
xenobiotics were bioactivated in the rat hepatocyte model used. However, using 
product ion scans, it was possible to ascertain more information regarding the 
chemistry of bioactivation, including the identification of a GSH adduct formed from 
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the previously described S-oxide metabolite of MP (Fig 3.4), both a hydroxyl GSH 
adduct, formed via and epoxide intermediate and an S-oxide GSH adduct of 2-PT, as 
described by Dansette et al (2005) (Fig 3.5), and both an hydroxyl GSH adduct and 
S-oxide GSH adduct of TC (Fig 3.7), in keeping with the literature (Lim et al., 2008; 
Shimizu et al., 2009; Wen et al., 2008) Previously however, these two metabolites 
have not been detected simultaneously. A non-oxygenated GSH adduct of TA was 
also detected (Fig 3.6). This GSH adduct has previously been described (Belghazi et 
al., 2001; Nishiya et al., 2008a). Here, the authors suggest that an S-oxide 
intermediate is formed, but that loss of H2O across the thiophene ring accounts for 
the resulting non-oxygenated GSH adduct. 
The presence of previously described metabolites of all four thiophene compounds 
stands to provide evidence that freshly isolated hepatocyte suspensions are a useful 
tool in metabolic profiling and metabolism. The ability to identify metabolic profile, 
assess toxicological potential and understand the importance of bioactivation and 
detoxification by use of ABT and DEM in one incubation affords a large amount of 
information which when visualised as a whole, provides an integrated picture of the 
chemistry of reactive metabolites and the hepatotoxic potential this bioactivation 
may cause. However, due to the short time scale in which hepatocytes in suspension 
remain viable (up to 6h), they are only able to provide a picture of an acute situation 
and not how cells may react to molecules or their metabolites over time.  
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6.3.2 The Use of Single P450 Expressing Cell Lines to Study Thiophene 
Bioactivation and Toxicity  
 
Single CYP expressing THLE cells as a method for assessing the role of 
bioactivation by discrete P450 enzymes in hepatocytotoxicity was evaluated in 
chapter four. Incubation of MP, 2-PT and TA in five cell lines (CYP1A2, CYP2C9, 
CYP2D6, CYP3A4 and a non CYP expressing line) and subsequent assessment of 
cell viability and GSH adduct formation aimed to inform about the role of the above 
P450 enzymes in thiophene metabolism and toxicity. Incubations (72h) with TA 
exhibited the most toxicity, though showed no difference in susceptibility between 
the cell lines (Fig 4.2C). Incubations with MP (72h) also resulted in a drop in cell 
viability at the highest concentrations (Fig 4.2B) in CYP3A4, CYP2D6 and CYP1A2 
cell lines. The lack of toxicity of MP in this system versus the cytotoxicity observed 
in freshly isolated rat hepatocytes was reflected in the lack of observation of any 
GSH adducts. The only evidence of bioactivation for any of the drugs was the 
presence of a GSH adduct and S-oxide dimer in incubations with 2-PT and CYP1A2 
and CYP2C9 cell lines, respectively. It was therefore difficult to make any 
meaningful connection between bioactivation and toxicity of thiophenes in these cell 
lines. This is particularly disappointing for the incubations of TA and MP with the 
CYP2C9 cell line. TA hepatotoxicity has previously been associated with CYP2C9 
(Lopez-Garcia et al., 1994). Metabolism of MP has also been linked to rat 
CYP2C11, the ortholog of human CYP2C9.  
Previously, THLE-CYP1A2 cells have been used to demonstrate metabolism and 
protein binding of thiabendazole (Coulet et al., 2000) and THLE-CYP2D6 cells have 
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been used to investigate metabolism of diltiazem (Molden et al., 2000). P450 
dependent toxicity of chlorpromazine has also been described using this model 
(Greer et al., 2010). However, metabolite identification and toxicity has only been 
demonstrated with troglitazone ns non-transfected THLE-2 cells (Saha et al., 2010a). 
Use of other human derived cell lines for investigating P450 dependent toxicity has 
proved more successful. Transfection or retroviral infection of HepG2 cells with 
human CYP2E1, has allowed exploration of the role of CYP2E1 of ethanol induced 
liver disease, but metabolites were not identified (Cederbaum et al., 2001). HepaRG 
cells, a human hepatoma derived cell line which differentiates into a hepatocyte like 
cell after two weeks at confluency, represent a promising model (Guillouzo et al., 
2007). These tumour derived cells, were found to form colonies, including formation 
of bile canalicular and epithelial cells following addition of dimethylsulfoxide 
(Aninat et al., 2006). PCR analysis also revealed expression of Phase I and Phase II 
metabolising enzymes, and activity of enzymes was found to be inducible in a 
similar fashion to in primary human hepatocytes. Both metabolite identification and 
determination of cell viability were achieved in this cell line, and the authors suggest 
they are a comparable model to cultured primary human hepatocytes (Aninat et al., 
2006). 
The data gathered on metabolism and toxicity of thiophenes in the THLE cell model, 
and the lack of published studies determining both metabolism and toxicity in this 
model suggest that predicting P450 dependant toxicity using the THLE cell model is 
potentially flawed method. However, useful information could be conceived about 
the roles of individual P450 enzymes in the metabolism or toxicity of certain drugs. 
Development of the HepaRG cell line could provide an alternative to the use of 
isolated hepatocytes in this field of study.  
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6.4 Mechanistic Biomarkers of Drug Induced Liver Injury 
 
As discussed previously, the mechanisms involved in DILI are varied and complex. 
Traditional routes of diagnosis have relied on determining certain clinical chemistry 
parameters and histology. Plasma levels of hepatic transaminase enzymes and other 
proteins, such as bilirubin, are taken to represent breakdown of cell disruption or 
organelle damage by either apoptotic or necrotic means. Differences in the order or 
level of protein or enzyme elevation are used to distinguish between cholestatic, 
mitochondrial or cytotoxic injury, but do not give information regarding the 
mechanisms behind the injury, are not predictive and are not entirely liver specific. 
For example, measurement of total serum ALT takes into account both ALT1 and 
ALT2. Whilst ALT1 is expressed highly in human liver tissue (as well as skeletal 
muscle and kidney), ALT2 is found in heart and skeletal muscle tissue (Lindblom et 
al., 2007). Enzyme levels can also be elevated in other disease states, such as liver 
cancer, fatty liver disease and viral hepatitis (Ozer et al., 2008). Ideally, a biomarker 
would be specific not only to hepatic injury, but reflective and preferably predictive, 
of the type of injury and the mechanisms behind that injury. It should also be 
minimally invasive, rapidly assayed, and to be useful both in preclinical safety 
studies and the clinic, transferable across in vitro and in vivo studies, as well as 
across species. Measurable changes in DNA, protein or metabolite levels could all 
act as biomarkers, alone or in a pattern or „fingerprint‟ of DILI.  
There are several novel biomarkers currently being developed as potential 
mechanism specific and markers reflective of DILI. High-mobility group box protein 
1 (HMGB1), is a nuclear binding protein with proinflammatory activity and has been 
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suggested as playing a role in indicating the presence of dying cells to the immune 
system (Scaffidi et al., 2002). Activation of the innate immune system following 
drug-induced hepatic necrosis is thought to play a key role in the extent of damage 
caused (Liu et al., 2004). HMGB1 is released in two forms; a hyper-acetylated form 
is released from activated innate immune cells (Bonaldi et al., 2003), and a hypo-
acetylated form is released passively from necrotic cells (Scaffidi et al., 2002). An 
increase in serum HMGB1 levels has been observed in endotoxin exposure and 
autoimmune disease. Measurable in a minimally invasive medium and reflective of 
mechanisms involved in injury, HMGB1 could potentially inform about the level of 
innate immune involvement in DILI. However, there are many other mechanisms 
involved in DILI for which a suitable biomarker still remains elusive. 
 
6.5.1 Biomarkers of Hepatic Glutathione Consumption  
 
Depletion of GSH is a phenomenon observed in DILI associated with several model 
hepatotoxins (Kitteringham et al., 2000). Conjugation of GSH to the electrophilic 
species following bioactivation of xenobiotics is a vital detoxification and therefore 
protection system within the hepatocyte.  However, in certain cases where GSH is 
depleted below a certain threshold, this can be a factor in the onset of cell death. 
High concentrations of GSH (5mM) are found in the hepatocyte, and this is critical 
to maintaining the redox status of the cell, and when depleted, free radicals and 
electrophilic species cannot be effectively detoxified, and can therefore modify 
cellular proteins. As covered in chapter five, the synthesis of GSH is a two step 
process controlled by two discrete enzymes, glutamate cysteine ligase (GCL) and 
glutathione synthetase. This enzyme is under a negative feedback inhibition 
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controlled by GSH concentrations, decreases in GSH increase the activity of the 
enzyme. It is because of this that it is proposed that levels of the GSH analog, 
ophthalmic acid (OA) will rise following depletion of GSH. A metabolomic 
investigation (Soga et al., 2006) found increased levels of a metabolite with a mass 
of 290amu following hepatic depletion of GSH in mice by acetaminophen (APAP) 
administration. This metabolite was revealed to be OA following examination by 
mass spectrometry. The authors suggest that depletion of GSH leads to an increase in 
the activity of GCL which, following a depletion in the cysteine pool, recruits 2-
aminobutyrate in place of cysteine, forming the precursor to OA. Evidence for this 
theory is also presented in the study. Mice were administered either buthionine 
sulphoximine (BSO), an inhibitor of GCL, or DEM, a GSH depletor. OA serum 
levels increased in the mice administered DEM, but not in those administered BSO. 
This suggests that serum OA increases would be reflective of direct depletion of 
hepatic GSH via conjugation, rather than through inhibition of either GCL or 
glutathione synthetase. OA could therefore serve as a non-invasive biomarker of 
direct hepatic GSH depletion.  
Chapter five aimed to explore the viability of OA as a biomarker of hepatic OA 
depletion. Firstly, in an attempt to replicate the results from Soga (Soga et al., 2006), 
and therefore to validate the MS method, APAP was administered to C57BL6 in a 
toxic dose (530mg/kg) in order to achieve GSH depletion. Whilst an increase in 
serum OA was observed, it was delayed from the original GSH depletion by 5h (Fig 
5.1). As discussed in chapter five, this may be due to differences in the experimental 
method used, specifically in that animals in the previous study were starved prior to 
treatment, possibly affecting enzymes related to 2-aminobutyrate metabolism(Kasai 
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T et al., 1989; Steele et al., 1984) , and potentially causing a depletion in hepatic 
GSH (Leeuwenburgh et al., 1998).  
Although chronic APAP dosing in rats by infusion did increase OA at late time 
points (48h, Fig. 5.2), administration of DEM to anesthetised rats did not produce a 
significant increase in serum or hepatic OA within the 2h of the study time, despite a 
huge depletion in hepatic GSH (Fig 5.3). Kinetic studies also revealed that OA has a 
short half-life (35min) in rat serum, potentially impacting on sampling time (Fig. 5.4 
and Table 5.3) if OA were to be developed as a biomarker. Therefore, although 
serum OA levels could be used alongside other investigations to provide 
supplementary information on the mechanisms of liver injury, alone it is unlikely to 
be suitable as a biomarker of GSH consumption, due to the delay between initial 
depletion of GSH and elevation of serum OA, and the lack of consistency in OA 
increase between the models presented.  
As well as OA, there are several other metabolites in the glutathione metabolomic 
pathway which may serve as potential biomarkers of disruption of GSH status or 
oxidative stress. Taurine, has already been assessed as both a urine biomarker of 
DILI and a heptatoprotectant in rats dosed with model hepatotoxins (Waterfield et 
al., 1993a; Waterfield et al., 1993b; Waterfield et al., 1993c). 5-oxoproline, has also 
been identified in rat biofluids following exposure to bromobenzene (Waters et al., 
2006).  
Whilst many other biomarkers are available to analyse for a state of oxidative stress, 
e.g. lipid peroxides, serum GSH and oxidised GSH concentrations and hydrogen 
peroxide, and of liver injury in general, e.g. serum transaminase concentrations, 
more specific biomarkers or a „signature‟ of proteins or metabolites would provide 
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much more information regarding the type of injury caused and, in clinic, aid in 
diagnosis and treatment. There is therefore currently, much focus on the use of 
proteomics, metabolomics and transcriptomics to provide an integrated systems 
biology approach for identifying possible biomarkers or to identify patterns 
associated with not only DILI (Amacher, 2010; Lee et al., 2009), but many other 
types of organ or system injury and various disease states (Nam et al., 2009; Rosner, 
2009; Waterman et al., 2010).  
 
6.5 Conclusions 
 
The thiophene ring is a potentially dangerous toxicophore, due to the ability of P450 
enzymes to form thiophene epoxides and thiophene S-oxides. However, 
incorporation of a thiophene ring into a therapeutic agent does not necessarily result 
in a drug capable of causing DILI. Despite this, care should be taken to ensure 
thorough pre-clinical metabolism and safety studies on any new drugs containing a 
thiophene ring. The H/D exchange method utilised in chapter one to define the 
reactive metabolite of methapyrilene formed in rat microsomal incubations is a 
simple technique which when used with mass spectrometry can provide information 
on the chemistry of  thiophene bioactivation. The well defined chemistry of reactive 
intermediates associated with thiophenes means that they are useful tools for 
studying mechanisms of DILI following bioactivation and to determine links 
between formation of reactive metabolites and onset of hepatocyte damage.  
The freshly isolated rat hepatocyte model is an ideal tool with which to carry out 
investigations into structure, metabolism and toxicity as results can be evaluated in 
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the same incubation. This model can also be used to determine covalent binding (if 
radioactive substrate is available), GSH concentrations and could be expanded to 
examine different toxicity endpoints, such as mitochondrial function or lactose 
dehydrogenase leakage. There is also the potential to measure proteomic or 
metabolomic biomarkers, using mass spectrometry. Ideally, human hepatocytes 
could be used to present a more true reflection of the in vivo situation in the patient; 
however, rat hepatocytes are more readily available and subject to less variation 
between donors. Unfortunately, incubations with single P450 expressing THLE cells 
did not enable any links to be extrapolated between individual enzymes and 
bioactivation or toxicity of thiophene drugs. The use of chlorpromazine as a positive 
control for toxicity validates the data obtained in the toxicity side of the work. 
However, despite some toxicity observed for MP and TA, no evidence of 
bioactivation was detected. Whether this a false negative is not known and would 
require further investigation, taking into account several factors, such as a „mis-hit‟ 
of the P450 enzymes involved in metabolism, the range of drug concentrations 
examined or the methods involved in incubation or in analysis by mass spectrometry. 
For example, other studies using THLE cells have used a larger incubation volume 
and number of cells in metabolism studies than was utilised in this work (Saha et al., 
2010b). Other human derived cell lines may be more appropriate for elucidating 
information on the mechanisms of DILI, such as the HepaRG cell line, shown to 
differentiate to a hepatocyte like phenotype, expressing metabolic enzymes at a 
similar level to isolated human hepatocytes (Aninat et al., 2006; Guillouzo et al., 
2007). 
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Biomarkers have the to potential to expand knowledge of mechanisms of DILI and 
to enhance preclinical safety studies, as well as translating to the clinic as diagnostic 
tools. In vivo investigations using depletors of hepatic GSH determined that 
elevation of serum OA is not a consistent product of hepatic GSH consumption and 
that there a is delay between decrease in GSH and increase in OA. However, despite 
the unsuitability of OA as a singular biomarker of GSH depletion, the kinetic and 
stability studies did provide evidence that OA is subject to the same routes of 
metabolism of GSH, via breakdown by γ-glutamyltranspeptidase on kidney cell 
membrane. Metabolic pathways could as yet be exploited to reveal a novel 
biomarker.  
 
 
 
6.6.1 Concluding Remarks 
 
The original aim of this thesis was to answer the following questions: 
 How mass spectrometry can be used to provide information on the chemistry 
of thiophene bioactivation? 
 Are thiophene GSH adducts formed in certain animal and human in vitro 
models, and if so can they be linked to any observed toxicity? 
 Can serum OA levels be exploited as a biomarker of hepatic GSH depletion? 
The overall scope of this work reveals the usefulness of H/D exchange in 
combination with mass spectrometry to define thiophene S-oxide and epoxide 
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intermediates, as well as the use of LC-MS/MS to identify these adducts in vitro 
studies. The freshly isolated rat hepatocyte model was a useful tool for providing 
integrated metabolic and toxicological data of thiophene containing molecules and 
has the potential to be expanded to include data on covalent binding and levels of 
DILI biomarkers. The single CYP expressing THLE cell model was not as useful in 
this case, but has been used in other studies to explore the role of discrete P450 
enzymes in toxicity (Greer et al., 2010) and metabolism (Coulet et al., 2000; Molden 
et al., 2000). Whilst it is unfortunate that serum OA did not reflect hepatic OA in 
such a way that it could be easily exploited as a biomarker, this does help us to 
understand that the plethora of potential biomarkers uncovered by proteomic, 
metabolomic and transcriptomic studies need to be investigated in depth in order to 
understand their applications across different species and systems.  
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